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General introduCtion & outline of 
thesis
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Acute myocardial infarction (AMI) is responsible for the majority of (sudden) deaths and sig-
nificant morbidity, thereby causing a major burden on health care. The prognosis of patients 
after an AMI is mainly determined by the size of the infarct, which is dependent of the area at 
risk (determined by localization of coronary occlusion), the duration of ischaemia, the severity 
of ischaemia (which is dependent on the degree of collateral flow and residual antegrade 
flow), and the mode of reperfusion.1 Any (ST-segment elevation) AMI should be reperfused as 
fast as possible (“time is muscle”), with primary percutaneous coronary intervention currently 
being considered as the optimal approach to the reperfusion therapy of myocardial infarction 
with ST-segment elevation.2 New insights into the pathophysiology, diagnosis and treatment 
strategies are generated striving to further improve treatment of patients with an AMI.
This thesis describes several aspects of acute myocardial infarction. Specifically it aims to:
1) Obtain better insight in the pathophysiology of by investigating atherosclerotic plaque 
formation.
2) Evaluate the accuracy of the electrocardiogram in the diagnosis of AMI.
3) Limit the complications of percutaneous coronary intervention in the treatment of AMI by 
use of the transradial artery approach and to study the efficacy and safety of drug-eluting 
stents in patients with AMI.
4) Reduce the sequelae of AMI by limiting reperfusion injury (i.e. revascularization by primary 
percutaneous coronary intervention or thrombolysis) itself; and finally, review clinical 
trials on reperfusion injury inhibitory strategies in patients with AMI.
PathoPhysioloGy of aCute myoCardial infarCtion: Plaque 
stability
An AMI occurs when a coronary artery supplying the heart becomes occluded. This occlu-
sion is typically caused by rupture of destabilized atherosclerotic plaques inside the arterial 
wall, triggering the formation of thrombus,3-7 which can occlude the artery, causing cardiac 
ischaemia. Prolonged ischaemia can lead to infarction, reducing the power of the heart to 
pump oxygenated blood around the body, and potentially leading to heart failure and death. 
Improved insight in the pathophysiology of AMI may generate potential treatment strate-
gies, therefore it is of importance to study the factors responsible for plaque destabilisation. 
Destabilisation of an atherosclerotic plaque is thought to be mainly caused by a dynamic 
inflammatory process8-10 and it has been suggested that the amount of wall shear stress may 
be partly responsible for the destabilisation of plaque content.11-14 Consequently, the influence 
of the direction of flow or shear stress on the distribution of cells in an atherosclerotic plaque will 
be studied in Chapter 2.
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1diaGnosis of aCute myoCardial infarCtion: the 
eleCtroCardioGram
The typical presentation of an AMI is a patient presenting with chest pain, discomfort and/or 
dyspnea, with or without radiation to the jaws and arms and/or vegetative symptoms (nausea, 
vomiting, anxiety) that lasts for at least twenty minutes. The clinical diagnosis is based on 
these complaints in combination with electrocardiographic changes. More than 100 years 
after Einthoven’s first publication on the electrocardiogram,15 the electrocardiogram has 
become indispensable for rapid diagnosis and management of patients with a wide variety 
of cardiac diseases, including AMI.16 The electrocardiogram is easily available, non-invasive, 
inexpensive and crucial in the diagnosis of AMI. The main criteria for ST-segment elevation 
myocardial infarction on the electrocardiogram are new or presumed new ST-segment eleva-
tions at the J point in two or more contiguous leads with the cut-off points ≥ 0.2 mV in men 
or ≥ 0.15 mV in women in leads V2-V3 and/or ≥ 0.1 mV in other leads.17 The electrocardiogram 
not only indicates the presence of AMI, but can also be used for estimation of the size of the 
area at risk18 and localization of jeopardized area. It has been claimed that localization of the 
infarct related coronary artery and infarct related (culprit) coronary segment can be predicted 
based on electrical vector theory of the ST-segment deviation (elevation or depression) from 
the isoelectric line in the 12-lead electrocardiogram.19,20 Several electrocardiographic criteria to 
diagnose the site of origin of occlusion in the coronary artery have been published,19,20 that are 
mainly based on (electrical vector) theories or non-blinded studies. Consequently, the validity and 
accuracy of the criteria in clinical practice are evaluated in Chapter 3.
treatment of aCute myoCardial infarCtion: novel treatment 
strateGies in Primary PCi
Limitation of myocardial infarct size is critical to improve immediate and long-term outcome 
and to reduce the incidence and prevalence of heart failure. The principal therapy to limit 
infarct size in patients with an AMI is reperfusion by revascularization with a mechanical (per-
cutaneous coronary intervention) or pharmacological intervention (thrombolysis).2 Currently, 
percutaneous coronary intervention with intracoronary stent implantation is considered to 
be superior to balloon angioplasty alone or thrombolysis in patients suffering from an acute 
ST-segment elevation myocardial infarction.21-23 In order to achieve a further improvement of 
outcome after a percutaneous coronary intervention with stent implantation, it is mandatory 
to further reduce complications, hospital stay and the need for repeat revascularization. These 
issues will be evaluated in Chapters 4-7.
Chapter 1
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Primary Percutaneous Coronary Intervention Using the Transradial Approach
In addition to percutaneous coronary intervention, recent studies have documented further 
improvement in outcomes after primary percutaneous coronary intervention when a glyco-
protein IIb/IIIa receptor blocker (abciximab) is added to the regime.24-27 A glycoprotein IIb/
IIIa receptor blocker may improve microvascular flow by preventing thrombus formation and 
embolization triggered by damage of the endothelium and stent material.25,28 Although not 
yet proven to be as beneficial as abciximab when administered supplementary to primary per-
cutaneous coronary intervention, the cheaper glycoprotein IIb/IIIa receptor blocker tirofiban 
is also widely used. Despite its beneficial effects, it is well recognized that, predominantly 
entry-site related bleeding complications, are a frequent companion of glycoprotein IIb/IIIa 
blocker treatment (12% in the ADMIRAL-trial)25 resulting in additional morbidity and prolonged 
hopitalization.29-31 By using the transradial approach for arterial access this additional morbid-
ity by local bleeding can be minimized.32,33 Furthermore, it has been suggested that patients 
with an AMI could be discharged early (3-4 days) when treated by a primary percutaneous 
coronary intervention.34 Reduction of hospital stay is not only generally well appreciated by 
patients, it also has advantages for the hospital and cardiology departments, since it allows 
effective use of hospital capacity and resources.34 The combination of the above mentioned 
potential beneficial strategies may improve the treatment regimen for patients with an AMI. 
Consequently, the feasibility to discharge patients shortly (3-4 days) after a primary percutaneous 
coronary intervention for AMI, in combination with the use of the transradial approach and the 
glycoprotein IIb/IIIa receptor blocker tirofiban is investigated in Chapter 4.
Drug-Eluting Stents in Acute Myocardial Infarction
Implantation of intracoronary stents has been shown to limit the need for repeat revascu-
larization in patients that underwent a primary percutaneous coronary intervention for AMI, 
compared to balloon angioplasty alone.21-23 However, restenosis may still develop after stent 
implantation,27,35 resulting in repeat revascularization rates up to 20% after bare metal stent 
implantation after primary percutaneous coronary intervention.36,37 Repeat revascularization 
exposes the patients to additional risk from repeat catheterization and revascularisation 
by percutaneous coronary intervention or coronary artery bypass grafting, resulting in an 
increased burden of death, recurrent myocardial infarction, and left ventricular dysfunction.38-40 
Drug-eluting stents reduce target-vessel revascularization for restenosis as compared with 
bare-metal stents in a variety of clinical pictures.41,42 Currently, there are several drug-eluting 
stents commercially available, the first two on the market were the sirolimus-eluting stent 
and the paclitaxel-eluting stent. Retrospective studies and one small randomized trial have 
suggested that the use of drug-eluting stents is also beneficial in the setting of primary 
percutaneous coronary intervention,43-46 warranting a larger randomized trial in patients with 
AMI. Consequently, the efficacy of paclitaxel-eluting stents was studied in the Paclitaxel-eluting 
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1Stent versus Conventional Stent in Myocardial Infarction with ST-segment Elevation (PASSION) 
trial, which is described in Chapter 5.
Recently, concern has arisen regarding serious adverse events caused by stent thrombo-
sis late after drug-eluting stent implantation.47-49 There is a growing concern that delayed 
endothelialization,50,51 late malapposition,52 impaired endothelial function53 and reduced 
neointimal response54 after drug-eluting stent implantation may lead to late (> 30 days) and 
very late (> 1 year) stent thrombosis. Stent thrombosis is a potentially hazardous adverse 
event, which may lead to recurrent myocardial infarction or death. Additionally, it has been 
suggested that the occurrence of late stent thrombosis may be associated with the cessation 
of clopidogrel after 6-12 months after stent implantation. It was recently stated by the Food & 
Drug Administration panel (Nov 2006) that off-label use of drug-eluting stents (i.e. including 
ST-segment elevation myocardial infarction) is associated with increased risks of both early 
and late stent thrombosis. However, the event rates late after primary percutaneous coronary 
intervention with drug-eluting stents are unknown. To address this issue, in Chapter 6 we 
evaluated the safety of paclitaxel-eluting stents compared to bare-metal stents in the setting of 
primary percutaneous coronary intervention, in terms of the rate of serious adverse cardiac events, 
especially in relation to the incidence of stent thrombosis at two years follow-up. Furthermore, 
in Chapter 7 the effects of drug-eluting stents in AMI were analyzed using meta-analysis of 8 
randomized trials, including the PASSION trial, with a total study population of 2.786 patients with 
a clinical follow-up of 18-24 months .
sequelae of aCute myoCardial infarCtion: rePerfusion injury
Besides reperfusion and conventional anti-platelet therapy, further infarct size limitation 
may be obtained by adjunctive pharmacological treatment. The importance of immediate 
reperfusion is not surprising as the primary insult is a decrease in oxygen supply resulting in 
a decrease of free energy from ATP-hydrolysis beyond a critical level required for maintaining 
cell processes such as ion channel function. However, despite its clear benefit, reperfusion 
itself has been proposed to cause irreversible myocardial damage, termed “reperfusion injury”, 
beyond that caused by the preceding period of ischaemia. This implies that optimization of 
reperfusion therapy by blunting this reperfusion injury could further limit infarct size.
The mechanism of reperfusion injury remains incompletely understood, but may include 
(i) cytosolic and mitochondrial Ca2+-overload, (ii) release of reactive oxygen species, (iii) an 
acute inflammatory response, and (iv) shift in substrate use.55-61 These pathways have been the 
therapeutic targets in experimental and clinical studies. Direct evidence for the existence of 
reperfusion injury stems from animal studies in which pharmacological agents administered 
just prior to reperfusion limited final infarct size.56,62-66 Pre-clinical studies, although sometimes 
equivocal, spurred a large number of clinical trials. Chapters 8 and 9 describe two randomized 
Chapter 1
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clinical trials which evaluated the efficacy of two novel reperfusion inhibitory agents (ITF-1697 
in the Protect Against Reperfusion Injury with ITF-1697 in Acute Myocardial Infarction [PARI-MI] 
and caldaret in the Caldaret [MCC-135] in Patients Undergoing Primary Percutaneous Coronary 
Intervention for ST-segment Elevation Myocardial Infarction [CASTEMI] trial). ITF-1697 has been 
shown to exert anti-inflammatory actions by preventing polymorphonuclear neutrophil 
adhesion and extravasation, preservation of vascular endothelial phenotype and vascular 
permeability, thereby reducing reperfusion injury (unpublished data on file at Italfarmaco). 
The intracellular calcium overload induced by ischaemia and reperfusion, another pathway of 
reperfusion injury, was targeted with the use of caldaret. Caldaret has been shown to enhance 
uptake and inhibit leakage of calcium from the sarcoplasmic reticulum.67,68
In the era of reperfusion therapy more than 35 large clinical trials have been conducted 
to evaluate the efficacy of several reperfusion injury inhibitory strategies. None of these 
strategies have indisputable been shown to exert beneficial effects in patients with AMI. Con-
sequently, in Chapter 10 clinical studies on reperfusion injury inhibitory strategies will be reviewed, 
with a special emphasis on potential factors that could account for the discrepancies between 
the oftentimes encouraging results from animal studies and the overall disappointing results from 
clinical studies. And what can we do to improve the likelihood of success for future studies?
Finally, in Chapter 11 the results presented in this thesis will be summarized and the impact 
discussed, with a special emphasis on future research directions. 
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abstraCt
Background The distribution of macrophages and smooth muscle cells (SMCs) within ath-
erosclerotic plaques is highly variable. This is clinically relevant because these cell types have 
opposite effects on the stability of atherosclerotic plaques. The present study was designed 
to investigate whether local variations in arterial flow over the plaque surface could relate to 
differences in the distribution of SMCs and macrophages in plaques.
Methods and Results Thirty-three entire carotid plaques were collected at autopsy and 
marked at their proximal (in relation to the direction of the blood flow) ends, and the cell 
composition of upstream parts (where high flow and high shear prevail) was compared with 
that of downstream parts (low flow and low shear stress). Seventy percent of plaques showed 
more SMCs in their downstream part, and 67% of plaques contained more macrophages in the 
upstream part. Immunostained macrophage areas were larger in upstream parts (P=0.011). 
Immunostained SMC areas were larger in downstream parts (P=0.031). Rupture sites of 6 of 9 
ruptured plaques were in the upstream part.
Conclusions Significant differences in cell composition between upstream and downstream 
parts of plaques indicate a role for arterial flow in the distribution of different cell types. The 
low-flow/low-shear downstream areas of plaques contain significantly more SMCs, which 
could provide the background for slowly progressive growth at distal ends of plaques. The 
significantly high number of macrophages in the upstream areas suggests a relationship 
between high flow/high shear and plaque instability.
introduCtion
Atherosclerotic plaques show marked variability with respect to the distribution of inflamma-
tory cells, not only from one lesion to the other but also within one and the same plaque.1-3 
This phenomenon is significant because plaque inflammation is widely considered to play 
a role in plaque destabilization and, eventually, plaque erosion and rupture.1,4-8 By the same 
token, plaques dominated by smooth muscle cells (SMCs) are considered stable. Indeed, 
coronary atherectomy specimens obtained from patients with chronic stable angina contain 
SMCs as the dominant cellular component, but in those obtained from patients with unstable 
angina or acute myocardial infarction, inflammation prevails.4,9,10
In view of these considerations, it is important to know which mechanisms could be 
responsible for these major variations in the cellular composition of atherosclerotic plaques. 
Hemodynamic factors, such as shear stress, are considered to play a role in plaque growth,11,12 
but thus far the effect of these factors on the cellular composition of atherosclerotic plaques 
has not been studied. This may well be an interesting enterprise, because the geometry of a 
bulging plaque dictates differences in the impact of blood flow in relation to the direction 
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of flow. In fact, the luminal endothelial lining on the upstream (proximal) sites of a plaque is 
under high shear stress, whereas at downstream (distal) sites, low shear stress prevails.13,14 We 
speculated that these differences may also have implications for local variation in the cellular 
composition of plaques.
To verify this hypothesis, we investigated the relationship between blood flow direction 
and the cellular composition of carotid plaques by quantitatively comparing SMC and mac-
rophage contents of the upstream shoulder part of plaques with those of the downstream 
shoulder parts. The common carotid artery with its bifurcation site was chosen, because previ-
ous studies by Zarins et al12 and Ku et al15 have shown that these arterial sites may serve as a 
good model to investigate the relationship between fluid dynamics and atherosclerosis and 
also because the carotid bifurcation is a predilection site for plaque formation.
methods
Tissue sampling
Sixty-three left and right carotid artery bifurcations were studied in a consecutive autopsy 
series of 45 patients (mean age, 69 years; range, 26 to 89 years). In all cases, the postmortem 
interval was <24 hours. Excluded from the study were immunocompromised patients and 
patients who had died under septic conditions. Left and right carotid arteries were carefully 
dissected from the surrounding tissues, and a segment was removed that contained 10 mm 
of the common carotid artery at the upstream end, the carotid bifurcation, and 10 mm of the 
internal and the external carotid arteries at the downstream ends. The arterial segment was 
opened longitudinally along its ventral side, fixed in 4% buffered formalin, and, if necessary, 
decalcified in EDTA for 4 days. Arteries with total luminal occlusion were excluded; none of 
the arteries showed recanalization. From the remaining samples, a longitudinal transmural 
tissue block of ≈20x4 mm was removed from both the internal and external carotid arteries. 
These tissue blocks were marked immediately with India ink at the upstream (proximal) site to 
ensure their topographic relation with the flow direction. They were then routinely processed 
for paraffin embedding and microscopic sectioning (Figure 1).
Light microscopy
Serial sections 6 μm thick were cut parallel to the long axis of the arterial segment, and 2 
sections were stained with hematoxylin-eosin and an elastic-van Gieson stain for screening. 
Arterial segments that appeared to contain diffuse atherosclerosis or fatty streaks, as well as 
plaque-free segments, were all excluded from the study. Ruptured or eroded plaques were 
excluded from morphometric evaluation; these plaques were studied to determine at which 
site of the plaque (upstream or downstream) rupture or erosion had occurred. The remaining 
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segments, containing raised plaques with intact upstream and downstream shoulders and 
cap parts, were used for further investigation (Figure 1).
Immunohistochemistry
Adjacent serial sections were stained for SMCs with an anti–α-actin antibody (SMA, clone 
1A4, DAKO, dilution 1:200). Macrophages were stained with an anti-CD68 antibody (clone 
PG-M1, DAKO, dilution 1:100). A 3-step indirect streptavidin-biotin technique with peroxidase 
was used, in which final visualization of the peroxidase activity was performed with diamin-
obenzidine as chromogen. Nuclei were faintly counterstained with hematoxylin. In negative 
controls, the primary antibody was replaced by an irrelevant mouse monoclonal antibody of 
the same subclass.
Morphometry
Surface areas of the upstream (proximal) shoulder and the downstream (distal) shoulder of 
plaques were planimetrically quantified in tissue sections with image-analysis software run-
ning on a PC connected with a video-mounted microscope. The shoulder parts were defined 
as the plaque area reaching from the adjacent normal intima (upstream or downstream) to 
the outer sides of the lipid core (atheroma) at both ends (Figure 1). These areas were outlined 
Figure 1. Schematic of sampling and further selection of carotid artery plaques.
carotid arteries were carefully dissected from the surrounding tis-
sues, and a segment was removed that contained 10 mm of the
common carotid artery at the upstream end, the carotid bifurcation,
and 10 mm of the internal and the external carotid arteries at the
downstream ends. The arterial segment was opened longitudinally
along its ventral side, fixed in 4% buffered formalin, and, if
necessary, decalcified in EDTA for 4 days. Art rie wi h total
luminal occlusion were excluded; none of the arteries showed
recanalization. From the remaining samples, a longitudinal transmu-
ral tissue block of 204 mm was removed from both the internal
and external carotid arteries. These tissue blocks were marked
immediately with india ink at the upstream (proximal) site to ensure
their topographic relation with the flow direction. They were then
routinely processed for paraffin embedding and microscopic section-
ing (Figure 1).
Light Microscopy
Serial sections 6 m thick were cut parallel to the long axis of the
arterial segment, and 2 sections were stained with hematoxylin-eosin
and an elastic–van Gieson stain for screening. Arterial segments that
appeared to contain diffuse atherosclerosis or fatty streaks, as well as
plaque-free segments, were all excluded from the study. Ruptured or
eroded plaques were excluded from morphometric evaluation; these
plaques were studied to determine at which site of the plaque
(upstream or downstream) rupture or erosion had occurred. The
remaining segments, containing raised plaques with intact upstream
and downstream shoulders and cap parts, were used for further
investigation (Figure 1).
Immunohistochemistry
Adjacent serial sections were stained for SMCs with an anti–-actin
antibody (SMA, clone 1A4, DAKO, dilution 1:200). Macrophages
were stained with an anti-CD68 antibody (clone PG-M1, DAKO,
dilution 1:100). A 3-step indirect streptavidin-biotin technique with
peroxidase was used, in which final visualization of the peroxidase
activity was performed with diaminobenzidine as chromogen. Nuclei
were faintly counterstained with hematoxylin. In negative controls,
the primary antibody was replaced by an irrelevant mouse monoclo-
nal antibody of the same subclass.
Morphometry
Surface areas of the upstream (proximal) shoulder and the down-
stream (distal) shoulder of plaques were planimetrically quantified in
tissue sections with image-analysis software running on a PC
connected with a video-mounted microscope. The shoulder parts
were defined as the plaque area reaching from the adjacent normal
intima (upstream or downstream) to the outer sides of the lipid core
(atheroma) at both ends (Figure 1). These areas were outlined
manually, and the percentage of immunostained surface was mea-
sured automatically with gray-scale detection. In this way, we
calculated the anti-CD68 (macrophages) and anti–-actin (SMC)
immunopositive areas as a percentage of the total area of each
shoulde part in square millimeters. The ratios of macrophage-
positive areas and SMC-positive areas were calculated for each
plaque individually. Results were recorded as meanSD.
Statistical Analysis
For comparison of morphometric data between different plaque
areas, which were not compatible with a normal frequency distribu-
tion, a paired Student’s t test with the logarithmic transformation of
individual values was used (SD). Values of P0.05 were consid-
ered significant.
Results
Six carotid arteries (10%) were occluded. Histopathological
analysis of the carotid artery samples resulted in 41 plaque-
free segments (36%), 31 segments containing diffuse athero-
sclerosis (27%), and 9 segments showing rupture or erosion
(8%). The site of rupture or erosion was upstream in 6 of the
9 plaques. Each of the remaining 33 carotid artery segments
(29%) contained an entire atherosclerotic plaque, and these
were used for further study (Figure 2). Immunohistochemis-
try revealed large variations in the numbers of SMCs and
macrophages among plaques of different patients but also
Figure 1. Schematic of sampling and further selection of
carotid artery plaques.
Figure 2. Top, Overview of an entire carotid artery plaque. Hori-
zontal arrow indicates direction of blood flow. Boxed area P is
in proximal (upstream) shoulder of plaque; boxed area D is in
distal (downstream) shoulder. Elastic–van Gieson stain; magnifi-
cation 12. Middle, Boxed area of proximal (upstream) shoulder
stained with anti-CD68 (P mac) and anti–-actin (P smc); magni-
fication 40. Bottom, boxed area of distal (downstream) shoul-
der stained with anti-CD68 (D mac) and anti–-actin (D smc);
magnification 40.
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manually, and the percentage of immunostained surface was measured automatically with 
gray-scale detection. In this way, we calculated the anti-CD68 (macrophages) and anti-α-actin 
(SMC) immunopositive areas as a percentage of the total area of each shoulder part in square 
millimeters. The ratios of macrophagepositive areas and SMC-positive areas were calculated 
for each plaque individually. Results were recorded as mean ±SD.
Statistical analysis
For comparison of morphometric data between different plaque areas, which were not 
compatible with a normal frequency distribution, a paired Student’s t test with the logarith-
mic transformation of individual values was used (±SD). Values of P<0.05 were considered 
significant.
results
Six carotid arteries (10%) were occluded. Histopathological analysis of the carotid artery 
samples resulted in 41 plaque free segments (36%), 31 segments containing diffuse athero-
sclerosis (27%), and 9 segments showing rupture or erosion (8%). The site of rupture or erosion 
was upstream in 6 of the 9 plaques. Each of the remaining 33 carotid artery segments (29%) 
contained an entire atherosclerotic plaque, and these were used for further study (Figure 2). 
Immunohistochemistry revealed large variations in the numbers of SMCs and macrophages 
among plaques of different patients but also within one and the same plaque. Some plaques 
contained only SMCs, whereas others were almost totally infiltrated by macrophages. On aver-
age, however, SMC areas were larger than macrophage areas.
The results of area quantification of SMCs and macrophage areas in the immunostained 
sections are shown in the Table 1. In 23 of the 33 sections (70%) stained with anti-α-actin, 
the SMC areas of the downstream (distal) shoulder were larger than those of the upstream 
shoulder part, with an upstream/downstream ratio [ln (U/D) ratio] of -0.41. In the downstream 
(distal) shoulder, the SMC areas were significantly larger than in the upstream (proximal) 
shoulder (P=0.031)(Figure 2). In 22 of 33 cases (67%), anti-CD68-stained sections showed 
larger macrophage areas in the upstream (proximal) shoulder part of the plaque, with a U/D 
table 1. Macrophage and SMC Area Quantification in the Upstream and Downstream Shoulder Parts of 33 Atherosclerotic Plaques in the Carotid Artery
Measurements Upstream Downstream P-value
Mean measured area, mm2 2.49 ± 1.81 2.38 ± 1.19
ln(Mac %) 1.55 ± 1.14 0.81 ± 1.95 0.011
ln(SMC %) 2.56 ± 1.09 2.97 ± 1.08 0.031
ln(Mac %/SMC %) -1.02 ± 1.51 -2.67 ± 2.53 0.001
Mac indicates macrophage.
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ratio [ln (U/D)] of 0.74. Macrophage areas were significantly larger in the upstream shoulder 
areas of plaques (P=0.011)(Figure 2).
disCussion
Several risk factors for atherosclerosis, including hemodynamic factors, may be implicated in 
determining the cellular composition of plaques. To the best of our knowledge, this is the first 
study that shows marked topographic variation in cellular composition within atherosclerotic 
plaques related to the direction of the blood stream. Planimetric quantification of the mac-
rophage contents in carotid plaques showed statistically significantly larger macrophage-rich 
areas in the upstream shoulder than in the downstream shoulder of the same atherosclerotic 
lesion. This phenomenon may render the upstream part of an atherosclerotic plaque more 
vulnerable to erosion or rupture than the downstream part. Indeed, 6 of 9 rupture sites were 
Figure 2. Top, Overview of an entire carotid artery plaque. Horizontal arrow indicates direction of blood flow. Boxed area P is in proximal 
(upstream) shoulder of plaque; boxed area D is in distal (downstream) shoulder. Elastic–van Gieson stain; magnification x12. Middle, Boxed 
area of proximal (upstream) shoulder stained with anti-CD68 (P mac) and anti–α-actin (P smc); magnification x40. Bottom, boxed area of distal 
(downstream) shoulder stained with anti-CD68 (D mac) and anti– α -actin (D smc); magnification x40.
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ing (Figure 1).
Light Microscopy
Serial sections 6 m thick were cut parallel to the long axis of the
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plaques were studied to determine at which site of the plaque
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Immunohistochemistry
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peroxidase was used, in which final visualization of the peroxidase
activity was performed with diaminobenzidine as chromogen. Nuclei
were faintly counterstained with hematoxylin. In negative controls,
the primary antibody was replaced by an irrelevant mouse monoclo-
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Morphometry
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immunopositive areas as a percentage of the total area of each
shoulder part in square millimeters. The ratios of macrophage-
positive areas and SMC-positive areas were calculated for each
plaque individually. Results were recorded as meanSD.
Statistical Analysis
For comparison of morphometric data between different plaque
areas, which were not compatible with a normal frequency distribu-
tion, a paired Student’s t test with the logarithmic transformation of
individual values was used (SD). Values of P0.05 were consid-
ered significant.
Results
Six carotid arteries (10%) were occluded. Histopathological
analysis of the carotid artery samples resulted in 41 plaque-
free segments (36%), 31 segments containing diffuse athero-
sclerosis (27%), and 9 segments showing rupture or erosion
(8%). The site of rupture or erosion was upstream in 6 of the
9 plaques. Each of the remaining 33 carotid artery segments
(29%) contained an entire atherosclerotic plaque, and these
were used for further study (Figure 2). Immunohistochemis-
try revealed large variations in the numbers of SMCs and
macrophages among plaques of different patients but also
Figure 1. Schematic of sampling and further selection of
carotid artery plaques.
Figure 2. Top, Overview of an entire carotid artery plaque. Hori-
zontal arrow indicates direction of blood flow. Boxed area P is
in proximal (upstream) shoulder of plaque; boxed area D is in
distal (downstream) shoulder. Elastic–van Gieson stain; magnifi-
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upstream. Differences in fluid mechanics at the luminal site of different regions of the plaque 
could be responsible for differences in plaque architecture.
The carotid artery has been used by several investigators to study the relationship between 
flow dynamics and plaque formation. Zarins et al12 and Ku et al15 showed that the upstream 
sites of plaques are preferentially under high flow/high shear stress, whereas downstream 
parts are under low flow/low shear stress. Plaque growth, moreover, has been shown to occur 
predominantly in regions of low shear stress.11,12,15-18 A recent angiographic study of femoral 
arteries also revealed that plaque growth in the downstream direction occurs significantly 
more frequently than in the upstream direction.19
It is known from in vitro studies of endothelial cells under shear stress conditions that 
high shear stress induces increased expression of endothelial adhesion molecules, such 
as ICAM and VCAM, resulting in enhanced leukocyte adherence, including monocytes and 
lymphocytes.20,21 Conversely, other investigators found a relationship between low shear 
and macrophage infiltration due to prolonged and intimate contacts between mononuclear 
cells and the endothelial lining.11,12 However, in the in vivo situation of human arteries, shear 
stress may not be the only rheological factor interfering with leukocyte adherence and influx. 
Recently, Tropea et al22 studied the differences in monocyte binding upstream and down-
stream to artificial coarctations in lipid-fed New Zealand White rabbits. They demonstrated 
that monocyte adhesion and VCAM-1 expression were increased upstream of the stenosis, 
which resulted in enhanced intimal thickening and accumulation of macrophages at these 
sites.
Because the common carotid artery conveys blood with high flow and high kinetic energies, 
one may assume that at sites of atherosclerotic plaques, similar mechanisms are involved, as 
described by Tropea et al.22 This, then, could account for the large macrophage-rich areas in 
the upstream shoulder of the lesions. Nevertheless, the dominant overall cell type in most 
plaques appeared to be the SMC. In individual plaques, however, the downstream shoulders 
showed (on average) larger SMC-rich areas than their upstream counterparts. This is of interest 
because an increase of shear stress activates endothelium-derived nitric oxide (NO) synthase 
and NO production,23,24 and a chronic increase in NO has an inhibitory effect on SMC protein 
synthesis and SMC proliferation.23,24 In areas with low shear stress, such as the downstream 
parts, there is no step-up in NO production. In fact, it has been shown that low shear stress 
increases endothelin production, which acts as a stimulating factor for the production of 
extracellular matrix components by SMCs and for SMC proliferation.25 Platelet adherence in 
low-flow areas, with release of platelet-derived growth factor and basic fibroblast growth 
factor, could provide another stimulus for SMC growth.2,26 SMC growth with connective tissue 
production is generally considered to be the mechanism responsible for a gradually pro-
gressive growth of atherosclerotic plaques.2 These phenomena, therefore, could provide an 
explanation for the differences in SMC content between the upstream and the downstream 
parts of plaques and the slowly progressive growth downstream of the main lesion.
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Limitations
Obviously, shear stress cannot be the only factor involved. It is likely that a balance between 
local hemodynamic variables, such as pulse pressure, wall stress, and turbulence, all play a 
role in the eventual component makeup of an atherosclerotic plaque.11,12,15-17,27 And because 
this study is based on specimens obtained at autopsy, without much clinical information, a 
variety of intrinsic and environmental risk factors for plaque development and growth could 
have been involved, which could be reflected in variability in macrophage and SMC contents 
in plaques of different patients. Conversely, one may anticipate that such factors affect the 
overall composition of plaques rather than inducing local changes. However, it appears from 
this study that the overall effect of the variables involved in human plaque formation results 
in increased macrophage infiltration at the upstream site and increased SMC growth at the 
downstream sites.
ConClusion
Our observations in human carotid arteries are of clinical relevance. Plaque instability leading 
to plaque rupture is considered to be a disbalance between reparative activities (SMC growth 
and collagen synthesis) and degrading activities induced by macrophages.1,7,8 Therefore, the 
large amounts of macrophages in the upstream parts of plaques could indicate a relationship 
between high flow/high shear stress and plaque instability.
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abstraCt
Objective It has been claimed that localization of the culprit coronary segment can be pre-
dicted based on electrical vector theory of the ST-segment deviation on the electrocardiogram 
(ECG). These criteria are based on theories and non-blinded studies and there is a need for 
evaluation in a clinical, prospective and blinded setting. 
Methods Patients (n=153) with a STEMI undergoing emergency coronary angiography were 
included in the analysis. Localization of the culprit coronary segment was based on electrical 
vector theory of the ST-segment deviation rather than a ST-segment deviation score compared 
to the verification of the culprit segment at coronary angiography.
Results The correct culprit coronary segment was identified in 39%. The sensitivity and speci-
ficity to detect a proximal site of occlusion in the coronary artery in the total study population 
was 47% and 57%, respectively, in anterior STEMI this was 31% and 67%, respectively.
Conclusion The interpretation of the ECG to predict the exact site of coronary occlusion based 
on electrical vector theories appeared to be not very accurate and showed low sensitivity 
and specificity values. These findings underscore the importance of immediate coronary 
angiography in patients with the typical clinical presentation of acute MI and any degree of 
ST-segment elevation.
introduCtion
The typical presentation of an acute myocardial infarction (MI) is a patient presenting with 
sudden onset of chest pain, discomfort and/or dyspnoe, with or without radiation and/or 
vegetative symptoms that lasts for at least twenty minutes. The clinical diagnosis is based 
on these complaints in combination with electrocardiographic changes. More than 100 years 
after Einthoven’s publication of the electrocardiogram (ECG),1 the ECG has become indispens-
able for rapid diagnosis and management of patients with a wide variety of cardiac diseases, 
including ST-segment elevation MI (STEMI).2 The ECG is easily available, non-invasive, inex-
pensive and crucial in the diagnosis of acute MI. The criteria for STEMI are new or presumed 
new ST-segment elevations at the J point in two or more contiguous leads with the cut-off 
points ≥0.2mV in men or ≥0.15mV in women in leads V2-V3 and/or ≥0.1mV in other leads.3 
The ECG not only indicates the presence of a STEMI, but can also be used for localization and 
extent of the jeopardized area.4 Among others, the area at risk is one of the major prognostic 
determinants for final infarct size, dependent on the site of occlusion in the coronary artery 
tree.5
Direct verification for the site of coronary occlusion in acute MI is obtained by emergency 
coronary angiography (CAG). ECGs can be analysed by computerized algorithms, but inter-
pretation by a experienced cardiologists, aware of the strengths and limitations of the ECG, 
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is the golden standard. It has been claimed that localization of the infarct related coronary 
artery and culprit coronary segment can be predicted based on electrical vector theory of the 
ST-segment deviation from the isoelectric line in the 12-lead ECG.6,7
The electrical vector theory for determining the site of occlusion in the coronary artery has 
been described extensively:6-11 In STEMI the direction of both ST-segment elevation and recip-
rocal ST-segment depression is determined by the direction and magnitude of all ST-segment 
deviations resulting in a main vector in the direction of the most pronounced ischaemia. This 
vector indicates the site of occlusion in the coronary artery. In inferior wall MI an occlusion of 
the right coronary artery (RCA) will result in an inferior and rightward orientated ST-segment 
vector, whereas an occlusion in the circumflex coronary artery (CX) will result in an inferior 
and leftward oriented vector. In anterior wall MI the ST-segment vector will point in a supe-
rior direction in proximal occlusion of the left anterior descending coronary artery (LAD), in 
contrast to the more inferiorly pointed vector in case of a more distal occlusion (distal to the 
first diagonal and septal branches). This and additional criteria are described in more detail 
by others.6-11
However, these criteria are mainly based on (electrical vector) theories or on non-blinded 
studies and there is a need to evaluate this in clinical practice in a prospective and blinded set-
ting. To examine the ECG in STEMI in relation to CAG we asked a cardiac electrophysiologist, 
blinded for CAG, to analyze a series of ECGs by using the electrical vector theory.
Patients and methods
From 1999 to 2003 ECGs were collected from patients with a STEMI in the Onze Lieve Vrouwe 
Gasthuis, Amsterdam, The Netherlands. The patients were all treated with primary angioplasty 
as part of different trial protocols enrolled at our institute.12-14 Enrolment in the trials was guided 
by in- and exclusion criteria that included a classical presentation and ST-segment elevation. 
The patients participating in these trials were included in the current analysis, provided that 
the ECG prior to CAG and patient data were available. Patients in whom an inferior infarct was 
present were only included when V4R was available.
For interpretation of the ECGs we asked an established cardiac electrophysiologist to judge 
the last ECG before CAG to predict the localization of the culprit coronary segment based on 
ECG and the following patient characteristics: age, sex, time of chest pain to ECG and location 
of previous MI. Localization of the culprit coronary segment was based on electrical vector 
theory of the ST-segment elevation as described by others6-11 rather than on the ST-segment 
deviation score. The coronary segments were depicted on a coronary artery tree according 
to the American Heart Association (AHA) classification.15 In case it was not possible to make a 
definite decision by electrocardiographical analysis a comment was required.
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The CAGs were analyzed for infarct site location by two interventional cardiologists (ER, MP). 
In anterior MI the position and size of the first diagonal and septal branches was analyzed.
Data were presented as mean ±SD, and for non-parametric measurements as median with 
percentiles (P25 and P75). For discrete variables a Chi-square test was used. T-tests were 
performed provided that data were not skewed. The Mann-Whitney-U test was used for non-
parametric analysis. Significance was defined as P<0.05. Sensitivity and specificity values were 
calculated for the total study population and subgroups (anterior wall STEMI and extensive 
ST-segment deviation (>median sum of ST-segment deviation)) related to a proximal or distal 
coronary occlusion at CAG. A secondary analysis was performed in cases the analysis of the 
ECG indicated the direct adjacent coronary segment next to the culprit segment.
results
Electrocardiographical analysis
From 280 patients presenting with a STEMI enrolled in clinical trials, 153 were included in 
the current analysis. Patients were excluded due to incomplete data sets (unavailability of 
ECGs with V4R or unavailability of ECGs prior to angiography). The baseline characteristics are 
shown in Table 1. The median sum of ST-segment deviation was 18mm, this was significantly 
different between anterior wall and inferior wall MI.
Analysis of the ECG indicated the RCA as the infarct related artery 33 times; the CX in 6 
patients; the LAD was scored in 89 patients. For proximal and mid LAD lesions the site in rela-
tion to first septal and diagonal branches was stated when feasible. Of the 34 times segment 
6 was scored, 29 were scored as being proximal to S1 and D1, and 5 times the occlusion was 
scored to be proximal of S1, though distal to D1. Conversely, for segment 7 the lesion was 
table 1. Baseline characteristics
Characteristics Total Anterior MI Inferior MI P-value
N = 153 (%) N = 105 (%) N = 48 (%)
Mean age (+/- SD) 61 (+/-13) 60 (+/-13) 63 (+/- 13) 0.141
Male 114 (75) 84 (80) 30 (63) 0.028
Diabetes Mellitus 18 (12) 13 (12) 5 (10) 0.794
Hypercholesterolaemia 32 (21) 21 (20) 11 (23) 0.674
Hypertension 34 (22) 20 (19) 14 (29) 0.208
Current Smoker 88 (58) 60 (57) 28 (58) 1.000
Family history 38 (25) 24 (23) 14 (29) 0.425
Median sum of ST-elevation [P25-P75] 13 [8.5-20] 15 [10-22] 10 [7-15] <0.001
Median sum of ST-deviation [P25-P75] 18 [11-24] 19 [11-25] 18 [13-23] 0.923
Previous MI 1 (0.7) 1 (1) 0 1.000
Previous PCI 8 (5) 6 (5.7) 2 (4.2) 1.000
Previous CABG 0 0 0 -
MI = myocardial infarction; SD = standard deviation; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft
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scored to be distal to S1 and proximal to D1 in 37 cases, versus 16 cases in which the lesion 
was scored to be distal to both D1 and S1. In the remaining 25 cases it was not possible to 
make a definite prediction, because of various reasons: in 17 of these because of insufficient 
ST-segment elevation (mainly in limb leads), the remaining because of intrusion and absence 
of sinus rhythm.
Angiographical analysis
All 153 angiographies were suitable for analysis and in none of the cases there was disagree-
ment between the two interventional cardiologists. The culprit segment was in the RCA in 35 
cases, in the CX in 13 cases, and the LAD was the culprit coronary in the remaining 105 cases. 
Coronary anatomy was variant in 16 cases. Concerning segment 7: Anatomy was variant in 8 
patients; S1 much larger than S2 (4 cases), S1 much smaller in size than the S2 (8 cases), a large 
D1 (2 cases), and a much larger D2 compared with the D1 (4 cases).
Primary analysis (Tables 2-4)
The results per coronary segment are shown in Table 2. Overall, the correct culprit coronary 
segment was indicated by analysis of the ECG in 39% (n=60) of cases. To specify, in patients 
with an anterior wall infarction the correct segment was scored in 36% (38/105) versus 46% 
(22/48) in inferior wall infarctions (Table 3). Underestimation (24%) was present when analysis 
table 2. Crosstabulation: Prediction of culprit lesion by ECG analysis (horizontal) versus angiography (vertical)
ECG
CAG
1 2 3 4 5 6 7 8 9 10 11 12a 12b 13 14 15 16
No definite
prediction
Total
1 17 1 1 19
2 8 3 1 12
3 2 0 2 4
4 - - 0
5 - - 0
6 16 28 1 9 54
7 16 21 8 45
8 1 3 1 0 5
9 1 0 0 1
10 - - 0
11 1 2 1 2 6
12a 1 0 0 1
12b 1 0 1 2
13 1 1 0 0 2
14 1 0 0 1
15 1 0 0 1
16 - - 0
Total 30 3 0 0 0 34 53 1 1 1 4 0 0 2 0 0 0 24 153
Coronary segment classification according to the American Heart Association.16
Bold numbers indicate a correct prediction of the culprit coronary segment in absolute numbers by analysis of the ECG.
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table 3. Primary analysis
Variable Total (%) Correct (%) Underestimated (%) Overestimated (%) No definite prediction
Anterior MI — no. (%) 105 (69) 38 (36) 29 (28) 21 (20) 17 (16)
Inferior MI — no. (%) 48 (31) 22 (46) 7 (15) 14 (29) 5 (10)
Total — no. (%) 153 (100) 60 (39) 36 (24) 35 (23) 22 (14)
Coronary Segment — no. (%)
1 19 (12) 17 (89) 1 (5) n.a. 1 (5)
5 or 6 54 (35) 16 (30) 28 (52) n.a. 10 (19)
11 6 (3,9) 2 (33) 1 (17) n.a 3 (50)
All proximal lesions 79 (52) 35 (44) 30 (38) n.a. 14 (18)
MI = myocardial infarction; n.a. = not applicable; coronary segment classification according to the American Heart Association.16
table 4. Cross tabulations and sensitivity/specificity calculation
Variable CAG proximal CAG distal Total
Total study population N N N
ECG proximal 37*# 32 69
ECG distal or no definite prediction 42 42 84
Total 79 74 153
Sensitivity / Specificity 47% / 57%
Subgroup Anterior MI
ECG proximal 17* 17 34
ECG distal or no definite prediction 37 34 71
Total 54 51 105
Sensitivity / Specificity 31% / 67%
Subgroup Inferior MI
ECG proximal 20# 15 35
ECG distal or no definite prediction 5 8 13
Total 25 23 48
Sensitivity / Specificity 80% / 35%
Subgroup >18mm ST-segment deviation
ECG proximal 24# 13 37
ECG distal or no definite prediction 20 19 39
Total 44 32 76
Sensitivity / Specificity 55% / 59%
Subgroup <18mm ST-segment deviation
ECG proximal 13* 19 32
ECG distal or no definite prediction 22 23 45
Total 35 42 77
Sensitivity / Specificity 37% / 55%
*One case: At ECG segment 5 or 6, at CAG segment 6; #One case: At ECG segment 1, at CAG segment 11; CAG = coronary angiogram; ECG = 
electrocardiogram; MI = myocardial infarction
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of the ECG indicated a more distal segment than on CAG, and overestimation (23%) when 
it was more proximal segment at CAG. In the 16 cases with variant coronary anatomy the 
culprit segment was correctly indicated in 10 cases. In case of a proximal occlusion (coronary 
segment 1, 5, 6, or 11) the correct segment was scored in 44%, in 18% there was no segment 
pointed out as site of occlusion. 
The median sum of ST-segment elevation was higher in the group in which the prediction 
was correct, 15mm [P25-P75;10-21] versus 11mm [P25-P75;8.0-19](P=0.057). The median sum 
of ST-segment deviation was significantly higher in the group in which the prediction was 
correct, 21mm [P25-P75;14-27] versus 16mm [P25-P75;9.0-23](P<0.001). In the total study 
population and in subgroups sensitivity en specificity values were calculated from cross tabu-
lations (Table 4). The sensitivity to detect a proximal site of occlusion in the coronary artery 
in the total study population, in the subgroups anterior wall MI and extensive ST-segment 
deviation were 47%, 31% and 55%, respectively. The specificity to a proximal site of occlusion 
in the total study population, in the subgroups anterior wall MI and extensive ST-segment 
deviation were 57%, 67% and 55%, respectively.
Secondary analysis (Table 5)
Analysis of the ECG indicated the site of occlusion at the adjacent coronary segment in 55 
cases. Consequently, the culprit or the adjacent coronary segment was correctly indicated in 
75%. In case of a proximal occlusion the prediction of the exact coronary segment was correct 
in 80%. The median sum of ST-segment elevation was higher in the group in which the predic-
tion was correct, 15mm [P25-P75;10-22] versus 8.5mm [P25-P75;5.0-11](P=0.057). The median 
sum of ST-segment deviation was significantly higher in the group in which the prediction 
was correct, 20mm [P25-P75;14-27] versus 11 mm [P25-P75;6-18](P<0.001). The sensitivity 
in the total study population, in the subgroups anterior wall MI and extensive ST-segment 
deviation were 47%, 31% and 55%, respectively. The specificity in the total study population, 
in the subgroups anterior wall MI and extensive ST-segment deviation were 57%, 67% and 
55%, respectively.
table 5. Secondary analysis
Variable Total (%) Correct (%) No definite prediction
Anterior MI — no. (%) 105 (69) 85 (81) 17 (16)
Inferior MI — no. (%) 48 (31) 30 (63) 5 (10)
Total — no. (%) 153 (100) 115 (75) 22 (14)
Coronary Segment — no. (%)
1 19 (12) 17 (89) 1 (5)
5 or 6 54 (35) 44 (81) 10 (19)
11 6 (3,9) 2 (33) 3 (50)
All proximal lesions — no. (%) 79 (52) 63 (80) 14 (18)
MI = myocardial infarction; coronary segment classification according to the American Heart Association.16
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Time
There was no indication that the duration of ischemia was of influence. The median time from 
onset of symptoms to the ECG was 131 minutes (P25-P75;87-199), and not significantly differ-
ent in patients in which the prediction was incorrect (P=0.317). The median time from last ECG 
to first CAG was 61 minutes (P25-P75;27-95).
disCussion
Overall analysis of the ECG indicated the correct culprit coronary segment in 39% (60/153). In 
almost a quarter of the cases there was an underestimation of the area at risk. Consequently, 
in the total study population and in all subgroups the sensitivity and specificity values were 
low to detect a large area at risk due to a proximal location of coronary occlusion. If analysis 
of the ECG is confined to cases with extensive ST-segment deviation (>18mm) the sensitivity 
and specificity remained low, 55% and 59%, respectively. It appeared that the ECG is not an 
accurate diagnostic tool for exact prediction of site of occlusion in the infarct related coronary 
artery, that reflects the area at risk, even when interpreted by a cardiac electrophysiologist. 
However, the secondary analysis showed that in case the analysis of the ECG was incorrect the 
direct adjacent coronary segment was indicated as the culprit lesion in 35% (53/153) cases, 
leading to a 75% accurate prediction. It is clear that the ECG interpretation in combination 
with clinical presentation remains the investigation of choice for the diagnosis of acute MI. 
The current analysis showed that a considerable amount of patients with proximal lesions, 
responsible for a large area at risk, may not show distinct ST-segment elevations at the ECG. 
This may have implications for the choice of treatment e.g reperfusion therapy by thromboly-
sis or primary PCI versus non-invasive therapy. Especially in the case when a clinician must 
decide between thrombolysis or primary PCI underestimation of area at risk on ECG alone 
can lead to undertreatment. Therefore, analysis of the ECG should not be used to decide the 
treatment strategy in STEMI. 
The question remains why the analysis of the ECG scored suboptimal. In a large proportion 
of the cases (14%) the ECG did not show sufficient ST-segment elevation to make an accurate 
prediction of the exact site of occlusion. Despite the fact that the majority of patients included 
had a STEMI caused by a large area of jeopardized myocardium in a large epicardial vessel 
eligible for acute PCI. For accurate interpretation of the ECG it appears to be essential that 
there is sufficient ST-segment deviation. This can partly be explained by the dynamic occlu-
sions in case of a acute MI, which in a large proportion is caused by a thrombotic occlusion. In 
these cases a coronary vessel may not be totally occluded the entire time and collateral flow 
may also vary in time in the setting of an acute MI. In other patients a proximal coronary lesion 
causes embolization occluding a distal part of the coronary vessel. This is also indicated by the 
observation that although the inclusion ECG for the trials all showed significant ST-segment 
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elevation, the analyzed ECGs were not eligible for proper analysis in 16%, mainly because 
the ECG did not show enough ST-segment elevation (mainly in limb leads). This ST-segment 
resolution may reflect the dynamics of an epicardial occlusion and may indicate an effect of 
pharmacological treatment with aspirin, clopidogrel, heparin and in some cases glycoprotein 
IIb/IIIa receptor blockers routinely administered prior to CAG in case of a STEMI. It may also be 
hypothesized that ST-segment deviation decreases the longer ischaemia is present, although 
in this analysis the difference in time from onset of symptoms to ECG did not change out-
come.
Secondly, coronary anatomy is clearly not similar in every patient and this could very well 
be responsible for failure of localization by vector theory alone. This is especially important 
when trying to differentiate between the proximal LAD lesions, e.g. between segment 6 and 
7. Moreover, in 15 patients the first diagonal or septal branches were not comparable in size, 
thereby notably influencing the vector of ischemia.
Thirdly, it was recently shown by cardiac magnetic resonance imaging that the assumed 
coronary ECG correlations may vary greatly depending on size and dependent on morphol-
ogy of the thorax and positioning of the heart in the thorax.16
Limitations
Limitations of the current analysis is the retrospective nature of the trial and the amount of 
ECGs analyzed for different angiographic acute MI’s. In a several patients the data or ECGs 
were not unavailable for currents analysis, this may have led to bias. The inclusion of inferior 
wall MI’s was limited mainly due to unavailability of an ECG with V4R registration. Therefore, 
the results in from patients with inferior wall MI should be interpreted with some caution. 
However there is no reason to expect improved sensitivity or specificity values in inferior 
wall infarction in larger study populations. Because of the nature of the trials from which we 
collected data acute MI’s were limited to stentable culprit lesions with at least a 2,5mm stent. 
It is conceivable that this caused the finding of a majority of culprit lesions in proximal part 
of the coronary arteries and the LAD. The ECGs were analyzed by one electrophysiologist, 
however based on vector theory and algorhythms that were extensively described before. 
We didn’t measure the amount of collateral flow or the area at risk. Finally, angiographical 
determination of culprit lesion might not relate well to final infarct size or actual area at risk 
in all patients.
ConClusion
The ECG interpretation in combination with clinical presentation remains the investigation by 
choice for the diagnosis of acute myocardial infarction. In practice a single ECG appeared to 
be inaccurate for exact prediction of the infarct related coronary segment, hence a reflection 
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of the area at risk, even when interpreted by an electrophysiologist. Large areas at risk in acute 
MI can be accompanied by ECGs with small amounts of ST-segment deviation in a consider-
able amount of patients. The findings of this study underscore the importance of immediate 
coronary angiography in patients with the typical clinical presentation of acute myocardial 
infarction and any degree of ST-segment elevation.
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abstraCt
Background Primary percutaneous coronary intervention (PCI) with stent implantation 
demonstrated to be superior to both PCI with balloon angioplasty and to thrombolysis for 
acute ST-segment elevation myocardial infarction (STEMI). The use of glycoprotein (GP) IIb/
IIIa blockers in this setting may be beneficial. However, GP IIb/IIIa receptor blocker treatment 
is frequently accompanied by femoral entry site-related bleeding complications, resulting in 
additional morbidity and prolonged hospitalization. These complications are minimized by 
using the transradial approach (TRA).
Methods This study prospectively explored the feasibility of early discharge (within 4 days) 
following primary PCI with transradial stent implantation under GP IIb/IIIa blockade with 
tirofiban in the setting of STEMI. One-hundred patients with STEMI eligible for PCI were 
included.
Results Of these 100 patients, 62% received treatment according to the protocol, e. g., TRA, 
successful PCI with stent implantation, fulldose GP IIb/IIIa receptor blocker infusion and early 
discharge. The PCI was successful in 95%. Early discharge was achieved in 75 patients of the 
total study population. Major adverse cardiac and cerebral events (MACCE) did not occur in 
the early discharge group, with a 1-year event-free survival rate of 91%. The combined MACCE 
rates in the total study population at 1, 6, and 12 months were 8%, 15% and 20%, respec-
tively.
Conclusion Early discharge is feasible following primary PCI with stent implantation via the 
radial artery under GP IIb/IIIa blockade for STEMI, however a larger study is needed to prove 
the efficacy of this strategy.
introduCtion
Primary percutaneous coronary intervention (PCI) with stent implantation demonstrated 
to be superior to balloon angioplasty and thrombolysis in patients suffering from an acute 
ST-elevation myocardial infarction (STEMI) by reduction of the occurrence of major adverse 
cardiac (and cerebral) events (MACCE).1-3
In addition, recently the RAPPORT, ISAR-2, ADMIRAL and CADILLAC trials have documented 
further improvement in outcomes after primary PCI when abciximab is added to the regime.4-7 
Although to date not yet proven to be beneficial as an adjunct to PCI for STEMI, the widely-
used and cheaper GPIIb/IIIa receptor blocker, tirofiban, has shown to be beneficial in the set-
ting of unstable angina pectoris by reduction of thrombotic events.8,9 Moreover, the TARGET 
Trial demonstrated that long-term outcomes did not differ between abciximab and tirofiban 
in patients with unstable angina pectoris.10
49
Results of the AGGRASTENT trial
C
h
ap
te
r 
4
However, it is well recognized that predominantly entry site-related bleeding complications 
are a frequent companion of GP IIb/IIIa blocker treatment (12% in the ADMIRAL Trial), result-
ing in additional morbidity and prolonged hopitalization.11,12 By using the tranradial approach 
(TRA) for arterial access, local bleeding can be minimized.13 The applicability of the TRA for 
primary PCI with GP IIb/IIIa receptor blockers in STEMI has been described earlier.14-16 The 
TRA provides a safe and possibly favorable alternative to primary PCI via the transfemoral 
approach (TFA) and the TRA.14,17,18
Early discharge may be achieved by the combined strategy of early reperfusion resulting 
in reduction of infarct size, with concomitant reduction in complications (e. g., congestive 
heart failure), and the use of a safe entry site.19 Additionally, the treating physician benefits 
from the angiographically-acquired information on the patient’s coronary anatomy. Reduc-
tion of the patient’s hospital stay is not only generally well appreciated by patients, it also 
has advantages for the hospital and cardiology departments since it allows effective use of 
hospital capacity and resources.20 The present prospective trial was conducted in order to 
evaluate the feasibility of our strategy of early discharge after transradial stent implantation 
and GP IIb/IIIa blockade in the setting of STEMI.
methods
This clinical study was a prospective, open, nonrandomized, single-center study designed to 
assess the feasibility of early patient discharge after transradial stent implantation under GP 
IIb/IIIa blockade in the setting of STEMI. All interventions were executed by four high-volume 
operators experienced in interventions by the TRA. Written, informed consent was obtained 
from all participating patients before intervention. The study design and protocol were 
approved by the institutional ethics committee. 
Patient selection
Consecutive patients between 18 and 80 years of age with STEMI (≥20 minutes of chest pain 
and electrocardiographic (ECG) signs of STEMI (≥1 mV ST-segmentelevation in ≥2 contiguous 
leads) were included in the trial. Patients had to be eligible for primary PCI and treatment with 
GP IIb/IIIa receptor blockers. Both treatments had to be established within 6 hours of symptom 
onset. Exclusion criteria were: 1) history of intractable hypertension; 2) (failed) thrombolysis 
prior to PCI; 3) poor palpable radial pulse, e. g., cardiogenic shock; 4) contraindication to 
tirofiban, aspirin or clopidogrel; 5) participation in another clinical study interfering with this 
protocol.
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Medication
Following consent, the patient received tirofiban (Aggrastat, MSD) intravenously (IV) at the 
earliest possible moment after presentation at the hospital: 0.4 μg/kg/minute bolus of 30 
minutes followed by 0.1 μg/kg/minute up to 12 hours after the procedure. Patients with 
renal failure (screening serum creatinine >2.48 mg/dL) received 0.05 μg/kg/minute following 
the bolus injection. Patients not on daily aspirin received at least 300 mg orally before the 
intervention, and this was continued (100 mg once daily). As soon as possible, the patients 
were transferred to the catheterization laboratory. After sheath insertion, 10,000 IU of heparin 
and 900 mg aspegic were administered. The administration of verapamil or nitroglycerin in 
the radial artery was at the discretion of the operator. In the event of stent implantation, clopi-
dogrel was given at a loading dose of 300 mg after PCI followed by 75 mg/day for 4 weeks. 
Heparin infusion (1,000 IU/hour) was started 6 hours after the intervention and was continued 
for 12 hours in total, irrespective of APTT.
Angioplasty and stent implantation
The radial approach was used if the radial artery was palpable and the Allen’s test was positive. 
In all instances, 6 Fr guiding catheters were used. The insertion site for both the radial as well 
as the femoral approach were prepared before beginning the procedure in all patients in order 
to limit procedural time in case there was crossover from the radial to the femoral approach. 
The target coronary segment was projected in two orthogonal planes. Balloon dilatation and 
stent implantation were performed according to current practice.
Assessment of angiographical result
A final angiogram was made in the same views following a bolus of 100-200 μg intracoronary 
nitroglycerin. Quantitative coronary analysis (QCA) was performed. An optimal PCI result 
was defined as a diameter stenosis (DS) <50%, and improvement of TIMI flow of at least two 
grades, or TIMI flow grade 3.
Laboratory
After admission, total creatine phosphokinase (CK) and CK-MB were repeated every 6 hours 
(3-4 times). For infarct size estimation, the peak values of CK-MB and CK were used.
Hemostasis and sheath removal
Immediately following the procedure, the radial sheath was removed in all instances, followed 
by application of a compressing bandage which was removed 4 hours after termination of 
the tirofiban infusion. In cases where the transfemoral approach was used, the sheath was 
removed 4-6 hours after cessation of the heparin infusion, followed by application of com-
pressing bandage for 4-6 hours. Vascular closure devices were not used. 
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Discharge
Following a successful procedure, the “early” mobilization scheme was used19: Day 0: Bed rest, 
sitting up in bed. Day 1: Transfer from the coronary care unit to the cardiology ward. Sitting 
up. Personal hygiene (standing by the bedside). Day 2: Walking across the ward (up to 100 
meters). Day 3: Walking stairs (and up to 500 meters). End of day 3, or for logistic reasons, early 
morning of day 4: discharge. Reasons for prolonged hospital stay were recorded and scored: 
1) vascular access site complication; 2) heart failure requiring optimal therapy; 3) postinfarct 
angina; 4) occurrence of troublesome arrhythmias; 5) medical condition not related to cardiac 
illness; 6) social reasons, e. g., patients in poor social circumstances (dependant, poor mental 
status).
Safety and feasibility
Safety was assessed as the occurrence of major adverse cardiac and cerebral events (MACCE) 
and bleeding complications. MACCE included death of any cause, recurrent myocardial 
infarction (MI), repeat revascularization of any vessel or target vessel (TVR) by coronary artery 
bypass grafting (CABG) or PCI, recurrent angina or stroke (ischemic or hemorrhagic). Major 
bleeding was defined as any bleeding requiring blood transfusion or additional surgery, 
continuous bleeding or iatrogenic aneurysm of the entry site artery, or any HB drop >3.2 g/dL; 
minor bleeding was defined as any bleeding complication or hematoma not requiring blood 
transfusion or surgery. The following ranking scale was used: 1 = death; 2 = stroke; 3 = MI; 4 = 
CABG; 5 = PCI of target vessel; 6 = any PCI; 7 = CAG.
Follow-up
The day following discharge and one week after discharge, the patient was interviewed 
by telephone, and at 1, 3, 6 and 12 months, the patient visited the outpatient department 
according to routine protocol. If an outpatient visit was made at a referring center, data were 
retrieved. In the event that data were missing, information was obtained from the outpatient 
clinic’s charts and correspondence. 
Statistics
It was stated that with the proposed sample size of 100 consecutive patients, insight could 
be obtained on the eligibility for this investigational approach in a cohort of patients referred 
for primary PCI. Continuous data are presented as mean (±SD), in the event that there were 
skewed data in median values with quartiles (P25-P75). The degree of skewing of data was 
calculated with SPSS 11.5 for windows, with a cutoff point of skewing >1 or <-1.
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results
Baseline clinical characteristics
From October 1999 to February 2001, 100 patients were recruited who presented to the 
Amsterdam Department of Interventional Cardiology or were transferred for a primary PCI. 
The flow chart (Figure 1) illustrates the patients’ stratification according to the protocol’s pre-
defined steps. Sixty-two patients received full treatment according to the protocol. Baseline 
characteristics are shown in Table 1. The mean time from the start of chest pain to balloon 
procedure was 3.4 (SD ±1.1) hours.
Angiographic and procedural data
The angiographicaldata are summarized in Table 2. From the total study population, 89 
patients underwent a successful TRA (Figure 1). Of the remaining 11 patients, 3 were primarily 
approached via the femoral artery, and in 8 patients, radial access was not successful due to 
various reasons such as severe arterial spasm, marked tortuosity of the radial/brachial artery, 
anatomical anomalies and weak arterial pulse. Hence, these patients were treated via the 
femoral artery approach. The mean duration of the procedure was 35 minutes (SD ±19.6) and 
was not prolonged in patients in which it was necessary to cross over from the TRA to the TFA. 
Figure 1. Patient stratification according to the treatment protocol. TRA = transradial approach; TFA = transfemoral approach; PCI = 
percutaneous coronary intervention.
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Figure 1. 
 
Total 
n = 100 
TRA 
n = 89 
TFA 
n = 11 
Stent 
n = 85 
Successful PCI 
n = 82 
12 hr tirofiban 
n = 77 
Early discharge 
n = 62 
No success 
n = 3 
No tirofiban 
n = 5 
Prolonged 
n = 15 
No stent 
n = 4 
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Procedural data are shown in Table 3. Stent placement was successful in 96 patients (Figure 
1), stent sizes ranged from 2.5 to 4.0 mm in diameter and 12 to 29 mm in length. The median 
postprocedural stenosis, assessed by QCA, was 9.0% (quartiles 1.4-17.4%). Overall procedural 
success was achieved in 95 patients (95%)(Figure 1). Finally, 77 patients underwent successful 
PCI with transradial stent implantation followed by the full dose of tirofiban (Figure 1).
Hospital phase
The median (quartiles) infarct size estimated by the peak CK and CK-MB was 1,711 (759-3,630) 
U/L and 182 (84-346) U/L, respectively. Ninety-one patients received a continuous infusion 
of tirofiban for 12 hours (Figure 1). Two patients died within 12 hours due to the initial infarc-
tion, and thus did not receive the full dose of tirofiban. In the remaining 7 patients, tirofiban 
was discontinued because of bleeding complications. One of the patients in the TRA group 
experienced a significant access site complication (avulsion of the radial artery), which was 
treated conservatively. Two patients required blood transfusions for a HB-drop due to femoral 
entry site bleeding complications. None of the patients suffered a stroke (hemorrhagic or 
ischemic).
table 1. Baseline clinical characteristics
Characteristics Total
N = 100
Age (SD) 59 (14)
Hypercholesterolaemia 21
Hypertension 18
Peripheral vascular disease 4
Family history 32
Current smoker 57
Diabetes mellitus 8
Previous MI 9 
Q/non-Q-wave 2/7
Previous PCI 4
Previous CABG 1
MI on ECG
1-Anterior/ lateral/ anterolateral 69
2-inferior 10
3-true posterior 0
4-inferoposterior 21
5-associated RV-infarct 19
Pain-to-balloon in hours (SD) 3,4 (1,1)
MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; ECG: electrocardiogram; RV: right 
ventricle.
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table 2. Baseline angiographical data
Angiographical data Total
N = 100
Femoral primary 3
Femoral secondary 8
1-vessel disease 72
2-vessel disease 18
3-vessel disease 10
Infarct related artery
LM 1
LAD 62
RCX 4
RCA 31
SVG (on left coronary) 1
TIMI flow grade
0/1 75
2 13
3 12
Mean ref diameter (SD) 2,95 (0,58)
Median MLD (quartiles) 0,0 (0,0-0,39)
Median DS % (quartiles) 100 (87-100)
Visual thrombus 72
TRA: transradial approach; LM: left main; LAD: left anterior descending; RCX: ramus circumflexus; RCA: right coronary artery; SVG: saphenous 
venous graft; TIMI: Thrombolysis in Myocardial Infarction; Ref: reference; MLD: mean luminal diameter; DS: diameter stenosis.
table 3. Procedural parameters
Parameters Total
N = 100
Dissection 12
Stent 96
Mean size in mm (SD) 3,16 (0,34)
Mean length in mm (SD) 17,91 (4,78)
Post-stent dilatation 28
Additional stenting 30
TIMI flow grade
0/1 1
2 9
3 90
Procedural success 95
Mean ref diameter (SD) 3,09 (0,56)
Median MLD (quartiles) 2,80 (2,41-3,14)
Median DS% (quartiles) 9,03 (1,44-17,43)
TIMI: Thrombolysis in Myocardial Infarction; ref: reference; MLD: mean luminal diameter; DS: diameter stenosis.
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Discharge
Seventy-seven patients in the study population underwent a successful PCI with stent implan-
tation through the radial artery followed by 12 hours of tirofiban infusion. Fifteen of those 
patients could not be discharged within 4 days, despite a successful PCI (Figure 1), 1 because 
of a major vascular access site complication, 8 due to heart failure requiring inhospital treat-
ment, 3 due to recurrent anginal complaints, of which 1 eventually died, and 2 were referred for 
CABG. An additional 3 patients remained in the hospital due to social and logistical reasons. 
Follow-up
Early discharge (3-4 days after admission) was achieved in 75 patients of the total study 
population (Figure 1). The early clinical follow-up data on these early discharge patients are 
table 4. Short-term follow-up in early discharged patients.
Events Discharge to 1 day 1 day to 1 week 1 week to 1 month
N = 75 (%) N = 75 (%) N = 75 (%)
Problems 2 (3) 5 (7)
Reasons
1. vascular complication 0 0
2. angina 0 1 (1)
3. dyspnoe 2 (3) 3 (4)
4. death 0 0
5. stroke 0 0
6. other medical problems 0 1 (1)
7. social problems 0 0
Anginal class (CCS)
I/IV 62 (100) 58 (98) 72 (99)
II/IV 0 0 1 (1)
III/IV 0 1 (2) 0
IV/IV 0 0 0
No info 13 (17) 16 (21) 2 (3)
Sub-acute closure 0 0 0
Re-CAG 0 0 0
Repeat PCI 0 0 0
Target restenosis 0 0 0
Re-MI 0 0 0
CABG 0 0 0
Death 0 0 1 (1)
Stroke 0 0 0
Events = Ranked. In case of death no anginal status scored.
Re-CAG: recurrent coronary angiography; PCI: percutaneous coronary intervention; Re-MI: recurrent myocardial infarction; CABG: coronary artery 
bypass graft.
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shown in Table 4. Of those patients who were discharged early, 2 experienced minor problems 
(dyspnea) the first day after discharge. Five patients experienced minor problems within the 
first week after discharge, while none required additional treatment or additional analysis. 
The anginal classes of the patients according to the Canadian Cardiovascular Society (CCS) 
classification at 1 day, 1 week and 1 month were class I/IV in 100%, 98% and 99%, respectively. 
Clinical follow-up data are shown in Table 5. Of those patients who were discharged early 
after an uncomplicated hospital stay, the mortality rates at 1 month, 6 months and 1 year 
were 1%, 3%, and 3%, respectively. For combined MACCE, the rates at 1 month, 6 months and 
12 months for the patients who were discharged early were 1%, 5%, and 9%, respectively. 
Mortality rates (including hospital phase) in the total study population at 1 month, 6 months 
and 1 year were 4%, 5% and 6%, respectively. The combined MACCE rates in the total study 
population at 1, 6, and 12 months were 8%, 15% and 20%, respectively.
table 5a. Ranked follow-up (hospital phase included) in early discharged patients.
Events 1 month 6 months 12 months
N = 75 (%) N = 75 (%) N = 75 (%)
Sub-acute closure 0 0 0
Re-CAG 0 0 3 (4)
Repeat PCI 0 0 0
Repeat PCI of target vessel 0 2 (3) 2 (3)
Re-MI 0 0 2 (3)
CABG 0 0 1 (1)
Death 1 (1) 2 (3) 2 (3)
Stroke 0 0 0
Combined 1 (1) 4 (5) 7 (9)
table 5b. Ranked follow-up (hospital phase included) in total study population.
Events 1 month 6 months 12 months
N = 100 (%) N = 100 (%) N = 100 (%)
Sub-acute closure 0 0 0
Re-CAG 0 0 3
Repeat PCI 0 1 2
Repeat PCI of target vessel 2 4 4
Re-MI 1 2 4
CABG 1 2 3
Death 4 5 6
Stroke 0 1 1
Combined 8 15 20
Re-CAG: recurrent coronary angiography; PCI: percutaneous coronary intervention; Re-MI: recurrent myocardial infarction; CABG: coronary artery 
bypass graft.
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disCussion
TRA versus TFA This study demonstrates that the primary PCI using the TRA is feasible. Primary 
PCI using the TRA resulted in a high procedural success rate (96%) and few complications. 
However, the TFA was required in 11% of patients, most likely due to detrimental hemody-
namics and extensive use of nitroglycerin intravenously during STEMI.14 In the ACCESS study 
successful coronary cannulation was achieved in a similar percentage of patients (93%) using 
the TRA compared with 95.7% and 99.7% for the transbrachial and the TFA groups, respective-
ly.13 More recent (unpublished) data show higher success rates, increasing with experience. 
GP IIb/IIIa blockers GP IIb/IIIa receptor blockage is beneficial in patients undergoing a pri-
mary PCI for STEMI, especially in terms of reducing repeat revascularization rates.5 The recent 
ADMIRAL Trial demonstrated a reduction in events with abciximab, mainly due to a reduction 
in events in the first week.5 Thus far, however, the expected benefit of GP IIb/IIIa receptor 
blockade with tirofiban for this indication is of unproven, but perceivable benefit.9,10 In addi-
tion, the dose regime for patients undergoing STEMI remains uncertain. The use of a GP IIb/
IIIa receptor blocker in combination with primary PCI and stent implantation has also demon-
strated improved myocardial salvage rates.21 Furthermore, it was recently demonstrated that 
tirofiban infusion improved microperfusion in the setting of primary PCI for STEMI.22
Mann et al. showed that with the use of the TRA in acute coronary syndromes, bleeding 
complications were lower compared to the TFA.17 The current study showed that the bleed-
ing complications were low despite additional GP IIb/IIIa receptor blockade usage. Bleeding 
rates with TRA were slightly lower compared to TFA in the ADMIRAL Trial in which 12% of the 
patients treated with a GP IIb/IIIa receptor blocker experienced minor bleeding (including 
groin in 6%), and 0.7% experiencedmajor bleeding.5 In the current trial, 2% of the study popu-
lation suffered a major bleeding event, and 9% a minor bleeding event; in the TRA group, 1 
major vascular access site complication occurred, no major bleeding events, and only 5 (5.6%) 
minor bleeding complications occurred. It should be noted, however, that we used a different 
GP IIb/IIIa receptor blocker with a different dose regimen for heparin infusion [10,000 IE bolus 
followed by 1,000 IE per hour, irrespective of the patient’s activated clotting time (ACT) versus 
ACT-monitored heparin dosing]. In this study, major access site-related bleeding complica-
tions were observed in 2 TFA patients (18%).
Early discharge This study demonstrated that the combination of strategies, early revas-
cularization with stenting and use of the TRA under GP IIb/IIIa receptor blockade, allowed 
early mobilization and early discharge. The inhospital mortality rate after STEMI was low (2%) 
compared to the Euro Heart Survey ( 7%).22 Overall mortality and MACCE at 1 month (4% and 
8%) in our group was also low compared to the Euro Heart Survey (1 month 8.4% mortality) 
and ADMIRAL Trial (in GP IIb/IIIa group 6% mortality at 1 month), but relatively high com-
pared with the CADILLAC Trial’s stent plus abciximab group.5,7,23 At 6 months, the mortality 
and MACCE rates were 5% and 15%, respectively, and were similar to those of the CADILLAC 
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(4.2% and 10.2%) and ADMIRAL (mortality 7.4%) results.5,7 Clinical adverse events remained 
low throughout the year (mortality 6% and MACCE 20%). It is worth noting that the mean 
CK-MB peak was 228 IU/L. Early discharge after primary angioplasty (via TFA) is safe for STEMI 
in low-risk patients.18,20,24 It should be noted, however, that 31% of the patients in the current 
study were ≥70 years, the percentage of anterior MIs was high (69%), and 28% of patients had 
angiographically-confirmed multivessel disease, resulting in higher risk for MACCE. None of 
our study patients suffered an adverse event within the first week after discharge, indicating 
that prolonged hospitalization (>4 days) would not result in better patient care in terms of 
adverse events in this STEMI patient group. Whether early discharge was due to the use of the 
TRA remains unproven and should be evaluated in a randomized trial. However, reduction of 
entry site complications with the use of the TRA may well have limited hospital stay. This is 
supported by the results from the randomized TEMPURA Trial and the large EPIC and EPISTENT 
trials, in which major bleeding complications were largely attributable to vascular access site 
complications, consequently resulting in prolonged hospital stays.12,18,25
Limitations
A single-center trial has its limitations and biases, and a relatively small population was studied, 
thus the results should be viewed with caution. However, in demonstrating the feasibility of 
our approach, it provides valuable information. Tirofiban was chosen although abciximab, at 
the time of the study’s launch, was shown to be more effective. However, the 6-month results 
of the TARGET Trial demonstrate that despite the fact that a different dosage of tirofiban was 
used, tirofiban provided a similar level of overall protection compared to abciximab with 
respect to the composite endpoints of death, MI, and any TVR.10 Furthermore, we realize that 
the protocol we used is not fully applicable to every clinic, since our interventional cardiologists 
are high-volume operators and our personnel and infrastructure are dedicated to the TRA.
ConClusion
In summary, the present investigation suggests that the TRA allows early discharge after 
primary PCI in combination with GP IIb/IIIa receptor blocker treatment and an uncomplicated 
hospital course, although a larger randomized study is needed to prove efficacy. Current prac-
tice. Currently, the majority of our patients undergoing primary PCI for STEMI are treated rou-
tinely according to the described protocol in the event of an uncomplicated hospital course. 
The majority of our patients are treated with the TRA and stent implantation in combination 
with GP IIb/IIIa receptor blockade followed by discharge within 3 to 4 days. Although early 
discharge proved to be feasible in this setting, current practice teaches that there is a need 
for an outpatient clinic visit or an intensive rehabilitation program within the first few weeks 
after hospital discharge.
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abstraCt
Background Drug-eluting coronary-artery stents have been shown to decrease restenosis 
and therefore the likelihood that additional procedures will be required after percutaneous 
coronary intervention (PCI). We evaluated the use of a drug-eluting stent in patients undergo-
ing PCI for acute myocardial infarction with ST-segment elevation.
Methods We randomly assigned 619 patients presenting with an acute myocardial infarction 
with ST-segment elevation to receive either a paclitaxel-eluting stent or an uncoated stent. 
The primary end point was a composite of death from cardiac causes, recurrent myocardial 
infarction, or target-lesion revascularization at 1 year.
Results Baseline clinical and angiographic characteristics in both groups were well matched. 
There was a trend toward a lower rate of serious adverse events in the paclitaxel-stent 
group than in the uncoated-stent group (8.8% vs. 12.8%; adjusted relative risk, 0.63; 95% 
confidence interval, 0.37 to 1.07; P=0.09). A nonsignificant trend was also detected in favor of 
the paclitaxel-stent group, as compared with the uncoated-stent group, in the rate of death 
from cardiac causes or recurrent myocardial infarction (5.5% vs. 7.2%, P=0.40) and in the rate 
of target-lesion revascularization (5.3% vs. 7.8%, P=0.23). The incidence of stent thrombosis 
during 1 year of follow-up was the same in both groups (1.0%).
Conclusions Although the use of paclitaxel-eluting stents in acute myocardial infarction with 
ST-segment elevation reduced the incidence of serious adverse cardiac events at 1 year by 
4.0 percentage points, as compared with uncoated stents, the difference was not statistically 
significant. (Current Controlled Trials number, ISRCTN65027270.)
introduCtion
Primary percutaneous coronary intervention (PCI) is now considered the optimal approach 
to the management of myocardial infarction with ST-segment elevation when the procedure 
is performed expeditiously and at a high-volume center.1-5 Stent implantation is associated 
with an improvement in both early and late outcomes, as compared with balloon angioplasty 
alone, predominantly as a result of a reduction in target-vessel revascularization.6,7 Further-
more, drug-eluting stents have been shown to reduce in-stent restenosis (and therefore the 
need for repeated intervention) in a number of subgroups of patients.8,9 Retrospective studies 
and one small, randomized trial have suggested that the use of drug-eluting stents is also 
beneficial in the setting of primary PCI.10-13 We aimed to determine whether paclitaxel-eluting 
stents are superior to uncoated stents in the setting of primary PCI in terms of the rate of 
serious adverse cardiac events at 1 year.
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methods
Study design
Our prospective, single-blind, randomized study, called the Paclitaxel-Eluting Stent versus 
Conventional Stent in Myocardial Infarction with ST-Segment Elevation (PASSION) trial, was 
performed at two centers in the Netherlands (Onze Lieve Vrouwe Gasthuis in Amsterdam 
and St. Antonius Hospital in Nieuwegein). The trial was entirely funded by the Department 
of Interventional Cardiology at Onze Lieve Vrouwe Gasthuis and was approved by the ethics 
committees at both institutions. All study participants provided oral informed consent, which 
was documented in the patients’ clinical records. This approach to informed consent was 
explicitly approved by the ethics committee at each center. 
Enrollment of patients
We enrolled patients who were between the ages of 18 and 80 years if they had had an acute 
myocardial infarction with ST-segment elevation (>20 minutes of chest pain and at least 1 mm 
of ST-segment elevation in at least two contiguous leads or a new left bundle-branch block), 
reperfusion was expected to be achieved within 6 hours after the onset of symptoms, and the 
native coronary artery was considered to be suitable for primary PCI with stent implantation. 
We excluded patients if they had received thrombolytic therapy; the infarction was caused by 
in-stent thrombosis or restenosis; there was a contraindication to aspirin, clopidogrel, or both; 
patients were participating in another clinical trial; cardiogenic shock was evident before ran-
domization; the neurologic outcome after resuscitation was uncertain; they had undergone 
intubation, ventilation, or both; there was known intracranial disease; or the estimated life 
expectancy was less than 6 months.
Procedures
We administered aspirin (at a dose of 100 to 500 mg) and clopidogrel (300 mg) when patients 
first arrived at the hospital. A glycoprotein IIb/IIIa receptor blocker was administered at the 
discretion of the operator. A bolus of 10,000 IU of unfractionated heparin was administered 
before the procedure.
Coronary angiography was performed through either the radial or the femoral artery. 
The target segment was filmed in at least two orthogonal planes after the intracoronary 
administration of 100 to 200 μg of nitroglycerin; quantitative coronary angiography was then 
performed. The use of thrombectomy devices and predilatation balloons was at the operators’ 
discretion.
As soon as the length and diameter of the stent had been chosen, patients were randomly 
assigned to receive either a paclitaxel-eluting stent (Taxus Express2, Boston Scientific) or an 
uncoated stent (Express2 or Liberté, Boston Scientific) in a 1:1 ratio, with the use of permuted 
blocks of 50. Assignment to study groups was performed with the use of sealed envelopes. 
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Patients, referring physicians, investigators responsible for obtaining follow-up information, 
and interventionalists performing repeated procedures were all unaware of treatment assign-
ments.
Stents were deployed with a minimum pressure of 12 atm. If dissection or incomplete 
coverage of the lesion occurred, additional stents of the same type as the assigned stent 
were used. Final angiography was performed to obtain views similar to those obtained 
before the procedure. Epicardial blood flow in the infarct-related artery before and after stent 
implantation was determined according to the Thrombolysis in Myocardial Infarction (TIMI) 
classification.14
Follow-up
We prescribed 80 to 100 mg of aspirin daily for life and 75 mg of clopidogrel daily for at least 6 
months. During each patient’s hospital stay, we recorded all adverse events; during follow-up 
visits at 30 days and at 12 months, we recorded all serious adverse cardiac events (death from 
cardiac or noncardiac causes, recurrent myocardial infarction, revascularization of the target 
lesion or target vessel, and coronary-artery bypass grafting [CABG]), as well as interventions 
to nontarget vessels.
Study end points and definitions
Drs. Laarman and Suttorp adjudicated all end points of the study in a blinded fashion. The 
primary end point was the first occurrence of a serious adverse cardiac event at 12 months, 
including death from cardiac causes, recurrent myocardial infarction requiring hospitaliza-
tion, and ischemia-driven revascularization of a target lesion. The secondary end points of the 
study were revascularization of a target lesion and a composite of death from cardiac causes 
or recurrent myocardial infarction. 
All deaths were considered to have been from cardiac causes unless a noncardiac cause 
could be identified. Recurrent myocardial infarction was defined by the development of either 
pathological Q waves lasting at least 0.4 second in at least two contiguous leads or an increase 
in the creatine kinase level to more than twice the upper limit of normal with an elevation of 
the creatine kinase MB isoenzyme. A creatine kinase level of more than five times the upper 
limit of normal was required for the diagnosis of myocardial infarction after bypass surgery. 
Patients who still had an elevation in cardiac enzymes received a diagnosis of reinfarction if 
there was an increase of at least 50% from the previous measurement.
Revascularization of the target lesion was defined as ischemia-driven PCI of the target lesion 
owing to restenosis or reocclusion within the stent or in the adjacent 5 mm of the distal or 
proximal segments and included CABG involving the infarct-related artery. Stent thrombosis 
was defined by the angiographic documentation of either vessel occlusion or thrombus 
formation within, or adjacent to, the stented segment. Stent thrombosis was categorized as 
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acute (occurring within 24 hours after the procedure), subacute (occurring 1 to 30 days after 
the procedure), or late (occurring more than 30 days after the procedure).
Statistical analysis
We calculated that a total of 262 patients would be required in each group, using a two-sided 
test for differences in independent binomial proportions with an alpha level of 0.05, for the 
study to have a statistical power of 90% to detect a reduction in the primary end point from an 
anticipated event rate of 21.7% in the uncoated-stent group to 10.9% in the paclitaxel-stent 
group, a relative reduction of approximately 50%. This assumption was based on the results of 
the TAXUS-II trial of the Taxus Express2 paclitaxel-eluting stent.15 Given the differences in the 
nature and design of that study and our study (primary vs. elective PCI and no angiographic 
follow-up), 10% was added to the number of patients. Allowing for attrition, the required 
study population was determined to be 620 patients.
Baseline data are presented as proportions or mean (±SD) values and were compared with 
the use of Student’s t-test or the Wilcoxon rank-sum test for continuous variables and with 
Fisher’s exact test for categorical variables. A two-sided P value of less than 0.05 was consid-
ered to indicate statistical significance.
We estimated the cumulative incidence rates of the primary and secondary end points at 
1 year with the Kaplan-Meier method.16 Data on patients who were lost to follow-up were 
censored at the time of the last contact. Relative risks were calculated by dividing the Kaplan-
Meier estimated rate of an event at 1 year in the paclitaxel-stent group by the rate in the 
uncoated-stent group. The 95% confidence interval (CI) for the relative risk was calculated 
with the use of the standard errors from the Kaplan-Meier curve. The significance of differ-
ences in rates of the end points between treatment groups was assessed by the log-rank test. 
A Cox proportional-hazards model was used to adjust for baseline variables for calculation of 
an adjusted relative risk for the primary end point.
results
Baseline characteristics and procedural results
We screened 1037 patients who had myocardial infarction with ST-segment elevation at 
the two sites between March 28, 2003, and December 31, 2004. Of these patients, 619 were 
enrolled in the study; 310 were randomly assigned to the paclitaxel-stent group and 309 to 
the uncoated-stent group. The most common reasons for exclusion from the trial were an 
anticipated delay of more than 6 hours between the onset of symptoms and reperfusion, coro-
nary anatomy that was not suitable for stent implantation, cardiogenic shock, and mechanical 
ventilation. The baseline clinical characteristics of both groups were well matched (Table 1). 
The mean age was 61 years; 75.9% of the patients were men. The prevalence of diabetes 
Chapter 5
68
mellitus was low (11.0%). All patients received aspirin and clopidogrel before percutaneous 
coronary intervention. The time from the onset of symptoms to the first balloon inflation was 
approximately 3 hours in both groups. 
The baseline angiographic characteristics are shown in Table 2. Approximately half the 
patients had multivessel disease, and in 50.1% of the cases, the left anterior descending 
coronary artery was the infarct-related artery. TIMI flow grade 2 or 3 was present in 29.3% of 
patients in the paclitaxel-stent group and in 28.4% in the uncoatedstent group. The majority 
of patients had an estimated lesion length between 10 mm and 19 mm. The mean reference 
diameter was 3.13±0.43 mm in the paclitaxel-stent group and 3.20±0.47 mm in the uncoated-
stent group.
The procedural characteristics were also well matched (Table 3). The average length of 
stents was 19 mm in both groups. Glycoprotein IIb/IIIa receptor blockers were used in three 
table 1. Baseline Clinical Characteristics.*
Characteristics Paclitaxel-Eluting Stent Uncoated Stent P-value
N = 310 N = 309
Age — yr 61±12 61±13 0.91
Male sex — (%) 229 (74) 241 (78) 0.26
Diabetes mellitus — (%) 31 (10) 37 (12) 0.44
Hypertension —(%) 95 (31) 98 (32) 0.80
Hypercholesterolemia —(%) 72 (23) 86 (28) 0.20
Family history of CAD —(%) 125 (40) 110 (36) 0.25
History of smoking cigarettes —(%) 165 (53) 154 (50) 0.42
Previous PCI —(%) 14 (4.5) 13 (4.2) 1.00
Previous stent — (%) 5 (1.6) 6 (1.9) 0.77
Previous CABG — (%) 2 (0.6) 2 (0.6) 1.00
Previous myocardial infarction — (%) 14 (4.5) 18 (5.8) 0.48
Aspirin before PCI — (%)† 219 (71) 199 (64) 0.10
Clopidogrel before PCI — (%)† 118 (38) 109 (35) 0.50
Warfarin — (%) 4 (1.3) 2 (0.6) 0.69
Heparin before PCI — (%)† 67 (22) 54 (18) 0.22
Glycoprotein IIb/IIIa–receptor blocker (abciximab) before PCI — 
(%)
87 (28) 80 (26) 0.59
Thrombolysis — (%)‡ 8 (2.6) 3 (1.0) 0.22
Nitrates before PCI — (%) 67 (22) 67 (22) 1.00
Beta-blockers — (%) 27 (8.7) 31 (10) 0.58
Calcium antagonists — (%) 10 (3.2) 8 (2.6) 0.81
Statins — (%) 25 (8.1) 42 (14) 0.03
Time from onset of chest pain to angioplasty — hr 3.00±1.70 2.97±1.80 0.86
Total ST-segment elevation — mm§ 11±8 11±9 0.76
* Plus–minus values are means ±SD. CAD denotes coronary artery disease. † The drug was administered at presentation (before entry into the 
catheterization laboratory). All patients received aspirin and clopidogrel before PCI; those who had not received these agents before entry into 
the catheterization laboratory were given them at that time. ‡ A total of 11 patients received a thrombolytic agent before undergoing PCI, which 
was considered a protocol violation. § This category is the total of measured millimeters of ST-segment elevation in all 12 electrocardiographic 
leads.
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quarters of both groups (abciximab in all cases). TIMI grade 3 flow was established in 93.2% 
of patients in the paclitaxel-stent group, as compared with 96.1% of patients in the uncoated-
stent group. The sizes of infarcts, reflected by the mean peak value of the creatine kinase MB 
isoenzyme, were similar (193±183 in the paclitaxel-stent group and 210±186 in the uncoated-
stent group).
Events during the first 30 days
Events during the first 30 days after the intervention are shown in Table 4 and in Tables 1 
through 9 of the Supplementary Appendix (available with the full text of this article at www.
nejm.org). No significant differences were found between the two treatment groups. The 
cumulative incidence of serious adverse cardiac events at 30 days was 4.2% in the paclitaxel-
stent group and 6.5% in the uncoated-stent group (P=0.21). Acute stent thrombosis (within 24 
table 2. Baseline Angiographic Variables.*
Variable Paclitaxel-Eluting Stent
(N = 310)
Uncoated Stent
(N = 309)
P-value
Coronary artery disease — no. (%)
1 Vessel 179 (58) 162 (52) 0.20
2 Vessels 82 (27) 100 (32) 0.11
3 Vessels 49 (16) 47 (15) 0.91
Infarct-related artery — no. (%)
Left main stem 2 (0.6) 0 0.50
Left anterior descending artery 156 (50) 154 (50) 0.94
Right coronary artery 129 (42) 118 (38) 0.41
Left circumflex artery 18 (5.8) 32 (10) 0.04
Intermediate branch 3 (1.0) 4 (1.3) 0.72
Saphenous-vein graft 2 (0.6) 1 (0.3) 1.00
TIMI flow grade — no. (%)
0 193 (62) 196 (63) 0.80
1 26 (8.4) 25 (8.1) 1.00
2 41 (13) 48 (16) 0.42
3 50 (16) 40 (13) 0.30
Lesion length — no. (%)
0–9 mm 41 (13) 48 (16) 0.49
10–19 mm 201 (65) 188 (61) 0.36
20–29 mm 50 (16) 52 (17) 0.83
≥30 mm 18 (5.8) 21 (6.8) 0.62
Proximal tortuosity — no. (%) 17 (5.5) 17 (5.5) 1.00
Calcified lesion — no. (%) 28 (9.0) 19 (6.1) 0.22
Thrombus present — no. (%) 213 (69) 204 (66) 0.49
Reference diameter — mm 3.13±0.43 3.20±0.47 0.04
Mean luminal diameter — mm 0.15±0.35 0.17±0.38 0.60
Stenosis — % 95±13 94±15 0.48
* Plus–minus values are means ±SD.
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table 3. Procedural Characteristics.*
Variable Paclitaxel-Eluting Stent
(N = 310)
Uncoated Stent
(N = 309)
P-value
Stent size — mm 3.21±0.30 3.26±0.38 0.08
Stent length — mm 19±5.6 19±5.5 0.71
No. of stents implanted per patient 1.26±0.55 1.33±0.63 0.14
Maximal balloon inflation pressure — atm 15.84±2.94 15.73±2.94 0.70
Glycoprotein IIb/IIIa–receptor blocker after PCI — (%) 227 (73.2) 230 (74.4) 0.78
Final TIMI flow grade — (%)
0 2 (0.6) 3 (1.0) 0.69
1 2 (0.6) 2 (0.6) 1.00
2 17 (5.5) 7 (2.3) 0.06
3 289 (93) 297 (96) 0.15
Reference diameter — mm 3.20±0.46 3.24±0.45 0.26
Luminal diameter — mm 3.15±0.47 3.13±0.57 0.66
Residual stenosis — % 3.03±6.6 4.66±12.1 0.04
Procedural success — (%)† 289 (93) 297 (96) 0.15
Maximum creatine kinase — U/liter 2046±2055 2244±2061 0.26
Maximum creatine kinase MB — U/liter 193±183 210±186 0.30
* Plus–minus values are means ±SD. 
† Patients in this category had TIMI flow grade 3 and were alive at hospital discharge.
Figure 1. Composite Primary End Point of Death from Cardiac Causes, Recurrent Myocardial Infarction, or Target-Lesion Revascularization at 1 
Year. The cumulative incidence of the primary end point of serious adverse cardiac events was 8.8% in the paclitaxel-stent group and 12.8% in 
the uncoated-stent group (relative risk, 0.69; 95% CI, 0.43 to 1.10; P = 0.12 by the logrank test).
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coated-stent group than in those reported previ-
ously.
The results of our study also differ from a 
series of retrospective analyses and one small, 
randomized trial evaluating the implantation of 
drug-eluting stents for myocardial infarction with 
ST-segment elevation.10-13 Subgroup analysis of 
patients undergoing PCI with sirolimus-eluting 
stents for myocardial infarction in the Thoraxcen-
ter Research Registry showed that the rate of 
serious adverse cardiac events at 300 days was 
reduced from 17.0% to 9.4% (P = 0.02).11 This pat-
tern was repeated in a retrospective analysis from 
the Washington Hospital Center using the same 
stent type.12 In the Single High-Dose Bolus Tiro-
fiban and Sirolimus-Eluting Stent vs. Abciximab 
and Bare-Metal Stent in Myocardial Infarction 
(STRATEGY) trial involving 175 patients, the rate 
of death, reinfarction, or target-vessel revascular-
ization at 8 months was reduced from 32% with 
an uncoated stent to 18% with a sirolimus-elut-
ing stent.13 These event rates are among the high-
est reported for any trial of PCI, and the reasons 
for the high event rates are not entirely clear, al-
though most of the patients in the STRATEGY 
trial underwent routine follow-up angiography 
and the mean reference-vessel diameter was con-
siderably smaller than that in our trial. An addi-
tional feature of the STRATEGY trial was that by 
design, a different glycoprotein IIb/IIIa inhibitor 
was used in the two study groups, which con-
founded the interpretation of the comparison be-
tween the two types of stents.
We did not observe a difference in the rates of 
stent thrombosis between our two study groups, 
although the definition of stent thrombosis was 
conservative (since angiographic documentation 
was required). Acute or subacute stent throm-
bosis occurred in two patients (0.6%) in the pac-
litaxel-stent group and three patients (1.0%) in 
the uncoated-stent group. This incidence is low, 
given the thrombotic environment at the time of 
stent placement, the potential for suboptimal 
stent deployment in the setting of PCI for acute 
myocardial infarction, and decreased blood flow 
in a vessel that supplies infarcted myocardium. In 
a recent retrospective study from the Thoraxcen-
ter, the incidence of stent thrombosis at 1 month 
(which was also defined on the basis of angi-
ography) after primary PCI with the use of a pac-
litaxel-eluting stent was 2.9%.17 We also found 
no evidence of an increase in the rate of late stent 
thrombosis, a topic that has recently caused con-
cern.18
In this issue of the Journal, a report on the Trial 
to Assess the Use of the Cypher Stent in Acute 
Myocardial Infarction Treated with Balloon Angio-
plasty (TYPHOON) by Spaulding et al.19 compares 
sirolimus-eluting stents with uncoated stents in 
primary PCI among 712 patients. The investiga-
tors report a significant difference in the primary 
end point (the composite of death from cardiac 
causes, recurrent infarction, and target-vessel re-
vascularization at 1 year) in favor of sirolimus-
eluting stents, as compared with uncoated stents 
(7.3% vs. 14.3%, P = 0.004). Differences between 
the two trials — including the type of drug-elut-
ing stent used, the study design (routine follow-up 
angiography was performed in a subgroup of pa-
tients in TYPHOON), primary end points, and in-
clusion and exclusion criteria — make it difficult 
to compare the outcomes of our trial with those 
of TYPHOON. It is worth noting, however, that 
the event rates in the two groups of patients in 
TYPHOON are not markedly different from those 
in our analysis.
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Figure 1. Composite Primary End Point of Death from Cardiac Causes, Re-
current Myocardial Infarction, or Target-Lesion Revascularization at 1 Year.
The cumulative incidence of the primary end point of serious adverse cardi-
ac events was 8.8% in the paclitaxel-stent group and 12.8% in the uncoat-
ed-stent group (relative risk, 0.69; 95% CI, 0.43 to 1.10; P = 0.12 by the log-
rank test). 
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hours) occurred in one patient (0.3%) in the paclitaxel-stent group. Subacute stent thrombosis 
occurred in one patient (0.3%) in the paclitaxel-stent group and in three patients (1.0%) in the 
uncoated-stent group. 
1-Year follow-up
A total of 97.4% of patients in the paclitaxel-stent group and 98.1% of those in the uncoated-
stent group underwent complete clinical follow-up. Events during the first year after the inter-
vention are shown in Table 4 and in Tables 10 through 18 of the Supplementary Appendix. 
The cumulative incidence of the primary end point was 8.8% in the paclitaxel-stent group 
and 12.8% in the uncoated-stent group (relative risk, 0.69; 95% CI, 0.43 to 1.10; P=0.12) (Fig. 
1 and Table 4). Multivariate adjustment (which incorporated all the variables in Table 1, Table 
2, and Table 3) did not substantially alter the estimate of the relative risk (relative risk, 0.63; 
95% CI, 0.37 to 1.07; P=0.09). The secondary end points are also shown in Table 4. Although 
trends were observed in favor of the paclitaxel-stent group, none of these differences were 
significant.
table 4. Follow-up at 30 Days and 1 Year.*
Variable Paclitaxel-Eluting Stent
N = 310 (%)
Uncoated Stent
N = 309 (%)
P-value
Follow-up at 30 days
Complete data available 308 (99) 306 (99)
Target-lesion revascularization 7 (2.3) 9 (3.0) 0.60
Recurrent myocardial infarction or death from cardiac causes 10 (3.2) 15 (4.9) 0.31
Composite of major adverse cardiac events 13 (4.2) 20 (6.5) 0.21
Death from any cause 8 (2.6) 13 (4.2) 0.27
Death from cardiac causes 8 (2.6) 13 (4.2) 0.27
Recurrent myocardial infarction 2 (0.7) 5 (1.7) 0.25
Stent thrombosis 2 (0.7) 3 (1.0) 0.65
Repeated PCI of target lesion 2 (0.7) 3 (1.0) 0.65
CABG of target vessel 6 (2.0) 6 (2.0) 0.99
Follow-up at 1 year
Complete data available 302 (97) 303 (98)
Target-lesion revascularization 16 (5.3) 23 (7.8) 0.23
Recurrent myocardial infarction or death from cardiac causes 17 (5.5) 22 (7.2) 0.40
Composite of major adverse cardiac events 27 (8.8) 39 (13) 0.12
Death from all causes 14 (4.6) 20 (6.5) 0.30
Death from cardiac causes 12 (3.9) 19 (6.2) 0.20
Recurrent myocardial infarction 5 (1.7) 6 (2.0) 0.74
Stent thrombosis 3 (1.0) 3 (1.0) 0.99
Repeated PCI of target lesion 6 (2.0) 10 (3.4) 0.29
CABG of target vessel 10 (3.3) 15 (5.1) 0.30
* Cumulative incidences were estimated from the Kaplan–Meier curves at 30 days and 1 year and are not simple proportions.
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Late stent thrombosis occurred in one patient (0.3%) in the paclitaxel-stent group and in 
none in the uncoated-stent group, a difference that was not significant. Clopidogrel was used 
for a median of 9 months (interquartile range, 6 to 12) in both groups; nine patients discontin-
ued clopidogrel prematurely. None of these patients had a thrombotic event. The six patients 
with stent thrombosis were all compliant with the specified regimen at the time of the event.
disCussion
Our study compared paclitaxel-eluting coronary artery stents with uncoated stents for primary 
PCI during acute myocardial infarction with ST-segment elevation. The cumulative incidence 
of the primary end point - a composite of death from cardiac causes, recurrent myocardial 
infarction, and target-lesion revascularization at 12 months - was 8.8% in the paclitaxel-stent 
group and 12.8% in the uncoated-stent group. The adjusted risk ratio was 0.63, which was 
not statistically significant. There was also a trend in favor of the paclitaxel-stent group in the 
rates of individual adverse events, but no single end point reached statistical significance. In 
contrast, trials comparing these two types of stents in elective PCI have consistently showed a 
significant benefit associated with the use of paclitaxel-eluting stents.8,9
There are a number of possible explanations for the difference between the results of this 
trial and those of previous studies. First, the trial power may have been insufficient. Event rates 
in the uncoated-stent group were much lower than those anticipated in our power calcula-
tions. The point estimate of the difference in the primary end point, if accurate, is clinically sig-
nificant; a larger trial could have demonstrated statistical significance. However, the estimated 
relative reduction of serious adverse cardiac events by 31% is considerably smaller than that 
observed in previous trials with drug-eluting stents. This finding has consequences for the 
cost–benefit profile of these stents for the indication of primary PCI.8-13 Second, the study 
design did not include angiographic follow-up. Recurrent stenosis observed during routine 
follow-up angiography could have led to reintervention without symptoms or objective evi-
dence of ischemia, thus increasing the event rate. In addition, after PCI for myocardial infarc-
tion, restenosis may have developed in some patients in the absence of ischemic symptoms, 
owing either to partial infarction or to a defective warning system. Third, there may have been 
a difference in response to vascular injury in the setting of primary PCI, as compared with that 
of more elective procedures. The literature, however, shows that angiographic and clinical 
restenosis after primary PCI remains an important issue.6,7 Fourth, the study was performed 
in patients with relatively large infarct-related arteries in which there was a decreased risk of 
restenosis. Finally, continuing improvements in the design of stents and the lower thickness 
of struts may have been responsible for lower rates of restenosis in the uncoated-stent group 
than in those reported previously.
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The results of our study also differ from a series of retrospective analyses and one small, 
randomized trial evaluating the implantation of drug-eluting stents for myocardial infarction 
with ST-segment elevation.10-13 Subgroup analysis of patients undergoing PCI with sirolimus-
eluting stents for myocardial infarction in the Thoraxcenter Research Registry showed that the 
rate of serious adverse cardiac events at 300 days was reduced from 17.0% to 9.4% (P=0.02).11 
This pattern was repeated in a retrospective analysis from the Washington Hospital Center 
using the same stent type.12 In the Single High-Dose Bolus Tirofiban and Sirolimus-Eluting 
Stent vs. Abciximab and Bare-Metal Stent in Myocardial Infarction (STRATEGY) trial involving 
175 patients, the rate of death, reinfarction, or target-vessel revascularization at 8 months was 
reduced from 32% with an uncoated stent to 18% with a sirolimus-eluting stent.13 These event 
rates are among the highest reported for any trial of PCI, and the reasons for the high event 
rates are not entirely clear, although most of the patients in the STRATEGY trial underwent 
routine follow-up angiography and the mean reference-vessel diameter was considerably 
smaller than that in our trial. An additional feature of the STRATEGY trial was that by design, a 
different glycoprotein IIb/IIIa inhibitor was used in the two study groups, which confounded 
the interpretation of the comparison between the two types of stents.
We did not observe a difference in the rates of stent thrombosis between our two study 
groups, although the definition of stent thrombosis was conservative (since angiographic 
documentation was required). Acute or subacute stent thrombosis occurred in two patients 
(0.6%) in the paclitaxel-stent group and three patients (1.0%) in the uncoated-stent group. 
This incidence is low, given the thrombotic environment at the time of stent placement, the 
potential for suboptimal stent deployment in the setting of PCI for acute myocardial infarc-
tion, and decreased blood flow in a vessel that supplies infarcted myocardium. In a recent 
retrospective study from the Thoraxcenter, the incidence of stent thrombosis at 1 month 
(which was also defined on the basis of angiography) after primary PCI with the use of a 
paclitaxel-eluting stent was 2.9%.17 We also found no evidence of an increase in the rate of 
late stent thrombosis, a topic that has recently caused concern.18
In this issue of the Journal, a report on the Trial to Assess the Use of the Cypher Stent in 
Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) by Spaulding et al.19 
compares sirolimus-eluting stents with uncoated stents in primary PCI among 712 patients. 
The investigators report a significant difference in the primary end point (the composite 
of death from cardiac causes, recurrent infarction, and target-vessel revascularization at 1 
year) in favor of sirolimus-eluting stents, as compared with uncoated stents (7.3% vs. 14.3%, 
P=0.004). Differences between the two trials - including the type of drug-eluting stent used, 
the study design (routine follow-up angiography was performed in a subgroup of patients 
in TYPHOON), primary end points, and inclusion and exclusion criteria - make it difficult to 
compare the outcomes of our trial with those of TYPHOON. It is worth noting, however, that 
the event rates in the two groups of patients in TYPHOON are not markedly different from 
those in our analysis. 
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ConClusion
In conclusion, our study did not show a significant benefit associated with the use of paclitaxel-
eluting stents in primary PCI for acute myocardial infarction with ST-segment elevation, as 
compared with uncoated stents with the same design.
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abstraCt
Aims This follow-up study was performed to assess the long-term effects of paclitaxel-eluting 
stents (PES) compared with bare-metal stents (BMS) in patients who had undergone a percu-
taneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
Methods and results The PASSION trial randomly assigned 619 patients with STEMI to receive 
either a PES or BMS. The composite endpoint for the follow-up study was the occurrence of 
the combination of cardiac death, recurrent myocardial infarction, target lesion revascularisa-
tion (TLR) or stent thrombosis at two years. A trend towards a lower rate of the composite 
endpoint was observed in the PES compared to the BMS group (hazard ratio [HR] 0.70; 95% 
C.I. 0.45-1.09). This was driven by a reduced TLR in favour of PES (HR 0.60; 95% C.I. 0.34-1.09). 
Angiographically proven stent thrombosis at two years did not differ significantly between 
groups (2.1% in the PES group versus 1.4%; HR 1.48; 95% C.I. 0.42-5.23).
Conclusions PES implantation for STEMI did not significantly improve clinical outcome at two 
years after the index event, although there was a trend towards a lower rate of target-lesion 
revascularisation. The rate of stent thrombosis did not differ significantly between groups.
introduCtion
Primary percutaneous coronary intervention (PCI) is now considered the optimal approach in 
the management of ST segment elevation myocardial infarction (STEMI) when the procedure 
is performed expeditiously and at a high-volume centre.1-4Stent implantation is associated 
with an improvement in both early and late outcomes, as compared with balloon angioplasty 
alone, predominantly as a result of a reduction in target-vessel revascularisation.5,6 Drug-
eluting coronary artery stents, including paclitaxel-eluting stents (PES), have been shown to 
improve both early and late outcomes, as compared with bare-metal stents in a variety of 
clinical settings, predominantly as a result of a reduction in target-vessel revascularisation.7,8 
In contrast, the one year follow-up of the Paclitaxel-Eluting Stent versus conventional Stent in 
Myocardial Infarction with ST-Segment Elevation (PASSION) trial showed no significant supe-
riority of PES compared to bare-metal stents (BMS) in STEMI, although non-significant trends 
in favour of PES were found.9 However, other studies have indicated a significant benefit of 
sirolimus-eluting stent use in patients with STEMI.10-11 The current analysis was performed to 
evaluate whether the differences between the PES and BMS group remained unchanged at 
two years after stent implantation for STEMI.
In addition, the occurrence of very late stent thrombosis was evaluated. Recently, concern 
has arisen about the occurrence of serious adverse events caused by stent thrombosis late 
after drug-eluting stent implantation.12-15 It has been postulated that delayed endothelialisa-
tion and malapposition after drug-eluting stent implantation may lead to late stent thrombo-
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sis resulting in myocardial infarction (MI) or death.16,17 It was recently stated by the FDA panel 
(November, 2006) that off-label use of drug-eluting stents (i.e. including STEMI) is associated 
with increased risks of both early and late stent thrombosis. However, the late rates of serious 
adverse cardiac events after primary PCI for STEMI with drug-eluting stents are unknown. 
Therefore, we sought to determine whether paclitaxel-eluting stents are safe compared to 
bare-metal stents in the setting of primary PCI as measured by the rate of serious adverse 
cardiac events, including the incidence of stent thrombosis, at two years follow-up.
methods
Study group
The Paclitaxel-Eluting Stent versus Conventional Stent in Myocardial Infarction with ST-Seg-
ment Elevation (PASSION) trial was a prospective, single-blind, randomised study, performed 
at two centres in the Netherlands (Onze Lieve Vrouwe Gasthuis in Amsterdam and St. Anto-
nius Hospital in Nieuwegein). The study has been registered as an International Randomised 
Controlled Trial, number ISRCTN65027270. The details of the design and the main results at 
one year have been published previously.9 Between March, 2003, and December, 2004, 619 
patients were enrolled if they were having an acute myocardial infarction with ST-segment 
elevation (>20 minutes of chest pain and at least 1 mm of ST-segment elevation in at least 
two contiguous leads or new left bundle-branch block) and reperfusion was expected to be 
achieved within six hours from the onset of symptoms. The major exclusion criteria were: 
cardiogenic shock evident before randomisation; uncertain neurological outcome after resus-
citation; mechanical ventilation; or an estimated life expectancy less than six months. This 
study complied with the principles set out in the Declaration of Helsinki. All study participants 
provided oral informed consent which was documented in the patients’ clinical records. This 
approach to informed consent was explicitly approved by the authorising ethics committees.
Treatment regimen
Patients were randomly assigned to receive either a paclitaxel-eluting stent (Taxus Express2, 
Boston Scientific, Natick, MA, USA) or a bare-metal stent (Express2 or Liberté, Boston Scientific, 
Natick, MA, USA) in a 1:1 ratio using permuted blocks of 50. The assignment to study groups 
was performed with the use of sealed envelopes. Patients, referring physicians, investigators 
who were responsible for obtaining follow-up information and the interventionalists perform-
ing follow-up procedures were all unaware of treatment assignments. We administered aspirin 
(100-500 mg) and clopidogrel (300 mg) as soon as patients arrived at the hospital, followed by 
aspirin 80 to 100 mg daily for life and clopidogrel 75 mg once daily for at least six months.
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Angiographic and procedural characteristics
QCA was performed to describe the angiographic profile of the included patient populations. 
The same QCA system was used in both participating centres and was performed by highly 
experienced operators familiar with QCA analysis. In the absence of anterograde flow the MLD 
was estimated as 0 mm and the reference diameter was measured in the angiographically 
normal looking segment proximal to the occlusion.
Follow-up and outcome
During each patient’s hospital stay and follow-up visits at 30 days, one and two years, we 
recorded all serious adverse cardiac events (death from cardiac or non-cardiac causes, 
recurrent myocardial infarction, revascularisation of the target lesion or target vessel, and 
coronary-artery bypass grafting [CABG]), as well as interventions to non-target vessels. 
Patients were contacted by telephone or by mail. In the event of a repeat hospital admission 
or any reported adverse event, detailed follow-up information was obtained. If the informa-
tion could not be checked directly with the patient, it was obtained from the patient’s family, 
family doctor, the insurance company or public records. When patients were lost to follow-up 
censoring was done at the date of last contact or clinical follow-up. Drs. Laarman and Suttorp 
adjudicated all endpoints of the study in a blinded fashion. The primary outcome was the 
first occurrence of a major adverse cardiac event (MACE; including death from cardiac causes, 
recurrent myocardial infarction, and ischaemia-driven revascularisation of a target lesion) 
within 24 months. All deaths were considered to be from cardiac causes unless a noncardiac 
cause could be identified. Recurrent myocardial infarction was defined by the development 
of either pathological Q waves lasting at least 0.4 second in at least two contiguous leads or 
an increase in the creatine kinase level to more than twice the upper limit of normal with an 
elevation of the creatine kinase MB iso-enzyme in combination with symptoms or the need 
for intervention. Revascularisation of the target lesion was defined as ischaemia-driven PCI of 
the target lesion if there had been restenosis or reocclusion within the stent or in the adjacent 
distal or proximal 5 mm and included CABG involving the infarct-related artery. As no routine 
follow-up angiography was performed, recurrent coronary angiography was performed 
according to the established clinical guidelines. PCI was then performed if the severity of the 
lesion was >50% on visual analysis.
A secondary outcome of the study was the occurrence of stent thrombosis. Definition of 
stent thrombosis in the initial protocol was angiographic confirmation of vessel occlusion 
or thrombus formation within, or adjacent to, the stented segment. Stent thrombosis was 
categorised as acute (occurring within 24 hours after the procedure), sub-acute (occurring 
one to 30 days after the procedure), late (occurring 30 to 365 days after the procedure) or 
very late (occurring after one year). In addition, the occurrence of stent thrombosis was evalu-
ated according to the Academic Research Consortium (ARC) criteria.18 Definite or confirmed 
stent thrombosis: Angiographic confirmation of vessel occlusion or thrombus formation 
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within, or adjacent to, the stented segment or proven stent thrombosis at autopsy. Probable 
stent thrombosis: Unexplained death within 30 days or target vessel recurrent MI without 
angiographic confirmation. Possible stent thrombosis: Unexplained death after 30 days. Stent 
thromboses following repeated target lesion revascularisation, with or without repeat stent 
implantation, were also counted.
Statistical analysis
Baseline data are presented as proportions or mean (±SD) values and were compared with 
the use of Student’s t-test or the Wilcoxon rank-sum test for continuous variables and with 
the Fisher’s exact test for categorical variables. A two-sided P value of less than 0.05 was 
considered to indicate statistical significance. We estimated the cumulative incidence rates of 
the primary and secondary endpoints at two years with the Kaplan-Meier method.19 Hazards 
ratios (HR) were calculated with Cox proportional-hazards models with treatment allocation 
(PES or BMS) as the only covariate. The 95% confidence interval (CI) for the relative risk was 
calculated with the use of the standard errors from the Kaplan-Meier curve. The significance 
of differences in rates of the endpoints between treatment groups was assessed by the log-
rank test. Statistical analysis was done with the Statistical Package for Social Sciences software 
(SPSS 13.0 for Windows).
results
Six-hundred and nineteen patients were enrolled in the study: 310 were randomly assigned to 
the paclitaxel-stent group and 309 to the bare-metal stent group. The most common reasons 
for exclusion from the trial were an anticipated delay of more than six hours between the 
onset of symptoms and reperfusion, coronary anatomy that was not suitable for stent implan-
tation, cardiogenic shock, or mechanical ventilation. The baseline clinical characteristics of 
both groups were well matched (see Table 1 of Chapter 5). The mean age was 61 years; 76% 
of the patients were male. Clopidogrel was used for a median of nine months (interquartile 
range, six to 12).
Angiographic and procedural characteristics
For baseline angiographic and procedural characteristics see Table 2 and 3 of Chapter 5. 
Approximately half of the patients had multivessel disease, and in 50% of the cases the left 
anterior descending coronary artery was the infarct-related artery. The majority of patients 
had an estimated lesion length between 10 mm and 19 mm. The mean reference diameter 
was 3.13±0.43 mm in the paclitaxel-stent group and 3.20±0.47 mm in the bare-metal stent 
group. The average length of stents was 19 mm in both groups. TIMI grade 3 flow was estab-
lished in 93% of patients in the paclitaxel-stent group, as compared with 96% of patients in 
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the bare-metal stent group (NS). The sizes of infarcts, reflected by the mean peak value of 
the creatine kinase MB iso-enzyme, were similar (193±183 in the paclitaxel-stent group and 
210±186 in the bare-metal stent group).
Incidence of MACE
A total of 96% of patients in the paclitaxel-stent group and 97% of those in the bare-metal 
stent group underwent complete two year clinical follow-up. Follow-up for death was com-
plete in 98% in both groups. The cumulative incidence of MACE at two years was 11.1% in the 
paclitaxel-stent group and 15.4% in the bare-metal stent group (HR 0.70; 95% C.I. 0.45-1.09; 
P=0.12) (Figure 1 and Table 1). The cumulative incidence of cardiac death, recurrent MI or stent 
thrombosis was 8.5% in both groups (HR 0.95; 95% C.I. 0.56-1.63; P=0.86). Figure 2 shows the 
incidence of target lesion revascularisation up to two years of follow-up. 
Stent thrombosis
The cumulative incidence of angiographically proven stent thrombosis was similar between 
the two treatment groups, 2.1% (n=6) in the paclitaxel-stent group versus 1.4% (n=4) in the 
bare-metal stent group. Acute stent thrombosis (within 24 hours) occurred in one patient 
(0.3%) in the paclitaxel-stent group. Sub-acute stent thrombosis occurred in one patient 
(0.3%) in the paclitaxel-stent group and in three patients (1.0%) in the bare-metal stent group. 
Very-late stent thrombosis occurred in three patients (1.0%) in the paclitaxel-stent group and 
Figure 1. Kaplan-Meier survival curves showing the composite endpoint of death from cardiac causes, recurrent myocardial infarction, or 
target-lesion revascularisation at two years. The cumulative incidence of the primary endpoint of serious adverse cardiac events was 11.1% in the 
paclitaxel stent (PES) group and 15.4% in the bare-metal stent (BMS) group (relative risk, 0.70; 95% CI, 0.45 to 1.09; P: 0.12 by the logrank test).
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Stent thrombosis
The cumulative incidence of angiographically proven stent
thrombosis was similar between the two treatment groups, 2.1%
(n=6) in the paclitaxel-stent group versus 1.4% (n=4) in the bare-
metal stent group. Acute stent thrombosis (within 24 hours) occurred
in one patient (0.3%) in the paclitaxel-stent group. Sub-acute stent
thrombosis occurred in one patient (0.3%) in the paclitaxel-stent
group and in three patients (1.0%) in the bare-metal stent group.
Very-late stent thrombosis occurred in three patients (1.0%) in the
paclitaxel-stent group and in one (0.3%) in the bare-metal stent
group. These four patients with stent thrombosis beyond one year
were all compliant with the use of aspirin at the time of the event and
there were no specific confounding factors involved. One of the
patients in the PES group had a very late stent thrombosis in the PES
that was implanted in a lesion adjacent to the initial stent six months
after the index event.
Table 2. Lesion characteristics, procedural characteristics and results.
PES BMS P-value
Coronary artery disease
1 Vessel disease 179 (58) 162 (52) 0.20
2 Vessel disease 82 (27) 100 (32) 0.11
3 Vessel disease 49 (16) 47 (15) 0.91
Infarct related artery
Left anterior 
descending artery 156 (50) 154 (50) 0.94
Left main stem 2 (0.6) 0 (0) 0.50
Right coronary artery 129 (41.6) 118 (38.2) 0.41
Left circumflex artery 18 (5.8) 32 (10.4) 0.04
Intermediate branch 3 (1.0) 4 (1.3) 0.72
Saphenous-vein graft 2 (0.6) 1 (0.3) 1.00
Thrombus present 213 (69) 204 (66) 0.49
Pre-procedural reference 
diameter (mm) 3.13±0.43 3.20±0.47 0.04
Pre-procedural mean minimal 
luminal diameter (mm) 0.15±0.35 0.17±0.38 0.60
Pre-procedural stenosis (%) 95±13 94±15 0.48
Lesion length (mm)
0-9 41 (13) 48 (16) 0.49
10-19 201 (65) 188 (61) 0.36
20-29 50 (16) 52 (17) 0.83
> 30 18 (5.8) 21 (6.8) 0.62
Stent size (mm) 3.21±0.30 3.26±0.38 0.08
Stent length (mm) 19±5.6 19±5.5 0.71
Mean number of stents 
implanted 1.26±0.55 1.33±0.63 0.14
Post-procedural 
reference diameter (mm) 3.20±0.46 3.24±0.45 0.26
Post-procedural mean minimal 
luminal diameter (mm) 3.15±0.47 3.13±0.57 0.66
Post-procedural stenosis (%) 3.03±6.6 4.66±12.1 0.04
Procedural success 
(=TIMI-3 and <30% stenosis) 289 (93) 297 (96) 0.15
Data are number (%) or mean (±standard deviation).
Figure 1. Kaplan-Meier survival curves showing the composite endpoint of
death from cardiac causes, recurrent myocardial infarction, or target-lesion
revas ul risation at two years. The cumulative incidence of the primary
endpoint of serious adverse cardiac events was 11.1% in the paclitaxel-
stent (PES) group and 15.4% in the bare-metal stent (BMS) group (relative
risk, 0.70; 95% CI, 0.45 to 1.09; P: 0.12 by the logrank test).
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Figure 2. Kaplan-Meier survival curves showing cumulative incidence of
target lesion revascularisation (TLR) at two years. The cumulative
incidence of TLR was 6.0% in the paclitaxel-stent (PES) group and
9.9% in the bare-metal stent (BMS) group (relative risk, 0.60; 95% CI,
0.34 to 1.09; P: 0.09 by the logrank test).
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The occurrences of stent thrombosis according to the ARC criteria are
shown in Table 3. The cumulative incidences of definite, probable or
possible stent thrombosis were 5.8% in the PES group versus 5.1% in
the BMS group (HR 1.19; 95% C.I. 0.59-2.42; P=0.62).
Discussion
This is the first randomised study to report clinical outcome with late
follow-up two years after PES or BMS implantation for STEMI. The
additional information pertaining to two year follow-up is important,
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in one (0.3%) in the bare-metal stent group. These four patients with stent thrombosis beyond 
one year were all compliant with the use of aspirin at the time of the event and there were 
no specific confounding factors involved. One of the patients in the PES group had a very 
late stent thrombosis in the PES that was implanted in a lesion adjacent to the initial stent six 
months after the index event.
The occurrences of stent thrombosis according to the ARC criteria are shown in Table 1. The 
cumulative incidences of definite, probable or possible stent thrombosis were 5.8% in the PES 
group versus 5.1% in the BMS group (HR 1.19; 95% C.I. 0.59-2.42; P=0.62).
table 1. Two year follow-up.
Events Paclitaxel-Eluting 
Stent N (%)
Uncoated Stent 
N (%)
HR (95% C.I.) Log Rank 
P-value
N 303 (98) 303 (98)
Death by all causes 21 (6.9) 27 (8.8) 0.77 (0.43-1.36) 0.36
Cardiac death 17 (5.6) 22 (7.2) 0.76 (0.41-1.44) 0.40
Paclitaxel-Eluting 
Stent N (%)
Uncoated Stent 
N (%)
HR (95% C.I.) Log Rank 
P-value
N 298 (96) 299 (97)
Recurrent MI 9 (3.1) 7 (2.4) 1.27 (0.47-3.40) 0.64
ST or recurrent MI 9 (3.1) 7 (2.4) 1.27 (0.47-3.40) 0.64
ST or cardiac death 23 (7.6) 25 (8.2) 0.91 (0.52-1.60) 0.74
ST or Re-MI or cardiac death 26 (8.5) 26 (8.5) 0.99 (0.57-1.70) 0.97
Repeat PCI of target lesion 8 (2.7) 15 (5.2) 0.52 (0.22-1.22) 0.13
CABG of target vessel 10 (3.3) 18 (6.1) 0.55 (0.25-1.18) 0.12
TLR (PCI + CABG) 18 (6.0) 29 (9.9) 0.60 (0.34-1.09) 0.09
MACE 34 (11) 47 (15) 0.70 (0.45-1.09) 0.12
ARC definite 6 (2.1) 4 (1.4) 1.48 (0.42-5.23) 0.54
ARC probable 2 (0.7) 4 (1.3) 0.49 (0.09-2.68) 0.40
ARC possible 9 (3.1) 6 (2.1) 1.47 (0.52-4.14) 0.46
ARC cumulative 17 (5.8) 14 (4.7) 1.19 (0.59-2.42) 0.76
Paclitaxel-Eluting 
Stent N (%)
Uncoated Stent 
N (%)
HR (95% C.I.) Log Rank 
P-value
N 298 (96) 299 (97)
Acute stent thrombosis (< 24 hours) 1 (0.3) 0
Sub-acute stent thrombosis (> 24 hours 
< 30 days)
1 (0.3) 3 (1.0)
Late stent thrombosis (> 30 days < 1 year) 1 (0.3) 0
Very late stent thrombosis (> 1 year) 3 (1.0) 1 (0.3)
Total 6 (2.1) 4 (1.4) 1.48 (0.42-5.23) 0.54
Cumulative incidences were estimated from the Kaplan-Meier curves at two year and are not simple proportions. ARC: Academic Research 
Consortium; CABG: coronary artery bypass grafting; MACE: major adverse cardiac event; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; TLR: target lesion revascularisation
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disCussion
This is the first randomised study to report clinical outcome with late follow-up two years after 
PES or BMS implantation for STEMI. The additional information pertaining to two year follow-up 
is important, as currently the information available on drug-eluting stents post STEMI is almost 
exclusively limited to one year of follow-up, a duration too short to fully appreciate the risks 
and/or benefits of drug-eluting stents, particularly as late stent thrombosis beyond one year 
seems to be of particular concern with drug-eluting stents. In our study, the use of a paclitaxel-
eluting stent was not superior to that of a bare-metal stent in patients undergoing a primary 
PCI for STEMI, apart from a trend towards less target-lesion revascularisation in the PES group. 
The cumulative incidence of the primary endpoint - a composite of cardiac death, recurrent 
myocardial infarction, and target-lesion revascularisation at 24 months - was 11.1% in the PES 
group and 15.4% in the BMS group. The relative risk of 0.70 (95% C.I. 0.45-1.09) was similar to 
that observed at one year (0.69; 95% C.I. 0.43-1.10) and was not statistically significant.9 The 
rates of individual adverse events were similar in both groups, except for target lesion revascu-
larisation that was in favour of the PES group, however this did not reach statistical significance. 
These results are in contrast to other trials with prolonged follow-up comparing the use of a 
PES with a BMS. Previous trials observed improved outcome with the use of PES in
Figure 2. Kaplan-Meier survival curves showing cumulative incidence of target lesion revascularisation (TLR) at two years. The cumulative 
incidence of TLR was 6.0% in the paclitaxel-stent (PES) group and 9.9% in the bare-metal stent (BMS) group (relative risk, 0.60; 95% CI, 0.34 to 
1.09; P: 0.09 by the logrank test).
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Stent thrombosis
The cumulative incidence of angiographically proven stent
thrombosis was similar between the two treatment groups, 2.1%
(n=6) in the paclitaxel-stent group versus 1.4% (n=4) in the bare-
metal stent group. Acute stent thrombosis (within 24 hours) occurred
in one patient (0.3%) in the paclitaxel-stent group. Sub-acute stent
thrombosis occurred in one patient (0.3%) in the paclitaxel-stent
group and in three patients (1.0%) in the bare-metal stent group.
Very-late stent thrombosis occurred in three patients (1.0%) in the
paclitaxel-stent group and in one (0.3%) in the bare-metal stent
group. These four patients with stent thrombosis beyond one year
were all compliant with the use of aspirin at the time of the event and
there were no specific confounding factors involved. One of the
patients in the PES group had a very late stent thrombosis in the PES
that was implanted in a lesion adjacent to the initial stent six months
after the index event.
Table 2. Lesion characteristics, procedural characteristics and results.
PES BMS P-value
Coronary artery disease
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2 Vessel disease 82 (27) 100 (32) 0.11
3 Vessel disease 49 (16) 47 (15) 0.91
Infarct related artery
Left anterior 
descending artery 156 (50) 154 (50) 0.94
Left main stem 2 (0.6) 0 (0) 0.50
Right coronary artery 129 (41.6) 118 (38.2) 0.41
Left circumflex artery 18 (5.8) 32 (10.4) 0.04
Intermediate branch 3 (1.0) 4 (1.3) 0.72
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Pre-procedural stenosis (%) 95±13 94±15 0.48
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Stent size (mm) 3.21±0.30 3.26±0.38 0.08
Stent length (mm) 19±5.6 19±5.5 0.71
Mean number of stents 
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reference diameter (mm) 3.20±0.46 3.24±0.45 0.26
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Data are number (%) or mean (±standard deviation).
Figure 1. Kaplan-Meier survival curves showing the composite endpoint of
de th from cardiac causes, recurrent myocardial infarction, or target-lesion
revascularisation at two years. The cumulative incidence of the primary
endpoint of serious advers  cardiac events was 11.1% in the pa litaxel-
stent (PES) group and 15.4% in the bare-metal stent (BMS) group (relative
risk, 0.70; 95% CI, 0.45 to 1.09; P: 0.12 by the logrank test).
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Figure 2. Kaplan-Meier survival curves showing cumulative incidence of
target lesion revascularisation (TLR) at two years. The cumulative
incidence of TLR was 6.0% in the paclitaxel-stent (PES) group and
9.9% in the bare-metal stent (BMS) group (relative risk, 0.60; 95% CI,
0.34 to 1.09; P: 0.09 by the logrank test).
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The occurrences of stent thrombosis according to the ARC criteria are
shown in Table 3. The cumulative incidences of definite, probable or
possible stent thrombosis were 5.8% in the PES group versus 5.1% in
the BMS group (HR 1.19; 95% C.I. 0.59-2.42; P=0.62).
Discussion
This is the first randomised study to report clinical outcome with late
follow-up two years after PES or BMS implantation for STEMI. The
additional information pertaining to two year follow-up is important,
EIJ14_012Dirksen_064a070.qxd  10/04/08  15:17  Page 67
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a number of clinical conditions (except for STEMI).7,8 As discussed previously,9 several 
factors may account for the discrepancies between our results and those reported for PES 
in other clinical settings. In summary, the event rates in the BMS group were much lower 
than those anticipated in our power calculations, possibly due to improvements in stent 
design and/or implantation techniques. This TLR rate was noticeably lower compared to the 
TLR rates after BMS implantation observed in all other randomised trials with sirolimus- and 
paclitaxel-eluting stents in STEMI.10,20 Secondly, the study design did not include angiographic 
follow-up in contrast to the majority of these previous trials. Third, there may be a difference 
in the response to vascular and myocardial injury after PCI for myocardial infarction, when 
compared with the response in more elective procedures. Importantly, the relative risks and 
non-significant trends were similar to those seen at one-year follow-up and we did not see a 
late ‘catch-up’ phenomenon with the use of PES after longer follow-up.
Whereas restenosis is considered a relatively benign adverse event, stent thrombosis may 
be fatal in up to 45%.21 Although this study was not powered to detect a difference in stent 
thrombosis, it is notable that the current study showed an equal safety profile for both stents 
at two years after implantation in patients with STEMI. There was no significant increase of 
catastrophic adverse events associated with the use of a PES. The cumulative endpoint of 
cardiac death, recurrent MI or stent thrombosis was similar in both groups, with a relative 
risk of 0.95. Although angiographically proven very late stent thrombosis was higher in the 
PES group (1.0%) compared to the BMS group (0.3%), the cumulative incidences of definite, 
probable or possible stent thrombosis (according to the ARC criteria) did not show an increase 
after PES implantation. However, these rates of stent thrombosis must be read with caution 
given the limited size of the study population evaluated for the occurrence of stent thrombo-
sis. Much larger numbers of patients are needed to prove statistical and clinical significance. In 
the current analysis we used a conservative definition of stent thrombosis - angiographically 
proven - and less conservative definitions of stent thrombosis - according to the ARC, includ-
ing stent thrombosis after repeat revascularisation.
Regardless of the definition, the incidence of stent thrombosis, according to the ARC crite-
ria, was low in both treatment groups, especially given the complex conditions of unstable 
patients during acute myocardial infarction, with a thrombotic environment at the time of 
stent placement, augmented platelet activation,22 the potential for suboptimal stent deploy-
ment, and decreased blood flow in the infarct-related artery. Therefore, the current analysis 
of patients two years after PES implantation suggests that the “offlabel” use of PES in primary 
PCI for STEMI shows an equal safety profile compared to BMS. These results are in line with 
recently published meta-analyses of randomised trials that had long-term follow-up after 
drug-eluting stent implantation showing no increase in the rates of stent thrombosis with 
the use of drug-eluting stents.23,24 However, our results differ from previously reported studies 
that suggest that drug-eluting stent implantation may be associated with an increase of stent 
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thrombosis and death.12-15 It should be noted that none of these studies were performed in a 
randomised manner in patients with STEMI.
In our study, all patients were expected to have discontinued the use of clopidogrel at one 
year after the index procedure. Although there was an increase of events in the PES group 
compared with the BMS group after one year, this was not statistically significant. Currently, all 
patients are advised to use clopidogrel for one year after drug-eluting stent implantation and 
the impact of this prolonged strategy on outcome is not yet known. Early discontinuation of 
anti-platelet therapy may be associated with an increased risk of thrombosis, but the optimal 
duration of clopidogrel remains undefined. This increase of events should be evaluated with 
longer follow-up in larger randomised trials.
Taken together, the mandatory use of PES in acute MI remains debatable. Additionally the 
use of drug-eluting stents may not be necessary for STEMI in view of the predominantly large 
sizes of culprit vessels that have a low expected risk of restenosis (TLR 9.9% in the BMS group). 
However, it is necessary to wait for the longer follow-up of larger randomised trials, meta-
analyses and substudies on the use of drug-eluting stents for acute MI as the literature shows 
that angiographic and clinical restenosis after primary PCI remains an important issue.4,5
Study limitations
A limitation of this study lies in the fact that the power calculations were not based on the 
hypothesis of the current analysis; e.g., the current study was not powered to detect differ-
ences in stent thrombosis or death: therefore these data remain observational. Larger studies 
with longer follow-up periods and larger patient numbers are required to definitively answer 
the question of whether the use of drug-eluting stents in primary PCI would improve or 
decrease survival after acute MI. A further limitation is the lack of an independent clinical 
event committee, as all events were adjudicated in a blinded fashion by two interventional 
cardiologists.
ConClusion
In conclusion, the PASSION study did not show any significant clinical benefit associated with 
the use of paclitaxel-eluting stents as compared with the use of bare-metal stents of same 
design. In addition, there was no significant increase of stent thrombosis after PES implanta-
tion in primary PCI at two years after stent implantation and one year after discontinuation 
of clopidogrel.
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abstraCt
Aims To compare the efficacy and safety of drug-eluting stents versus bare-metal stents in 
patients with acute ST-segment elevation myocardial infarction.
Methods and results We performed a meta-analysis of 8 randomised trials comparing drug-
eluting stents (sirolimus-eluting or paclitaxel-eluting stents) with bare-metal stents in 2.786 
patients with acute ST-segment elevation myocardial infarction. All patients were followed up 
for a mean of 12.0 to 24.2 months. Individual data were available for 7 trials with 2476 patients. 
The primary efficacy end point was the need for reintervention (target lesion revascularisa-
tion). The primary safety end point was stent thrombosis. Other outcomes of interest were 
death and recurrent myocardial infarction. Drug-eluting stents significantly reduced the risk 
of reintervention, hazard ratio of 0.38 (95% confidence interval: 0.29 to 0.50), P<0.001. The 
overall risk of stent thrombosis: hazard ratio of 0.80 (0.46 to 1.39), P=0.43; death: hazard ratio 
of 0.76 (0.53 to 1.10), P=0.14; and recurrent myocardial infarction: hazard ratio of 0.72 (0.48 to 
1.08, P=0.11) were not significantly different for patients receiving drug-eluting stents versus 
bare-metal stents.
Conclusion The use of drug-eluting stents in patients with acute ST-segment elevation myo-
cardial infarction is safe and improves clinical outcomes by reducing the risk of reintervention 
compared with bare-metal stents.
introduCtion
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for 
patients presenting with acute myocardial infarction with ST-segment elevation.1,2 As com-
pared with balloon angioplasty, routine implantation of bare metal stents has been associ-
ated with improved clinical outcome mainly due to the decreased risk for reintervention.3,4 
Nevertheless, restenosis remains an important limitation of the use of bare-metal stents in 
patients with acute myocardial infarction.4-7
Drug-eluting stents effectively reduce restenosis while maintaining a good safety profile in 
many lesion and patients groups.8,9 However, concerns have been raised with regard to the 
safety of drug-eluting stents in patients with acute myocardial infarction.10 Data from registry 
studies have suggested that implantation of drug-eluting stents during primary PCI could be 
associated with an increased risk for stent thrombosis, which is associated with high morbid-
ity and mortality rates.11,12 Recently, the results of several randomised trials of drug-eluting 
stents in patients undergoing primary PCI for acute ST-segment elevation myocardial infarc-
tion have been reported. These studies had, however, insufficient power to assess the risk of 
rare adverse events. Furthermore, they did not consistently show the superior effectiveness of 
drug-eluting stents in that particular setting.13-15 Meta-analyses of randomised trials have the 
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potential to increase power and improve precision of treatment effects.16 A meta-analysis has 
recently been published including 7 randomised trials with a total number of 2.357 patients.17 
However, this meta-analysis was based on summary data exctracted from meeting abstracts 
in 4 of the 7 trials.17 Toma et al.18 suggest caution in the use of these data due to common 
discrepancies in results between meeting abstracts and subsequent full-length publications. 
A meta-analysis based on individual patient data yields much more accurate results and is the 
“gold standard” to perform time-to-event analyses.19
We performed a meta-analysis predominantly based on individual patient data from ran-
domised trials comparing drug-eluting stents with bare metal stents to evaluate the efficacy 
and safety of drug-eluting stents in patients with acute ST-segment elevation myocardial 
infarction.
methods
Literature search
We performed an electronic search of the United States National Library of Medicine (PubMed, 
at www.pubmed.gov), the United States National Institutes of Health clinical trials registry 
(www.clinicaltrials.gov), and the Cochrane Central Register of Controlled Trials (http://www.
mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html). The key words 
used included: ´myocardial infarction´, ´primary´, ´angioplasty´, ´PCI´, ´ST-segment elevation´, 
´drug-eluting stent´, ´sirolimus-eluting stent´, ´paclitaxel-eluting stent´, ´clinical trial´, ´ran-
domized´. Internet-based sources of information on the results of clinical trials in cardiology 
(www.theheart.org, www.cardiosource.com/clinicaltrials, www.clinicaltrialresults.com, and 
www.tctmd.com) were also searched. Additional data sources included conference proceed-
ings from the American College of Cardiology, American Heart Association, and European 
Society of Cardiology meetings. We also identified relevant reviews and editorials from major 
medical journals published within the last year and assessed for possible information on trials 
of interest. The search period was between January 2002 and February 2007.
Study selection
To be selected for this meta-analysis, studies comparing drug-eluting stents with bare metal 
stents in patients undergoing primary PCI of ST-segment elevation acute myocardial infarction 
had be randomised and had their results reported or made available by the trial investiga-
tors for a mean follow-up period of at least 12 months. Articles were searched and reviewed 
independently by two of the authors (A.D. and J.M.); those meeting the inclusion criteria were 
selected for further analysis. A total of 9 trials were identified. The trial of Pasceri et al.20 was 
excluded because it only reported preliminary data of the first 34 patients over a follow-up of 
4±2 months. Finally, 8 trials were included in this meta-analysis (Figure 1).13-15,21-25
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Study outcomes and data collection
The primary efficacy end point of this meta-analysis was the need of reintervention (target 
lesion revascularisation). The primary safety end point of this meta-analysis was stent throm-
bosis. Secondary end points were death and recurrent myocardial infarction. The composite 
of death, recurrent myocardial infarction or reintervention was also assessed. The event defi-
nitions used in individual trials are displayed in the Table 1. The adjudication of events in each 
trial was performed by the same event committee over the entire follow-up period. Survival 
was calculated from the date of randomisation to the date of death. Data for surviving patients 
were censored on the date of last follow-up. 
An electronic form containing the data fields to be completed for individual patients was 
sent to all principal investigators of the trials. Individual patient data could be obtained for 7 
trials.13-15,21-24
The data requested for each enrolled patient included the date of randomisation, allocated 
treatment, diabetes status, event status (including death, myocardial infarction, coronary 
reintervention [percutaneous or surgical], stent thrombosis and their respective dates of 
occurrence) and date of last follow-up. All data were thoroughly checked for consistency 
(logical checking and checking against the original publications). Any queries were resolved 
and the final database entries verified by the responsible trial investigator. 
Figure 1. Flowchart of selected studies. BMS, bare-metal stent; DES, drug-eluting stent; RCT, randomized control trial.
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Figure 1. 
Search Criteria and Period:
RCT of DES vs. BMS in patients with
acute myocardial infarction
January 2002 to February 2007
9 RCT identified for more detailed evaluation (n=2820)
Excluded:
Pasceri et al.(20) 
Reason: Only
preliminary data
reported for first 34 
patients over a follow-
up of 4±2 months
8 RCT included in meta-analysis (n=2786)
DES (n=1474) BMS (n=1312) 
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Each trial was evaluated for the adequacy of allocation concealment, performance of the 
analysis according to the intention-to-treat principle, and blind assessment of the outcomes 
of interest. We used the criteria recommended by Altman et al.26 and Jüni et al.27 to assess the 
adequacy of allocation concealment. In 2 trials, a modified intention-to-treat principle, i.e. 
exclusion of patients who did not receive the study stent, was used.14,25
Statistical methods
We performed survival analyses using the Mantel-Cox method stratified by trial. The log-rank 
test was used to calculate hazard ratios and their 95% confidence intervals.
Trials in which the event of interest was not observed in either treatment group were dis-
carded from the analysis of that event. In case only one of the groups of an individual trial had 
no event of interest, the treatment effect estimate and its standard error were calculated after 
adding 0.5 to each cell of the 2x2 table for that trial.28
We used the Cochran-test to assess heterogeneity across trials. We also calculated the I2 
statistic to measure the consistency between trials with values of 25%, 50%, and 75% showing 
respectively, low, moderate and high heterogeneity.29 Hazard ratios from individual trials were 
pooled using the DerSimonian and Laird method for random effects.30
We performed sensitivity analyses by comparing the treatment effects obtained with each 
trial removed consecutively from the analysis with the overall treatment effects. Results were 
considered statistically significant at two-sided P<0.05. Statistical analysis was performed by 
using the Stata software, version 9.2 (Stata Corp, College Station, Tex). Survival curves are 
presented as simple, non-stratified Kaplan-Meier curves across all trials and constructed with 
the use of S-Plus software version 4.5. (Insightful Corporation, Seattle, WA). 
results
Eight trials with 2.786 patients were included in this meta-analysis. The main characteristics of 
these trials are summarised in Table 2. The mean age of participants in individual trials varied 
from 59.2 years to 64.0 years. Drug-eluting stents consisted of paclitaxel-eluting stents in 2 of 
the trials and sirolimus-eluting stents in 4 other trials; in the remaining 2 trials, a 3-arm design 
was used including both paclitaxel-eluting and sirolimus-eluting stents.21,22 The recommended 
length of postprocedural thienopyridine therapy was 315, 613,14,21,22 or 12 months.23-25 The mean 
length of follow-up ranged from 12.0 to 24.2 months. Patient-level data were available for 7 
trials with 2476 patients.13-15,21-24
Figure 2A shows the absolute numbers of patients who experienced the primary efficacy 
end point of reintervention in each trial by treatment group, with the hazard ratio for each 
trial. Overall, use of drug-eluting stents was associated with a hazard ratio for reinterven-
tion of 0.38 (95% confidence interval: 0.29 to 0.50), P<0.001, compared with use of the bare 
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table 1. End Point Definitions in Each Trial
Study Death Recurrent MI Reintervention Stent Thrombosis
BASKET-AMI22 Cardiac, if 
clearly due to a 
cardiac event, 
otherwise 
noncardiac
Typical chest pain with 
typical rise (and fall) 
of cardiac enzymes or 
new Q-waves/ST-T wave 
changes on ECG
PCI or CABG driven by 
a lesion in the same 
epicardial vessel as 
initially treated
Angiographic evidence in the 
presence of an ischemic clinical 
event
Di Lorenzo21 Cardiac, unless 
a noncardiac 
cause could be 
identified
Recurrence of anginal 
symptoms with typical 
ECG changes and increase 
of CK-MB or troponin 
Any CABG or PCI of 
the target vessel in the 
presence of symptoms 
or signs of ischemia
Angiographically documented 
thrombus within the stent associated 
to typical chest pain and ST-segment 
modification with or without a 
significant rise of enzymes
HAAMU-
STENT23
Cardiac, 
if sudden 
unexpected 
death or 
witnessed fatal 
arrhythmia or 
cardiac failure
Clinical picture of 
myocardial infarction 
with ST-segment changes 
and elevated cardiac 
markers or angiographic 
stent thrombosis
Any CABG of the 
target vessel or a PCI 
due to angiographic 
restenosis in the 
presence of symptoms 
or signs of ischemia
Acute ST-segment elevation 
myocardial infarction plus 
angiographic thrombus
MISSION*25 Cardiac, unless 
a noncardiac 
cause could be 
identified
Development of new 
Q-waves on ECG or a 
troponin-T rise above 
normal (>25% above 
previous value) with 
symptoms or need for 
reintervention
Any CABG or PCI of the 
target vessel
Angiographically documented 
thrombus within the stent and/or 
typical chest pain with recurrent ST-
segment elevation in combination 
with a significant rise of troponin 
levels and/or the presence of new 
Q-waves
PASSION13 Cardiac, unless 
a noncardiac 
cause could be 
identified
Q waves on ECG or an 
increase in the CK level 
≥2 times the ULN or 50% 
higher than the previous 
value with symptoms or 
need for reintervention
Any CABG of the 
target vessel or a PCI 
due to angiographic 
restenosis in the 
presence of symptoms 
or signs of ischemia
Angiographic documentation of 
either vessel occlusion or thrombus 
formation within, or adjacent to, the 
stented segment
SESAMI24 Cardiac, unless 
an unequivocal 
noncardiac 
cause could be 
established
Recurrent ischemic 
symptoms or ECG 
changes accompanied 
by an increase in cardiac 
enzymes ≥2 times the 
ULN or 50% higher than 
the previous value
Any CABG of the 
target vessel or a PCI 
due to angiographic 
restenosis in the 
presence of symptoms 
or signs of ischemia
Angiographic evidence in the 
presence of an acute coronary 
syndrome
STRATEGY15 Cardiac, unless 
an unequivocal 
noncardiac 
cause could be 
established
Recurrent ischemic 
symptoms or ECG 
changes accompanied 
by an increase in cardiac 
enzymes above the 
normal limit or 50% 
higher than the previous 
value
Any CABG or PCI of 
the target vessel in the 
presence of symptoms 
or signs of ischemia
Angiographic evidence in the 
presence of clinical symptoms or 
ECG changes suggestive of acute 
ischemia
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table 1. End Point Definitions in Each Trial
Study Death Recurrent MI Reintervention Stent Thrombosis
TYPHOONa14 Cardiac, if a 
cardiac cause 
cannot be 
excluded
Recurrence of clinical 
symptoms or the 
occurrence of ECG 
changes accompanied by 
new elevation of cardiac 
enzymes (1.5 times the 
previous value or 3 times 
the ULN)
Any CABG of the 
target vessel or a PCI 
due to angiographic 
restenosis in the 
presence of symptoms 
or signs of ischemia, 
or only due to severe 
restenosis (≥70% 
diameter stenosis)
Acute and subacute stent 
thrombosis were defined as 
angiographic proof of vessel 
occlusion, any recurrent Q-wave MI 
in the territory of the stented vessel, 
or any death from cardiac causes. 
Late stent thrombosis was defined as 
any recurrent MI with angiographic 
proof of vessel occlusionb
CABG, aorto-coronary bypass surgery; PCI, percutaneous coronary intervention; HAAMU-STENT, The Helsinki area acute myocardial infarction-
treatment re-evaluation—should the patient get a drug-eluting or a normal stent trial; MISSION, a prospective randomized controlled trial 
to evaluate the efficacy of drug-eluting stents vs. bare-metal stents for the treatment of acute myocardial infarction; PASSION, the paclitaxel-
eluting stent vs. conventional stent in myocardial infarction with ST-segment elevation trial; SESAMI, the randomized trial of sirolimus stent 
vs. bare stent in acute myocardial infarction trial; STRATEGY, the single high-dose bolus Tirofiban and sirolimus eluting stent vs. Abciximab and 
bare-metal stent in myocardial infarction trial; TYPHOON, the trial to assess the use of the Cypher stent in acute myocardial infarction treated 
with balloon angioplasty.
aA ‘modified intention-to-treat’ principle was adopted in the trial, i.e. a randomized patient was included in the analysis only if he received 
stent(s).
bAccording to protocol, patients undergoing reintervention had to be censored from further assessment of stent thrombosis.
table 2. Main Characteristics of the Trials
Study N Age Type of DES Individual 
Patient Data 
Available
Primary End Point Thienopyridine 
Therapy 
(months)
Mean 
Follow-Up 
(months)
BASKET-AMI22 216 62 PES and SES Yes
Cardiac death, MI, or 
reintervention 
6 18.0
Di Lorenzo21 270 64 PES and SES Yes Death, MI, or reintervention 6 12.0
HAAMU-
STENT23
164 63 PES Yes Angiographic late lumen loss 12 16.7
MISSION25 310 59 SES No Angiographic late lumen loss 12 12.0
PASSION13 619 61 PES Yes
Cardiac death, MI, or 
reintervention 
6 12.0
SESAMI24 320 62 SES Yes
Angiographic binary 
restenosis
12 12.3
STRATEGY15 175 63 SES Yes
Death, MI, stroke, or 
angiographic binary 
restenosis
3 24.2
TYPHOON14 712 59 SES Yes
Cardiac death, MI, or 
reintervention 
6 12.1
DES - drug-eluting stent,; PES - paclitaxel-eluting stent; SES - sirolimus-eluting stent; MI - myocardial infarction; BASKET-AMI - Basel Stent 
Kosten Effektivitäts in Acute Myocardial Infarction trial; HAAMU-STENT - The Helsinki area acute myocardial infarction-treatment re-evaluation 
- Should the patient get a drug-eluting or a normal stent trial; MISSION - A Prospective Randomized Controlled Trial to Evaluate the Efficacy of 
Drug-Eluting Stents versus Bare-Metal Stents for the Treatment of Acute Myocardial Infarction; PASSION - the Paclitaxel-Eluting Stent versus 
Conventional Stent in Myocardial Infarction with ST-Segment Elevation trial; SESAMI - the Randomized Trial of Sirolimus Stent vs. Bare Stent 
in Acute Myocardial Infarction trial; STRATEGY - the Single High Dose Bolus Tirofiban and Sirolimus Eluting Stent vs. Abciximab and Bare Metal 
Stent in Myocardial Infarction trial; TYPHOON - the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon 
Angioplasty.
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metal stent. There was no heterogeneity across trials (I2=0%) and no significant interaction 
(P=0.07) between treatment effect and type of drug-eluting stent (sirolimus-eluting stent or 
paclitaxel-eluting stent) used. Sequential exclusion of each individual trial from the analysis 
of the primary endpoint yielded hazard ratios ranging from 0.33 (0.24 to 0.45) to 0.42 (0.30 
to 0.57), which were not significantly different from the overall hazard ratio. Specifically, the 
hazard ratio for reintervention associated with the use of drug-eluting stents was 0.39 (0.29 to 
0.53) when the trial for which no individual patient data were available was excluded.25 Figure 
2B shows one-year probability curves for reintervention in the 2 treatment arms. An early and 
Figure 2. (A) Absolute numbers of patients requiring reintervention and hazard ratios for this endpoint with drug-eluting stents vs. bare-metal 
stents for individual trials and the pooled population. Hazard ratios are shown on a logarithmic scale. The size of the square is proportional to the 
weight of the individual studies, measured as the inverse of the estimated variance of the log hazard ratio. DES, drug-eluting stent; BMS, bare-
metal stent. (B) Kaplan–Meier curves of reintervention in each of the stent groups for the pooled population.
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continuous separation of the curves is readily visible. The probability of reintervention was 
5.0% in the drug-eluting stent group and 13.3% in the bare-metal stent group. 
Figure 3A shows the number of patients who suffered the primary safety end point of stent 
thrombosis (as defined in the individual trials). The hazard ratio for stent thrombosis was 0.80 
(0.46 to 1.39), P=0.43. There was no heterogeneity across trials (I2=0%) and no significant 
interaction (P=0.89) between treatment effect and type of drug-eluting stent used (sirolimus-
eluting stent or paclitaxel-eluting stent). In addition, the hazard ratio for stent thrombosis 
associated with the use of drug-eluting stents was 0.82 (0.46 to 1.47) when the trial for which 
Figure 3. (A) Absolute numbers of patients with stent thrombosis and hazard ratios for stent thrombosis associated with drug-eluting stents 
vs. bare-metal stents for individual trials and the pooled population. Hazard ratios are shown on a logarithmic scale. The size of the square is 
proportional to the weight of the individual studies, measured as the inverse of the estimated variance of the log hazard ratio. DES, drug-eluting 
stent; BMS, bare-metal stent. (B) Kaplan–Meier curves of stent thrombosis in the pooled population according to stent type.
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no individual patient data were available was excluded.25 Figure 3B shows one-year curves of 
stent thrombosis probability for the 2 treatment groups. The probability of stent thrombosis 
was 1.6% in the drug-eluting stent group and 2.2% in the bare-metal stent group. Three stent 
thromboses occurred after 1 year: two in the drug-eluting stent group and one in the bare-
metal stent group.
Figure 4A shows the absolute numbers of deaths in each trial by treatment group with 
the hazard ratio for each trial. There was no heterogeneity across the trials (I2=1%) and no 
significant interaction (P=0.48) between treatment effect and type of drug-eluting stent used. 
Figure 4. (A) Absolute numbers of patients experiencing death and hazard ratios for death associated with drug-eluting stents vs. bare-metal 
stents for individual trials and the pooled population. Hazard ratios are shown on a logarithmic scale. The size of the square is proportional to the 
weight of the individual studies, measured as the inverse of the estimated variance of the log hazard ratio. DES, drug-eluting stent; BMS, bare-
metal stent. (B) Kaplan–Meier curves of mortality in each of the stent groups for the pooled population.
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Overall, use of the drug-eluting stent was associated with a hazard ratio for death of 0.76 
(0.53 to 1.10), P=0.14, compared with use of the bare metal stent. Ninety-eight of the 121 
death cases (81.0%) observed in the 7 trials for which patient-level data were available were 
of cardiac origin, without any significant difference between the drug-eluting stent group (45 
of 58 cases) and bare-metal stent group (53 of 63 cases), P=0.36. Figure 4B shows one-year 
mortality curves for the 2 treatment groups. The probability of death was 4.0% in the drug-
eluting stent group and 5.0% in the bare-metal stent group. Twelve patients died after 1 year: 
6 in the drug-eluting stent group and 6 in the bare-metal stent group.
Figure 5. (A) Absolute numbers of patients experiencing recurrent myocardial infarction associated with drug-eluting stents vs. bare-metal 
stents for individual trials and the pooled population. Hazard ratios are shown on a logarithmic scale. The size of the square is proportional to the 
weight of the individual studies, measured as the inverse of the estimated variance of the log hazard ratio. DES, drug-eluting stent; BMS, bare-
metal stent. (B) Kaplan–Meier curves of recurrent myocardial infarction in each of the stent groups for the pooled population.
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Figure 5A shows the absolute numbers of patients who suffered a recurrent myocardial 
infarction according to the treatment group, with the hazard ratio for each of these trials. No 
evidence of heterogeneity was observed across the trials (I2=0%). Overall, use of the drug-
eluting stent was associated with a hazard ratio for recurrent myocardial infarction of 0.72 
(0.48 to 1.08), P=0.11, compared with use of the bare metal stent. Figure 5B shows one-year 
probability curves for recurrent myocardial infarction in the 2 treatment arms. The probability 
of recurrent myocardial infarction was 2.5% in the drug-eluting stent group and 3.3% in the 
bare-metal stent group. 
The composite of death, recurrent myocardial infarction or reintervention was observed 
in 158 of the 1.474 patients in the drug-eluting stent group and 252 of the 1.312 patients 
in the bare-metal stent group. Use of the drug-eluting stent was associated with a hazard 
ratio for this composite end point of 0.53 (0.42 to 0.67), P<0.001, compared with use of the 
bare metal stent. The probability of the composite of death, recurrent myocardial infarction 
or reintervention was 9.5% in the drug-eluting stent group and 17.8% in the bare-metal stent 
group.
disCussion
In this study, we performed a meta-analysis of 8 randomised trials comparing drug-eluting 
stents with bare metal stents in patients with acute ST-segment elevation myocardial infarc-
tion. We found no significant differences in the risk of stent thrombosis, death or recurrent 
myocardial infarction between patients treated with drug-eluting stents versus bare-metal 
stents. On the other hand, we found that treatment with drug-eluting stents was associated 
with a 62% reduction in the hazard of reintervention as compared with bare metal stents. The 
advantage of drug-eluting stents was notable within the first month after the stent implanta-
tion procedure and continued to increase thereafter.
A large number of studies have shown that the use of drug-eluting stents is associated 
with favourable outcomes in patients with various clinical and angiographic characteristics.9,31 
However, data on the outcome of patients undergoing primary PCI with implantation of drug-
eluting stents have been limited and whether the favourable results obtained with drug-eluting 
stents in other settings also extend to patients with acute ST-segment elevation myocardial 
infarction has not been firmly established. A major concern with drug-eluting stents in this 
group of patients has been an increased risk for stent thrombosis, especially acute (within 24 
hours of stent implantation) and subacute (within 30 days of stent implantation).10 There is 
an increased platelet activation in acute coronary syndromes, especially in acute myocardial 
infarction,32 and coronary stenting is associated with a more intense platelet activation than 
balloon angioplasty alone.33 A greater platelet activation coupled to delayed healing, lack of 
endothelialisation, and exposure of proinflammatory and prothrombogenic environment of 
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the necrotic core could provide the rationale for an increased risk of drug-eluting stent throm-
bosis in patients with acute myocardial infarction.10 Recently, Park et al.12 found that primary 
stenting with implantation of sirolimus-eluting or paclitaxel-eluting stents in patients with 
acute myocardial infarction was a major predictor for acute and subacute stent thrombosis. 
However, registry studies of patients with acute ST-segment elevation myocardial infarction 
have not shown an increased risk of stent thrombosis with drug-eluting stents as compared 
with bare metal stents.34-36
In our meta-analysis, the incidence of stent thrombosis was similar among patients treated 
with drug-eluting stents versus bare-metal stents, as was the incidence of death or recurrent 
myocardial infarction. These findings support the safety of use of these stent types. However, 
they should be interpreted with caution. Despite the advantage conferred by meta-analysis 
which has the potential to increase the statistical power, the rare occurrence of the previously 
discussed adverse events might limit the capacity of this meta-analysis to detect a possible 
difference between the two treatment arms with regard to the safety outcomes. Larger stud-
ies with a longer follow-up period will be needed to definitely answer the question of whether 
primary stenting with drug-eluting stents is safe.37,38
ConClusion
In conclusion, the results of this meta-analysis show that the use of drug-eluting stents in 
patients undergoing PCI for acute ST-segment elevation myocardial infarction is safe and 
improves clinical outcomes by reducing the risk of reintervention compared with bare-metal 
stents.
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abstraCt
Aim ITF-1697 is a C-reactive protein-derived tetrapeptide that, based on pre-clinical studies, 
is thought to reduce reperfusion injury. We performed a dose-finding study to assess safety, 
preliminary efficacy and clinical outcome of prolonged i.v. infusion of ITF-1697 in patients 
with an acute myocardial infarction (AMI) who were eligible for percutaneous coronary inter-
vention (PCI).
Methods and Results This was a multicenter dose-finding study that was randomised, double 
blind, and placebo-controlled. Four-hundred-and-two patients were enrolled. Intravenous 
infusion of four dosages of ITF-1697 (0.1, 0.5, 1.0 or 2.0 µg/kg/min) or placebo was started 
before PCI and continued for 24 hours. After interim analysis of data from 242 patients the 
study continued with the 0.1 and 1.0 µg/kg/min ITF-1697 regimes. Analysis did not raise any 
safety concerns. Post-procedure perfusion, assessed by TIMI flow, corrected TIMI frame count, 
blushgrade and ST-segment resolution, was similar for the placebo, 0.1 and 1.0 µg/kg/min 
regimes. Furthermore, the results showed no differences between the treatment regimes in 
enzymatic infarct size or clinical outcome up to 30 days.
Conclusion ITF-1697 was well tolerated. However, neither a dose-relation nor improvement of 
perfusion, clinical outcome or reduction of myocardial damage could be demonstrated with 
ITF-1697 during and after primary PCI for AMI.
introduCtion
Acute myocardial ischaemia caused by thrombotic coronary occlusion leads to time-depen-
dent loss of myocytes. Percutaneous coronary intervention (PCI) and thrombolytic therapy 
are effective and commonly used therapies to obtain early reperfusion in acute myocardial 
infarction (AMI).1-3 Early reperfusion conveys tissue salvage, i.e. reduction in infarct size and 
preservation of left ventricular function, thereby improving short- and long-term outcome 
after AMI.4 However, it is has been suggested that reperfusion itself can precipitate further 
myocardial injury, known as ‘reperfusion injury’.5-7 If this ‘reperfusion injury’ could be treated 
and eliminated, the outcome for patients with AMI might improve further.8 Reperfusion injury 
is thought to be mainly mediated by an inflammatory response (polymorphonuclear neu-
trophil, complement and platelet activation), intracellular Ca+ overload and reactive oxygen 
species. Several pharmacological agents or adjunctive therapies have been used in the clinical 
setting to attempt to reduce the injury caused by these pathways.9-13
This report presents the first study investigating the effects of ITF-1697 on reperfusion injury 
in humans. ITF-1697 is a proprietary tetrapeptide Gly-(Et)Lys-Pro-Arg that corresponds to 
sequence 113-116 of C-Reactive Protein (CRP) and has been shown to exert anti-inflammatory 
actions and marked anti-anaphylactive properties.14 ITF-1697 is a new substrate that showed 
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promising results in the pre-clinical phase to prevent reperfusion injury in AMI, mainly by 
inhibiting the inflammatory response. Experimental data, obtained in models of ischaemia 
and reperfusion, have shown that ITF-1697 prevents PMN adhesion and extravasation, pre-
serves vascular endothelial phenotype and limits the increase in vascular permeability and 
loss of microcirculatory blood flow (unpublished data on file at Italfarmaco). For example, 
in the hamster cheek pouch model of microcirculation subjected to 30 min of ischaemia 
followed by reperfusion, ITF-1697 (1.0 µg/kg/min) virtually abolished microvascular damage 
(capillary leak, fluid extravasation, PMN adhesion and capillary plugging) and resulted in 
preservation of microcirculatory flow. Also, in a study in the in vivo dog heart, 0.83 µg/kg/min 
ITF-1697 (administered i.v. just prior to reperfusion after 90 minutes of coronary artery occlu-
sion) reduced myeloperoxidase activity (reflecting reduced neutrophil activity) and decreased 
myocardial infarct size by 50% resulting in preservation of ejection fraction (unpublished data 
on file at Italfarmaco). Other in vivo studies in rat, rabbit, and dog showed improved survival 
with ITF-1697 with doses as low as 0.05 µg/kg/min, administered either before coronary artery 
ligation or just prior to reperfusion after coronary occlusion resulting in myocardial infarc-
tion.
Accordingly, it was hypothesized that ITF-1697 may provide benefit on top of optimal drug 
and interventional therapy in patients with acute ST elevation myocardial infarction. The 
present study was designed to assess safety, and to compare preliminary efficacy and clinical 
outcome of prolonged intravenous infusion of four doses of ITF-1697 and placebo during and 
after a primary PCI procedure in patients with acute myocardial infarction.
methods
The Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction (PARI-MI) 
was a multicenter, randomised, double blind, placebo controlled, dose finding study 
conducted in eleven centres in Italy and The Netherlands between January and December 
2001. The study was started comparing 4 doses ITF-1697 (0.1, 0.5, 1.0, 2.0 µg/kg/min) and 
placebo with about 50 patients in each group. After interim analysis the study was designed 
to continue with another 50 patients in each of 2 doses ITF-1697 and placebo. Thus, finally 3 
groups of 100 patients each (2 doses ITF-1697 and placebo) and 2 groups of 50 patients each 
(ITF-1697) were to be enrolled.
Study population
Patients with typical symptoms of AMI and electrocardiographic (ECG) signs of a large or 
medium size infarction, who were eligible to undergo invasive revascularization through pri-
mary PCI, were included in the trial. Written informed consent was obtained from all patients 
and the study design was approved by the institutional ethics committees.
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Patients of both sexes had to be at least 18 years of age and time from symptom onset to 
enrolment had to be within 12 hours. Chest pain had to last for at least twenty minutes and 
thrombolytic treatment prior to PCI was not allowed. In order to enrol patients with large and 
medium size AMIs ST segment elevation had to be ≥0.2 mV in two or more contiguous leads 
with the cumulative ST deviation ≥10 mV on a 12-lead ECG. Patients were excluded having 
a history of bleeding diathesis; major bleeding ≤30 days; major surgery ≤30 days; history 
of known hemorrhagic stroke at any time or any stroke ≤30 days; uncontrolled hyperten-
sion (>200/110 mmHg); participation in another trial; inability to perform 30 day follow up; 
pregnancy or women of childbearing potential; concomitant disease that interferes with 
prognosis; contra-indications to standard drugs for coronary intervention and coronary heart 
disease; weight >105 kg. Study medication was started in eligible patients after informed 
consent without further delay. When subsequent platelet count <60,000/mm3 (<60x109 /L), 
hematocrit <30% or creatinine ≥2.9 mg/dL (≥177 µmol/L) indicated that the patient should 
have been excluded, the infusion of study medication was stopped. Nevertheless, the patient 
remained in the study and all measurements were performed according to the intention to 
treat principle.
Treatments
Patients were randomised by an Interactive Voice Response System to an 1-2 minutes i.v. load-
ing dose followed by a continuous i.v. infusion of ITF-1697 in different doses (0.1, 0.5, 1.0, 2.0 
µg/kg/min) or placebo. The intravenous loading dose was 11, 55, 110, and 220 µg/kg in the 0.1, 
0.5, 1.0 and 2.0 µg/kg/min ITF-1697 treatment groups, respectively. The rationale for the dose 
regimen employed was based on (unpublished) animal data. In an in vivo dog heart study, 
ITF-1697 was injected intravenously starting with a slow bolus of 100 µg/kg (starting 10 min 
prior to reperfusion) followed by 0.83 µg/kg/min throughout the 4.5 h reperfusion protocol 
and markedly reduced myocardial infarct size (unpublished data on file at Italfarmaco). Study 
drug was started after enrolment prior to angiography, and continued up to 24 hours. PCI of 
the infarct related coronary artery was performed at the investigator’s discretion. Aspirin was 
given daily starting on hospital admission with a loading dose of 300 to 500 mg. In the case 
of stenting, clopidogrel was given at a loading dose of 300 mg followed by 75 mg/day for 
four weeks. Concomitant treatment with (low molecular weight) heparin, glyco-protein IIb/
IIIa inhibitors and all other therapies was at the investigator’s discretion.
Safety
The safety endpoints were death, recurrent AMI, bleeding and other Serious Adverse Events 
(SAE) from hospital admission until 30 days. This was assessed by laboratory blood samples, 
routine ECG and an outpatient clinic visit at 30 days (23-37). All deaths were included (cardiac 
and non-cardiac) and classified whenever possible on the basis of an autopsy. Bleeding, 
including intracranial haemorrhage, was classified according to the TIMI criteria.15 SAE’s were 
111
The effect of ITF-1697 on reperfusion in patients
C
h
ap
te
r 
8
defined as any medical occurrence that resulted in death, life-threatening situations, hospi-
talisation or prolongation of the existing hospitalisation, or persisting significant disability.
Efficacy
The efficacy endpoints were myocardial perfusion and myocardial infarct size. Perfusion was 
assessed by TIMI flow grade,16 corrected TIMI frame count (CTFC, corrected for 30 frames/
second (f/s): LAD),17 myocardial blush grade,18 ST-segment resolution and recurrent ischaemia 
or recurrent AMI. With regard to the CTFC the distribution plot of TIMI frame counts were 
drawn for placebo and ITF 1697-treated patients. Values below 28 f/s were taken into account 
for defining normal reperfusion. Leftward shift of the mean frame count of at least 6 f/s was 
considered clinically significant. In case of an occluded vessel the maximum frame count 
measurement was scored. Two independent observers performed ST-segment analysis. The 
sum of ST segment elevation and depression was measured with lens-intensified callipers 
to the nearest 0.025 mV, 60 ms after the end of the QRS complex (J-point) of all 12 leads. 
Measurements were done at 1 and 3 hours after intervention. 
Myocardial infarct size
Myocardial damage was estimated by the area under the curve of serial alpha-hydroxybutyrate 
dehydrogenase (HBDH).19-21 Haemolysed samples were discarded. and all other measurements 
were performed centrally by independent, blinded, and qualified personnel in the core labo-
ratory. The angiographic measurements, the ST-segment measurements, as well as infarct size 
analysis and calculation were all performed centrally by independent and qualified personnel 
in the core laboratory, blinded for treatment assignment.
Clinical outcome
Re-infarction was defined as a second rise in CK-MB or total CK ≥2 times the upper limit of 
normal and the onset of recurrent angina or new significant Q-waves of ≥0.04 seconds in 
duration or having a depth > one fourth of the corresponding R-wave amplitude in two or 
more contiguous leads.
Recurrent ischaemia was defined as 1) an episode of chest pain at rest, associated with new 
ST segment shift of ≥ 0.1 mV or T-wave inversion/pseudo-normalization in at least two con-
tiguous leads, 2) chest pain resulting in an invasive cardiac intervention (including diagnostic 
catheterisation, intra-aortic balloon pump counterpulsation, PCI or Coronary Artery Bypass 
Graft (CABG)) within the same hospitalisation, or 3) readmission for unstable angina.
Statistical analysis
Two interim analyses were performed to evaluate safety and dose-response relationships in 
order to select two dosages for continuation and final analysis. With respect to preliminary 
efficacy assessment the following information regarding clinically significant changes in the 
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relevant parameters applied, based on the control group data versus the ITF-1697 treatment 
group: A TIMI flow grade 3 of 85 versus >90%2, myocardial blush grade 3 of 25 versus >30%18 
and enzymatic infarct size of 4.4 versus <3.9 g-eq.4 In addition, if any dose relationship in the 
incidence of adverse events seemed to be present, logistic regression analysis was used for 
trend analysis.
The first interim analysis was performed after 125 patients, and the second interim analysis 
after about 250 patients had received ITF-1697 infusion or placebo. The following criteria were 
applied: a) If dose-response was detected, two safe and effective dosages were to be selected. 
b) If a dose-response was not evident, the number of 50 patients per group allowed to have 
90% statistical power to select the best dosage with respect to the aforementioned param-
eters of TIMI flow grade, blush grade and infarct size.22 The final sample size of 100 patients for 
the 2 selected dosages and placebo allowed an estimate of two-sided 90% C.I. equal to ±10% 
for differences between the response rate of active doses and placebo.
Data were presented as mean ±SD, and for non-parametric measurements as median with 
percentiles. All analyses were performed comparing each active ITF-1697 dosage group sepa-
rately with placebo. For discrete variables a Chi-square test was used. Binomial confidence 
intervals were constructed and a Fisher’s Exact Test was performed to compare the incidence 
of adverse events of ITF-1697 with placebo. No adjustments were made for multiple testing. 
A Student’s t-test was performed on normally distributed continuous data or a Wilcoxon rank 
test in case of skewed data distribution. Significance was defined as P<0.05.
Subgroup analyses. 
Additional subgroups analysis was performed for gender; blush grade before procedure; ST-
segment resolution; age (above or below median, < or ≥70 years); use of GPIIb/IIIa antagonist; 
time from onset of symptoms and intervention (≥ or <2 hours); infarct location; LAD or RCA 
as culprit lesion; infarct size (above or below median); and an event free history prior to the 
AMI.
results
Patient groups
A total of 402 patients were enrolled. Ten patients were excluded from the analysis: seven 
patients were randomised but did not receive study medication for various reasons, one other 
patient died shortly after randomisation before study medication was given, one patient 
refused written informed consent although he had given with oral consent in the presence 
of a witness, and one patient withdrew the informed consent before discharge. Finally 392 
patients were enrolled and received study medication. After the first interim analysis the study 
was continued without modification. After the second interim analysis, with 242 patients, the 
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study was continued with the placebo, 0.1 and 1.0 µg/kg/min dose regimes. The 1.0 µg/kg/min 
ITF-1697 regime was chosen as it was closest to the 10% absolute difference in TIMI flow grade 
3 indicated by the protocol. The 0.1 µg/kg/min ITF-1697 was chosen to maintain reasonable 
pharmacological interval. Ninety-two patients received placebo, 93 were treated with ITF-1697 
0.1 µg/kg/min and 94 with 1.0 µg/kg/min. The treatment groups ITF-1697 0.5 and 2.0 µg/kg/
min contained 55 and 58 patients, respectively. Baseline characteristics were similar between 
the groups (table 1). In total 18 patients did not undergo a PCI because of various reasons, 
and did not continue on study medication after the initial loading dose and infusion, hence 
were expelled from further analysis. Three of these patients underwent emergency coronary 
bypass surgery. Pre-procedurally there were no significant differences apparent, except for 
TIMI flow: the ITF-1697 1.0 treatment group contained a higher percentage of patients with 
an occluded vessel (TIMI flow grade 0, 1) at baseline. Because of this unbalanced distribution 
it was decided post-hoc to perform a subgroup analysis in 208 patients with occluded vessels 
treated with placebo, 0.1 or 1.0 µg/kg/min ITF-1697.
Angiographic results
A successful PCI procedure, indicated by a post-procedural epicardial TIMI flow grade 3, was 
achieved in the placebo, ITF-1697 0.1 and ITF-1697 1.0 group in 82%, 84% and 88%, respectively 
(table 2). Coronary stenting was performed in 84 (92%) of the placebo cases compared with 80 
(85%) and 83 (89%) in the ITF-1697 0.1 and 1.0 group, respectively. GPIIb/IIIa antagonists were 
used in 122 patients, 44%. The median CTFC in the total population was 24 f/s. The results 
table 1. Baseline Demographics
Characteristics Placebo 0.1 ITF-1697 1.0 ITF-1697
N = 92 (%) N = 93 (%) N = 94 (%)
Mean age — yr ± SD 61 ± 13 62 ± 11 60 ± 12
Male — (%) 76 (83) 70 (75) 79 (84)
Non smokers — (%) 29 (32) 33 (36) 29 (31)
Diabetes (N)IDD — (%) 11 (12) 9 (10) 17 (18)
Previous MI — (%) 17 (19) 11 (12) 14 (15)
Previous angina —(%) 20 (22) 15 (16) 14 (15)
Previous PCI —(%) 8 (9) 6 (6) 11 (12)
Previous CABG — (%) 2 (2) 1 (1) 2 (2)
Previous stroke — (%)
Non-Hemorrhagic 1 (1) 3 (3) 3 (3)
TIA 2 (2) 4 (4) 3 (3)
Heart Failure (Killip Classification) — (%)
Class I 82 (89) 92 (98) 84 (89)
Class II-IV 10 (11) 2 (2) 10 (11)
No significant differences between the groups.
(N)IDDM = (non) insulin dependent diabetes mellitus; MI = myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary 
artery bypass grafting; TIA = transient ischaemic attack.
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table 2. Angiographic and Angioplasty Results 
Variable Placebo 0.1 ITF-1697 1.0 ITF-1697
Total study population — no. (%)
TIMI flow Pre-procedure 91 93 92
0-1 63 (69) 69 (74) 76 (83)*
2 13 (14) 14 (15) 13 (14)
3 15 (17) 10 (11) 3 (3)
p-value 0.51 0.013*
TIMI flow Post-procedure 90 90 88
0-1 4 (4) 1 (1) 3 (3)
2 12 (13) 13 (14) 8 (9)
3 74 (82) 76 (84) 77 (88)
p-value 0.63 0.34
CTFC Pre-procedure 83 93 91
Median f/s (P25-P75) 173 (173-173) 173 (173-173) 173 (173-173)
p-value 0.92 0.16
CTFC Post-procedure 70 77 72
Median f/s (P25-P75) 24 (17-36) 26 (17-41) 24 (14-41)
p-value 0.52 0.99
Blushgrade Post-procedure 77 78 81
0-1 32 (41) 38 (49) 43 (53)
2 20 (26) 27 (35) 23 (28)
3 25 (33) 13 (17) 15 (19)
p-value 0.16 0.13
Subgroup TIMI flow grade 0, 1 pre-intervention — no. (%)
TIMI flow Post-procedure 62 66 73
0-1 4 (6) 1 (2) 3 (4)
2 12 (19) 11 (17) 7 (10)
3 46 (74) 54 (82) 63 (86)
p-value 0.25 0.09
CTFC Post-procedure 49 57 58
Median f/s (P25-P75) 24 (19-46) 26 (17-43) 24 (14-42)
p-value 0.97 0.62
Blushgrade Post-procedure 53 56 81
0-1 20 (38) 29 (43) 36 (55)
2 14 (26) 18 (32) 18 (27)
3 19 (36) 9 (16) 12 (18)
p-value 0.06 0.05
p-value: ITF-1697 dosage compared with placebo.
*: statistically significant.
TIMI = thrombolysis in myocardial infarction; CTFC = corrected TIMI frame count.
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of the angiographic measurements (TIMI flow, CTFC and blush grade) used as markers of 
reperfusion efficacy did not show any significant difference between the treatment groups.
Electrocardiographic results
ECG’s at enrolment as well as at 1 vs. 3 hours post PCI were available in 372 patients (of the 
total of 392). There was no effect of either one of the ITF-1697 treatment regimes on the extent 
of ST-segment resolution (table 3).
Infarct size
The median enzymatic infarct size, as measured by the area under the HBDH curve in the 
total group was 5.2 g-eq. The infarct size for placebo, ITF-1697 0.1 and ITF-1697 1.0 and in 
the subgroup TIMI 0, 1 pre-intervention as shown in table 4 was not significantly different. 
table 3. ECG resolution of ST-segment elevations at one and three hours after intervention
Variable Placebo 0.1 ITF-1697 1.0 ITF-1697
Total study population — no. (%)
1hr ST-resolution 72 69 83
Complete resolution 22 (31) 20 (29) 20 (24)
Partial resolution 22 (31) 30 (44) 36 (43)
No resolution 28 (39) 19 (28) 27 (33)
p-value 0.45 0.96
3hr ST-resolution 78 78 80
Complete resolution 29 (37) 30 (39) 23 (29)
Partial resolution 32 (41) 36 (46) 44 (55)
No resolution 17 (22) 12 (15) 13 (16)
p-value 0.56 0.71
Subgroup TIMI 0, 1 pre-intervention — no. (%)
1hr ST-resolution 48 50 66
Complete resolution 11 (23) 15 (30) 15 (23)
Partial resolution 16 (33) 20 (40) 31 (47)
No resolution 21 (44) 15 (30) 20 (30)
p-value 0.19 0.32
3hr ST-resolution 53 56 64
Complete resolution 14 (26) 21 (38) 19 (30)
Partial resolution 27 (51) 27 (48) 35 (55)
No resolution 12 (23) 8 (14) 10 (16)
p-value 0.15 0.43
p-value: ITF-1697 dosage compared with placebo.
Complete resolution is ≥70% ST-segment resolution; Partial resolution is 30%-70% ST-segment resolution; No resolution is <30% ST-segment 
resolution; TIMI = thrombolysis in myocardial infarction.
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Larger infarct size was found in the total population in the TIMI 0, 1 pre-intervention subgroup 
compared to TIMI 2, 3 pre-intervention.
Clinical outcome
Clinical endpoints did not raise any safety concerns in any group. Ten patients died during the 
initial hospitalisation. At thirty days there were 16 deaths reported (table 5). The occurrence 
of adverse events such as recurrent MI, CABG, or bleeding did not show significant differ-
ences between the regimes. After thirty days 10 (3.6%) patients had suffered from recurrent 
ischaemia. A combination of the endpoints of mortality, recurrent ischaemia or recurrent AMI 
did not reveal a treatment effect of ITF-1697 (table 5). Fifteen of the total of sixteen reported 
table 4. Median enzymatic infarct size
Variable Placebo 0.1 ITF-1697 1.0 ITF-1697
Total study population — no. 88 90 92
g-eq/L (P25-P75) 4.5 (3.2-9.1) 5.0 (3.2-7.3) 5.3 (3.6-9.8)
p-value 0.84 0.36
Subgroup TIMI 0,1 pre-intervention — no. 59 65 74
g-eq/L (P25-P75) 5.8 (3.7-9.1) 5.6 (3.7-9.4) 6.0 (3.9-11.2)
p-value 0.98 0.24
p-value: ITF-1697 dosage compared with placebo.
g-eq = gram equivalents; TIMI = thrombolysis in myocardial infarction. 
table 5. Endpoints: Events at 30 days
Variable Placebo 0.1 ITF-
1697
0.5 ITF-
1697
1.0 ITF-
1697
2.0 ITF-
1697
ITF total
Total study population — no. (%) 92 93 55 94 58 300
Mortality
p-value
3 (3.3) 3 (3.2)
1.0
4 (7.3)
0.43
2 (2.1)
0.68
4 (6.9)
0.43
13 (4.3)
0.77
Recurrent MI
p-value
0 0
1.0
1 (1.8)
0.37
2 (2.1)
0.50
2 (3.4)
0.15
5 (1.7)
0.60
CABG
p-value
2 (2.2) 3 (3.2)
1.0
1 (1.8)
1.0
2 (2.1)
1.0
3 (5.2)
0.38
9 (3.0)
1.0
Bleeding
p-value
13 (14) 7 (7.5)
0.16
7 (13)
1.0
14 (15)
1.0
3 (5.2)
0.11
31 (10)
0.35
Mortality or MI or re-Ischemia
p-value
6 (6.5) 4 (4.3)
0.54
5 (9.1)
0.75
10 (11)
0.43
7 (12)
0.25
26 (8.7)
0.66
Subgroup TIMI 0, 1 pre-intervention — no. 
(%)
63 68 45 76 40 229
Mortality
p-value
3 (4.8) 2 (2.9)
0.67
4 (8.9)
0.45
2 (2.6)
0.66
4 (10)
0.43
12 (5.2)
1.0
Recurrent MI
p-value
0 0
1.0
1 (2.2)
0.42
2 (2.6)
0.50
2 (5.0)
0.15
5 (2.2)
0.59
Recurrent-Ischemia
p-value
1 (1.6) 1 (1.5)
1.0
0
1.0
5 (6.6)
0.22
2 (5.0)
0.56
8 (3.5)
0.69
p-value: ITF-1697 dosage compared with placebo.
MI = myocardial infarction; CABG = coronary artery bypass grafting TIMI = thrombolysis in myocardial infarction.
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deaths had TIMI flow grade 0, 1 pre-intervention. Recurrent myocardial infarction or recurrent 
ischaemia was not evidently higher in this subpopulation compared with those having TIMI 
2, 3 flow pre-intervention.
Subgroup analysis
Analysis of the before mentioned subgroups on safety and efficacy between either one of 
the treatment groups compared with placebo did not reveal a dose response relation. Also, 
the angiographic outcome in the TIMI flow grade 0, 1 pre-intervention subgroup showed no 
significant differences, albeit a trend was observed for post-procedural TIMI flow in favour of 
both ITF-1697 treatment groups. The CTFC and blush grade did not differ significantly in this 
subgroup. In fact, the latter showed a possible adverse trend (table 2).
disCussion
The principal finding of the present study was that prolonged i.v. administration of ITF-1697 
as an adjunct to primary angioplasty was well tolerated and without safety concerns. In fact, 
the mortality after a large AMI in the total study population was low (4.1% at 1 month), which 
compares favourably with the overall 8.4% one-month mortality after myocardial infarction 
in the European Heart Survey.23 Overall ITF-1697 did not appear to exert a significant effect 
on indices of reperfusion (TIMI flow grade, CTFC, or blush grade), ST-segment resolution, 
myocardial infarct size, or clinical outcome, and no dose response was apparent. However, 
a trend towards better TIMI flow post-procedure was observed in the ITF-1697 1.0 µg/kg/
min dose group. Furthermore, there appeared to be an imbalance in the number of patients 
with occluded infarct related vessels at angiography (TIMI flow 0, 1). These patients showed a 
larger infarct size and a higher mortality rate. In a separate analysis of patients with an initially 
occluded vessel a possible dose-effect relation was observed for post-procedural TIMI flow in 
favour of both ITF-1697 treatment groups. However, no such trends were apparent for rep-
erfusion, infarct size or clinical outcome, while blush grade even showed a possible adverse 
trend (table 2). Future studies might investigate whether the latter observations in patients 
with an initially occluded vessel are true, or a chance finding.
Reperfusion injury: Purported mechanisms
Reperfusion is the only intervention that has been proven to halt the process of myocardial 
infarction after coronary artery occlusion. However, benefits of reperfusion may be limited 
by untoward effects, termed “reperfusion injury”.5-8 The mechanism of reperfusion injury is 
not completely understood, but may include (i) cytosolic and mitochondrial Ca+-overload, 
(ii) massive release of reactive oxygen species, (iii) damage to the extracellular matrix, (iv) 
impaired cellular energetics, and (v) an acute inflammatory response.5,8,24,25 The latter involves 
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recruitment of polymorphonuclear neutrophils (PMN), complement and platelet activation, 
and disturbed endothelial function, which leads to increased permeability and results in more 
necrosis and myocardial damage. Recruitment and activation of PMN results in capillary plug-
ging (thereby mechanically blocking flow), capillary leakage and enhancement of generation 
of reactive oxygen species, together culminating in secondary impairment of microcirculatory 
flow (“no-reflow” phenomenon) despite initial restoration of epicardial coronary patency and 
blood flow.24-27 The occurrence of no-reflow correlates with increased final infarct size and 
a poorer long-term clinical outcome.28,29 Consequently, targeting one or more of the above 
mentioned mechanisms could further improve the benefit of early reperfusion.
Apparent lack of effect of ITF-1697 in patients with myocardial infarction
Results from different animal models of reperfusion injury indicated that with ITF-1697 
the infarct size, occurrence of ventricular tachycardias and fibrillation as well as mortality 
was reduced. These beneficial effects were observed in models in which the substrate was 
administered before and during ischaemia as well as when administered at the time of rep-
erfusion (unpublished data on file at Italfarmaco). In contrast to these findings the present 
study showed neither consistent benefit nor a dose-effect relation of ITF-1697 on indices of 
perfusion after direct PCI. To detect a dose-response in this study population an extensive 
prospectively prescribed statistical analysis was developed, unfortunately this analysis could 
not demonstrate a dose-response. Several factors may contribute to the discrepancy between 
animal experiments and the present study in humans.
Collateral blood flow
Collateral blood flow is an important determinant of infarct size.30 In the AMISTAD trial the 
authors speculated that the benefit of adenosine (as an adjunct to thrombolysis) which 
occurred selectively in patients with an anterior AMI, could be attributed to collateral flow.10 In 
contrast, the present study failed to reveal any evidence of a differential outcome in patients 
with culprit lesions in either RCA or LAD.
Timing of administration
It could be argued that ITF-1697, administered prior to, during and after PCI, did not reach the 
jeopardized myocardium in sufficient concentrations prior to the onset of reperfusion, except 
perhaps via microvascular collateral vessels that are undetectable by coronary angiography.31,32 
Yet, it should be appreciated that ITF-1697 was infused intravenously several minutes before 
PCI was performed. This should give ample time to achieve adequate plasma levels of ITF-
1697, so that at the time of onset of reperfusion most neutrophils should have been exposed 
to ITF-1697. The apparent lack of benefit in patients with an open IRV at angiography may be 
related to the timing of drug administration, since in those patients spontaneous reperfusion 
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had already occurred, implying that ITF-1697 was administered at a considerable time after 
(partial) reperfusion.
Duration of ischaemia
In a previous study in dogs, ITF-1697 limited myocardial infarct size when administered just 
prior to reperfusion after up to 90 minutes coronary artery occlusion. In contrast, in the pres-
ent study coronary artery occlusions lasted more than two hours. It is possible that ischaemia-
related damage predominates in patients with such prolonged coronary occlusion (which is 
typical for clinical studies), with few cardiomyocytes left to be affected by reperfusion injury.31 
Consequently, little effect might then be expected of reperfusion injury limiting strategies. 
This may, at least in part, explain why over the past few years several pharmacological agents 
that have shown considerable promise in the experimental setting have failed to show any 
benefit in the clinical setting of ischaemia and reperfusion.9,11-13 However, even when we an-
alysed the subgroup of patients that had re-established flow within two hours of symptom 
onset, no benefit was observed.
Presence of pre-infarct angina
Another important difference between the clinical and experimental setting is that the myo-
cytes used in animal studies are, in contrast to human coronary arteries, generally not subjected 
to the process atherosclerosis, endothelial dysfunction and/or myocardial ischaemia prior to 
the sustained coronary artery occlusion.27,31 It is thus possible that patients, particularly those 
that experience angina prior to infarction, are protected via ‘ischemic-preconditioning’,33,34 so 
that less additional benefit of ITF-1697 might be expected. However, also in patients with an 
event free history prior to the AMI no benefit of ITF-1697 was observed in the present study.
Micro-embolization
Another consequence of the process of atherosclerosis in the human heart versus coronary 
artery ligation in experimental animals,26,31 is that impaired post-procedural perfusion or the 
no-reflow phenomenon could be, at least in part, the result of embolization of plaque debris 
into the distal microvasculature rather than of reperfusion injury.35-38
Co-medication
It may be hypothesized that treatment with heparin and GPIIb/IIIa blockers may influence 
the effect of ITF-1697 on adherence and extravasation of PMNs and possibly on endothelial 
permeability.39-41 Subgroup analysis did not support such a hypothesis, as we did not observe 
any effect of ITF-1697 in patients who did or did not receive heparin and GPIIb/IIIa blockers.
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Doses of ITF-1697
The highest dose used in the current trial (2.0 µg/kg/min) was 2.4 fold higher then the dose 
the limited infarct up to size 50% in the dog. Nevertheless, it is possible that the dose regimes 
that were employed in this study may not have been optimal in humans.
Sample size
The sample size used was large enough for safety assessment and dose effect detection, but 
not large enough to conclude definitely whether ITF-1697 administration, as an adjunct to 
primary PCI, can modulate reperfusion. We do realise that an effect of ITF-1697 could have 
been missed in this relatively small study. Furthermore, it should be appreciated that this 
study was rather complex, concerning many different measurements in patients admitted 
with myocardial infarction. Because of this complexity measurements were incomplete in part 
of the patients. Yet, the primary angiographic endpoints were complete in 84% (blushgrade) 
to 96% (TIMI flow grade) of the patients.
ConClusion
Reperfusion injury in clinical practice
The concept of reperfusion injury has been clearly demonstrated in many experimental stud-
ies, although even in those studies data are not fully consistent.8,24,25,31,42 In contrast, in clinical 
myocardial infarction, the importance of reperfusion injury has not been established. In fact, 
clinical studies with anti-inflammatory drugs,11,13 Na+/H+ exchange inhibitors,9 glucose-insulin-
potassium,12,43,44 and adenosine10,45 so far led to inconclusive results. This in mind, one might 
raise the question that possibly treatment in clinical practice is too late to reduce reperfusion 
injury or that there is no (relevant) reperfusion injury in humans, and thus no clinical benefit 
of decreasing such injury. Similarly, the PARI-MI study did not reveal a clear benefit, and no 
dose-relation, even though higher dosages were studied than in the pre-clinical studies, in 
which ITF-1697 was shown to be beneficial. The main reason for discrepancy between animal 
and human findings would be the different pathophysiologic context in which the drug was 
tested, leaving open the hypothesis that the drug might have beneficial effects in different 
pathophysiological settings, more appropriate for the drug activity.
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abstraCt
Aims To examine the safety and efficacy of intravenous caldaret in patients with large acute 
ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention 
(PCI).
Methods and results STEMI patients (n=387) with ≥10 mm summed ST-deviation on electro-
cardiogram were randomized to receive a 48 h infusion of caldaret 57.5 mg [lower dose (LD)], 
caldaret 172.5 mg [higher dose (HD)], or placebo, starting before PCI. Both HD and LD were 
well tolerated. In 247 patients with pre-PCI TIMI 0/1, there was no effect of HD or LD on single 
photon emission computed tomography infarct size or ejection fraction assessed at Day 7 
and Day 30. Subgroup analyses suggest that future work in patients with anterior MI might 
be warranted.
Conclusion This first human experience with caldaret prior to direct PCI for large STEMI shows 
a good safety profile. No evidence of efficacy was discerned. Subgroup analyses in anterior MI 
patients showed some effects in endpoints studied, however, these findings require confirma-
tion in a further study if a drug effect is to be established.
introduCtion
Percutaneous coronary intervention (PCI) for patients with acute ST-elevation myocardial 
infarction (STEMI) achieves high epicardial recanalization rates and low mortality.1,2 Even when 
epicardial reperfusion is successful, microvascular ‘reperfusion injury’ may account for up to 
50% of the final infarct size and mechanisms of reperfusion injury may include intracellular 
calcium overload.3-5 Acidotic conditions associated with ischaemia and reperfusion activate 
the Na+/H+ exchanger, and Na+ extrusion is prevented by inhibition of Na+/K+ ATP-ase, leading 
to elevated intracellular sodium levels, which in turn increase intracellular calcium levels via 
Na+/Ca2+ exchange.3,6 Calcium overload contributes to cell death, myocardial hypercontracture, 
and arrhythmias.7 Damage by reperfusion injury may also be mediated by other cell-mediated 
processes.3,4,8
Therapies targeting reperfusion injury might reduce infarct size and improve outcomes.4,9-11 
In animal models, caldaret (5-methyl-2-[piperazine-1-yl] benzenesulfonic acid monohydrate; 
MCC-135) inhibits intracellular calcium overload induced by ischaemia and reperfusion,12 
enhances calcium uptake into and inhibits calcium leakage from the sarcoplasmic reticulum,13,14 
and is selective for ischaemic myocardium.13 In reperfusion models, caldaret reduces myocar-
dial infarct size,15 decreases cardiac markers,16 and improves left ventricular (LV) function.16 
To test the theoretical benefit of caldaret, as an indirect calcium scavenger and an adjunct 
to direct PCI for STEMI, a pilot study of the safety and effectiveness of two doses of caldaret 
compared with placebo was conducted in human subjects.
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methods
Dose
In this study, 57.5 mg caldaret [lower dose (LD) group], 172.5 mg caldaret [higher dose (HD) 
group], or placebo as a 45 min loading infusion (40 mL/hour) started prior to PCI, followed by 
maintenance infusion (4.2 mL/hour) for 24-48 h (minimum requirement of 24 h), was utilized 
in this study. These doses covered the anticipated therapeutic dose range, based on cardio-
vascular pharmacology studies in dogs, and a previous Phase I trial in healthy volunteers, 
which demonstrated that intravenous caldaret at doses up to the HD used were safe and well 
tolerated.
Trial design
CASTEMI, a multicentre, randomized, double-blind, placebo-controlled trial, examined the 
safety and efficacy of intravenous infusions of caldaret in patients undergoing primary PCI for 
STEMI. Caldaret was administered in addition to accepted standard therapy.
Within 6 h of the onset of symptoms of STEMI, eligible patients were randomized unstrati-
fied in blocks of six (1:1:1) using an interactive voice recognition system to receive LD, HD, 
or placebo. Coronary angiography determined thrombolysis in myocardial infarction (TIMI) 
flow grade prior to PCI. Angiograms were assessed by a blinded angiographic core labora-
tory (Heart Core, Leiden, The Netherlands). Efficacy endpoints and clinical evaluations were 
performed on Days 1-5, Day 7 [or discharge, if sooner (Day 7/discharge)], and Day 30. The PCI 
technique used followed local protocol.
Patient population
Patients were enrolled between April 2002 and February 2003 in 29 centres in Belgium, Ger-
many, Israel, The Netherlands, and Spain. The study complied with the Declaration of Helsinki, 
was approved by local Ethics Committees, and written informed consent obtained from all 
patients.
Inclusion criteria 
Inclusion criteria: male or female patients ≥18 years of age (≥35 years in Germany) with 
ongoing chest pain of ≥20 min, presenting within 6 h of onset of symptoms; confirmatory 
electrocardiogram (ECG) showing a large STEMI defined as ST-segment elevation of ≥0.2 mV 
(2 mm) in two contiguous anterior or extremity leads, and ≥1.0 mV (10 mm) summed from all 
leads; with a vascular access suitable for angiography.
Exclusion criteria
Major exclusion criteria: fibrinolytic therapy for the index infarct; previous MI overlapping the 
location of the index MI; cardiogenic shock unresponsive to intravenous fluid; severe conges-
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tive heart failure (CHF; NYHA grade IV); known renal dysfunction (serum creatinine >1.5 x 
upper limit of normal); cerebrovascular event within the past 6 months; current therapy with 
catecholamines, phosphodiesterase inhibitors, or calcium sensitizers.
Study endpoints
Safety assessments
The safety population comprised 381 (98.4%) of 387 patients receiving study infusions. Safety 
endpoints were frequency and nature of treatment-related treatment-emergent adverse 
events (TEAEs); 30-day mortality; vital signs and laboratory safety; heart rhythm, conduction 
abnormalities, and ST-segment recovery by continuous 12-lead digital ECG monitoring over 
24 h from the onset of drug infusion (eECG Core Laboratory, Duke University Medical Center, 
Duke Clinical Research Institute, NC, USA). An independent Data and Safety Monitoring Com-
mittee reviewed safety data during the study. Safety analyses were performed in all patients 
treated regardless of initial TIMI flow.
Efficacy measures
Efficacy analyses, prospectively defined, included 247 patients with initial TIMI 0/1 flow. The 
primary efficacy endpoint was infarct size, determined by single photon emission computed 
tomography (SPECT) on Day 7/discharge in patients with pre-PCI TIMI flow grade 0/1. Rest-
ing SPECT imaging was obtained using 22-25 mCi 99mTc-sestamibi and analysed in a blinded 
core laboratory (Heart Core, Leiden, The Netherlands) using Quantitative Gated SPECT and 
Quantitative Perfusion SPECT analytical packages (Software version 1.0, Cedars-Sinai Medical 
Center, Los Angeles, CA, USA) on a UNIX system. All participating centres were tested by the 
core laboratory to verify the quality of SPECT images.
Secondary endpoints:
- Area under the concentration–time curve (AUC) for total creatine kinase (CK) and its MB 
isoenzyme (CK-MB) to 72 h; for troponin T (TnT) and lactate dehydrogenase (LDH) to Day 
5 (Quest Diagnostics, Heston, UK or St George’s Hospital, London, UK).
- Infarct size on Day 30; LV end-systolic volume (LVESV) and LV enddiastolic volume (LVEDV) 
on Day 7/discharge and Day 30; global LV ejection fraction (LVEF) on Day 7/discharge and 
Day 30, determined by SPECT.
- Clinical endpoints, adjudicated by an independent blinded committee (Dr Marc A. Pfef-
fer, Brigham and Women’s Hospital Cardiovascular Division, Boston, MA, USA), consisted: 
all-cause mortality, cardiac mortality, and resuscitated sudden death up to Day 30; CHF 
and re-admission for CHF up to Day 30; stroke and re-infarction up to Day 30; composite 
clinical endpoint up to Day 30, consisting of time to event for major adverse cardiovascu-
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lar events (death, re-infarction, revascularization procedures, CHF, and re-admission for 
CHF).
- Blood samples at intervals up to 72 h measured caldaret concentrations (Covance Labo-
ratories Ltd, Harrogate, UK).
Sample size and statistical analyses
The safety set analyses includes all randomized patients who received at least one dose or 
partial dose of study medication; the full analysis population included all randomized patients 
who received any study medication and who provided any efficacy data after the start of study 
medication. Following the principle of intention-to-treat, the full analysis TIMI 0/1 population 
were patients who were defined as the full analysis population who also recorded a TIMI 0/1 
flow at entry.
Assuming SPECT infarct size standard deviation of 20%, and 20% of patients being unevalu-
able at Day 7/discharge, 240 patients with pre-PCI TIMI flow grade 0/1 provide a 80% power 
to detect a mean absolute difference of 10% in infarct size between caldaret and placebo. An 
estimated 60% of patients would have pre-PCI TIMI flow grade 0/1, giving a final sample size 
of ~ 400.
Analyses included pairwise comparisons between each active treatment group and pla-
cebo. Statistical tests were two-sided, at the 5% level of significance, and differences between 
treatment groups were presented with 95% confidence intervals. No adjustment was made 
for multiple comparisons, since this was an exploratory study - the emphasis was on estima-
tion of differences vs. placebo.
Primary and secondary efficacy variables were log-transformed and analysed using analy-
sis of covariance, including factors for centre, age, and treatment. Statistical analyses were 
performed with the SAS software Version 8.2. Further exploratory analysis was performed to 
identify other significant covariates (advanced age >70, gender, hypertension, diabetes mel-
litus, prior MI, angina, summed ST, location of infarct anterior/non-anterior) pre-specified in 
the analysis plan. No estimation of missing values was conducted. Efficacy data were missing 
due to deaths, withdrawals and non-evaluable SPECT, and numbers in each treatment group 
were similar; however, potential bias cannot be completely ruled out.
results
Patient population
Figure 1 describes patient disposition. Of note was the lower number of patients with non-
anterior MI in the HD group. Baseline characteristics were well balanced (Table 1). A higher 
incidence of pre-PCI TIMI flow grade of 0 in the placebo group was detected (Table 2).
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Safety assessments
Mortality at Day 30 was 2.4%, with no difference between treatment groups (Table 3). The 
most frequently reported treatment-related TEAEs (possible or probable relationship to study 
table 1. Patient characteristics
Baseline characteristics Safety 
population
Pre-PCI TIMI flow grade 0/1 efficacy population 
(n = 247)
n = 381 LD, n = 88a HD, n = 70 Placebo, n = 89
Age, years [mean (SD)] 60 (13) 60.0 (11) 61 (13) 59 (13)
Male — (%) 303 (80) 71 (81) 53 (76) 76 (85)
Weight, kg [mean (SD)] 78 (13) 82 (15) 78 (13) 80 (14)
Body mass index, kg/m2 [mean (SD)] 27 (3.7) 28 (4.2) 26 (3.4) 27 (3.3)
Hypertension — (%) 151 (40) 33 (38) 25 (36) 37 (42)
Diabetes — (%) 69 (18) 16 (18) 14 (20) 14 (16)
Hypercholesterolaemia — (%) 157 (41) 31 (35) 25 (36) 41 (46)
Current cigarette smoking — (%) 194 (51) 40 (46) 36 (51) 45 (51)
Prior PCI — (%) 28 (7.3) 6 (6.8) 6 (8.6) 8 (9.0)
Congestive heart failure — (%) 6 (1.6) 2 (2.3) 1 (1.4) 0
Prior MI — (%) 29 (7.6) 5 (5.7) 7 (10) 9 (7.9)
Anterior MI — (%) 239 (63) 53 (60) 51 (73) 48 (54)
Summed ST-elevation at screening, mm [median 
(range)]
n/a 17 (4.0–67) 18 (5.5–47) 19 (3.0–46)
Time to treatment
Pain to hospital, min [median (range)] n/a 113 (18–360) 118 (30–318) 114 (12–348)
Pain to start of study drug, min [median (range)] n/a 163 (60–558) 169 (48–372) 166 (78–378)
Pain to first balloon, min [median (range)] n/a 206 (84–390) 211 (78–438) 199 (102–426)
Hospital to first balloon, min [median (range)] n/a 85 (18–234) 90 (18–198) 85 (36–174)
Start of study drug to first balloon, min [median 
(range)]b
n/a 35 (-17–81) 35 (-6–143) 34 (-2–100)
MI, myocardial infarction; n/a, not available; SD, standard deviation.
aInfarct location unknown in one patient; bNegative number indicates balloon achieved prior to study drug administration.
table 2. Pre-procedure TIMI flow grades, full analysis population
Variable LD
n = 126 (%)
HD
n = 110 (%)
Placebo
n = 123 (%)
TIMI flow grade
0 69 (55) 56a (51) 80a (65)
1 19 (15) 14 (13) 9 (7.4)
0/1 88 (70) 70 (64) 89 (72)
2 23 (18) 30 (28) 20 (17)
3 14 (11) 10 (9.2) 13 (11)
2/3 37 (30) 40 (37) 33 (27)
Missing 1 (<1) 0 1 (<1)
aData from one patient from local rather than core laboratory assessment.
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drug) were hypotension, bradycardia, angina pectoris, headache and, vomiting; however, 
frequency of each was the same for drug and placebo groups.
Three patients withdrew from the study due to adverse events (AEs)/medical conditions 
and 8% of patients had interruption or discontinuation of the study drug due to a TEAE. Only 
one AE was considered by the investigator to be ‘probably’ related to study drug, an SAE of 
cardiac failure in the placebo group.
table 3. Overview of AEs (safety population)
Events LD HD Placebo Total
N = 130 (%) N = 124 (%) N = 127 (%) N = 381 (%)
Deaths 3 (2.3) 3 (2.4) 3 (2.4) 9 (2.4)
All TEAEs 116 (89) 115 (93) 118 (93) 349 (92)
Severe TEAEs 24 (19) 20 (16) 30 (24) 74 (19)
Treatment-related TEAEsa 15 (12) 13 (11) 22 (17) 50 (13)
Most frequently reported severe intensityb TEAEs
Cardiogenic shock 6 (4.6) 2 (1.6) 5 (3.9)
Ventricular fibrillation 0 4 (3.2) 6 (4.7)
Cardiac failure congestive 4 (3.1) 0 3 (2.4)
Cardiac failure unspecified 2 (1.5) 2 (1.6) 2 (1.6)
Hypotension 3 (2.3) 2 (1.6) 1 (0.8)
aPossibly or probably related to study drug.
bMissing intensity assessments were set to severe for six patients (two in each treatment group).
table 4. Myocardial infarct size at Day 7/discharge and at Day 30 in patients with pre-PCI TIMI flow grade 0/1 determined by SPECT
Population Day 7/discharge Day 30
LD, n = 88 HD, n = 70 Placebo, n = 89 LD, n = 88 HD, n = 70 Placebo, n = 89
na 71 54 73 71 56 68
Arithmetic mean (SD), % 19.5 (14.5) 22.1 (14.3) 20.0 (14.6) 16.8 (13.1) 19.5 (13.1) 16.1 (13.1)
LS mean (SE), % 19.5 (1.7) 23.5 (1.9) 21.6 (1.7) 17.1 (1.5) 20.6 (1.7) 17.7 (1.6)
Ratio of LS meanb 
(95% CI)
0.90
(0.7-1.1)
1.09
(0.9-1.3)
— 0.97
(0.7-1.2)
1.17
(0.9-1.4)
—
P-value 0.348 0.438 — 0.783 0.194 —
Reasons for missing SPECT 
infarct size data (TIMI 0/1)a
Medical condition 8 2 4 4 1 6
SPECT imaging problems 6 10 5 9 11 8
Withdrawal of consent 1 1 5 3 1 6
Death 1 1 0 1 1 1
Otherc 1 2 2 0 0 0
Total 17 16 16 17 14 21
CI, confidence interval; LS, least square; SE, standard error.
aThe number of patients in which a SPECT was performed; bCalculated as LD/PL; cSPECT not available.
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The median time to stable ST-segment resolution of 1.6, 1.3, and 1.4 h were not significantly 
different for the LD, HD, and placebo groups, respectively. No differences in QT
c
 or cardiac 
rhythm were observed.
table 5. Cardiac markers of infarct size in patients with pre-PCI TIMI flow grade 0/1
Variable LD
n = 88
HD
n = 70
Placebo
n = 89
CK, na 83 68 86
Meanb (SD) AUC
0–3d
, IU/L 965 (726) 977 (1143) 1146 (910)
Ratio (95% CI) 0.82 (0.67-1.02) 0.84 (0.68-1.05) —
P-value 0.071 0.136 —
CK-MB, na 84 68 86
Meanb (SD) AUC
0–3d
, IU/L 44 (26) 44 (31) 48 (30)
Ratio (95% CI) 0.90 (0.74-1.08) 0.90 (0.73-1.10) —
P-value 0.26 0.292 —
TNT, na 84 68 87
Meanb (SD) AUC
0–5d
, mg/L 4.2 (3.4) 4.1 (3.3) 4.3 (3.4)
Ratio (95% CI) 0.94 (0.78-1.15) 0.90 (0.73-1.12) —
P-value 0.566 0.347 —
LDH, na 83 68 87
Meanb (SD) AUC
0–5d
, IU/L 493 (274) 497 (257) 514 (260)
Ratio (95% CI) 0.94 (0.82-1.09) 0.95 (0.82-1.10) —
P-value 0.423 0.492 —
aNumber of patients with data available for analysis; bWeighted geometric mean.
table 6. LV function parameters determined by SPECT on Day 7/discharge and on Day 30 in patients with pre-PCI TIMI flow grade 0/1
Variable Day 7/discharge Day 30
LD, n = 88 HD, n = 70 Placebo, n = 89 LD, n = 88 HD, n = 70 Placebo, n = 89
na 64 52 70 64 52 70
LVESV
Meanb (SD), mL 77 (33) 81 (40) 91 (52) 77 (40) 82 (41) 86 (46)
Ratio (95% CI) 0.93 (0.78-1.10) 0.95 (0.79-1.13) — 0.91 (0.76-1.09) 0.99 (0.82-1.19) —
P-value 0.377 0.550 — 0.307 0.920 —
LVEDV
Meanb (SD), mL 125 (38) 131 (46) 141 (57) 130 (43) 135 (48) 140 (53)
Ratio (95% CI) 0.91 (0.80-1.02) 0.93 (0.82-1.05) — 0.94 (0.82-1.06) 0.97 (0.85-1.10) —
P-value 0.106 0.278 — 0.313 0.662 —
LVEF
Meanb (SD), mL 40 (11) 41 (12) 39 (12) 43 (13) 42 (11) 42 (12)
Ratio (95% CI) 1.02 (0.92, 1.12) 1.03 (0.92, 1.14) — 1.05 (0.95, 1.15) 1.00 (0.90, 1.10) —
P-value 0.683 0.567 — 0.331 0.964 —
aNumber of patients with data available for analysis; bArithmetic mean.
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Efficacy analyses
Infarct size, LV function, clinical endpoints 
In patients with initial TIMI 0/1 flow, there was no difference between caldaret treatment 
and placebo Day 7/discharge and Day 30 infarct size by SPECT (Table 4). SPECT assessment 
occurred between Days 5 and 9 in the majority (87.8%) of patients, 11 patients having SPECT 
on Day 10 or later and 17 patients on Day 4 or earlier. There were also no differences in second-
ary endpoints of MI size by serum marker AUCs of CK, CK-MB, TnT, and LDH (Table 5); LVEF, 
LVESV, or LVEDV at either Day 7/discharge or Day 30 (Table 6); 30-day mortality, major adverse 
cardiovascular events, or new/worsening CHF (Table 7); heart rate, systolic and diastolic pres-
sure at Day 7/discharge.
Subgroup analyses
Prospectively planned stepwise regression analyses of the efficacy endpoints identified that 
infarct location had a highly significant (P <0.0001) effect on the primary efficacy parameter 
compared with other covariates. Figures 2 and 3, respectively, describe the treatment effects 
in the subgroup of anterior and non-anterior MI patients with initial TIMI 0/1 flow. The com-
posite clinical endpoint (MACE, CHF, and re-admission for CHF) was 22 (42.3%), 14 (27.5%), 
and 13 (27.1%) patients in the anterior MI-LD, HD, PL groups, respectively, up to Day 30. Higher 
cardiac marker values in the TIMI 0/1 placebo group were not due to the higher proportion 
of placebo TIMI 0 patients as analyses for patients with TIMI 0 showed both CK and CK-MB 
geometric mean values were still lower with drug than with placebo (CK: HD 11.5%; LD 16.2%, 
and CKMB: HD 10.6%; LD 9.9%).
table 7. Clinically adjudicated endpoints up to Day 30 in patients with pre-PCI TIMI flow grade 0/1
Events LD
n = 88 (%)
HD
n = 70 (%)
Placebo
n = 89 (%)
Endpoint
Cardiac mortality 1 (1.1) 1 (1.4) 1 (1.1)
Non-cardiac mortality 0 0 0
Resuscitated sudden death 1 (1.1) 1 (1.4) 1 (1.1)
CHF 19 (22) 14 (20.0) 14 (16)
Re-admission for CHF 3 (3.4) 1 (1.4) 2 (2.2)
Re-infarction 4 (4.5) 1 (1.4) 1 (1.1)
Stroke 1 (1.1) 0 0
Composite clinical endpointa 28 (32) 15 (21) 20 (23)
aConsisted of major adverse cardiovascular events (death, re-infarction, revascularization procedures, CHF, and re-admission for CHF).
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disCussion
The CASTEMI study is the first human experience with caldaret in patients with large STEMI under-
going primary PCI. The most important finding of this pilot study was the safety of caldaret in 
patients selected for large MI by ECG criteria. Unlike reports of calcium channel blockers in this set-
ting, this unique intracellular calcium modulator appears to be well tolerated even at HD. In theory, 
active prevention of intracellular calcium overload using this new molecular entity might promote 
more favourable cellular response to reperfusion associated with epicardial recanalization.
The limitations of this pilot study with regard to efficacy evaluations are associated with 
smaller treatment effects that might still be clinically meaningful (which could be missed in 
this relatively small cohort), the careful interpretation required of surrogate marker data, and 
a low overall endpoint and mortality rate even with selection of large infarctions into the 
study. The data showing higher rates of better pre-PCI TIMI flow in the treatment groups may 
also point to properties of caldaret for which there is no currently understood mechanism.
Within this negative study, the observations from the analyses controlling for infarct loca-
tion showed some directional trends, possibly chance findings, in biomarkers measured. 
Understanding these observations requires study in an independent clinical trial.
Although the benefits of reperfusion may be limited by ‘reperfusion injury’,3,4,8 the mecha-
nism and clinical relevance of such injury remains poorly understood and multiple negative 
human studies have been reported,9,17,18 including those with agents that modulate calcium 
homeostasis.19 However, when administered before the onset of ischaemia, peri-operative 
infarct size has been reduced with Na+/H+ exchange inhibitors in CABG.11
Reperfusion injury in clinical practice has long been reported in anecdotes of epicardial 
reperfusion followed by rapid clinical deterioration. In animal studies, pre-treatment with a 
number of compounds prior to reperfusion can limit infarct size. In human patients, however, 
similar drugs have not shown clear benefit,17 including in this pilot report with caldaret treat-
ment prior to PCI. Thus, the ultimate contribution of such medical strategies for ‘facilitated PCI’ 
in STEMI to reduce infarct size remains controversial.4,17
ConClusion
With direct effect on intracellular calcium modulation, but different from calcium channel 
blockers, this first human pilot study demonstrates the safety of caldaret in patients with large 
STEMI treated with bolus and infusion of drug beginning prior to PCI. Efficacy measures were 
confounded by dependence on surrogates and the modest size of the cohort enrolled, with 
the study failing to show benefit in primary and secondary endpoints. The numerical trends in 
anterior infarct patients may be viewed as chance findings or hypothesis generating worthy 
of further study.
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abstraCt
The principal therapy in patients with myocardial infarction to limit infarct size is myocardial 
reperfusion by mechanical or pharmacological intervention. Reperfusion has been proposed 
to cause myocardial injury beyond that caused by the preceding ischaemia, termed “reperfu-
sion injury” (RI). While the precise mechanism of RI is still incompletely understood, a large 
number of clinical studies have been performed over the past decade targeting some of 
the postulated mechanisms of RI. These clinical studies were based on experimental data 
demonstrating significant myocardial salvage. Nevertheless, clinical benefits were absent or 
very limited. The purpose of this review is to provide an overview of the various strategies 
that inhibit RI and to discuss potential mechanisms that may contribute to the discrepancy 
between the promising pre-clinical data and the rather disappointing results obtained from 
prospective clinical trials. There are numerous differences between the experimental models 
and clinical studies, including the fact that experimental studies typically use abrupt occlusion 
and reperfusion protocols in animals with previously healthy myocardium that apparently do 
not predict the therapeutic efficacy of novel cardioprotective agents in a clinical setting with 
pre-existing progressive coronary disease, intermittent coronary occlusion, and relatively 
late reperfusion. However, discrepancies also exist between experimental studies. Future 
experimental studies of reperfusion injury should use models that mimic the clinical situa-
tion more closely. Furthermore, future large clinical trials should only be performed in cases 
where the drug under investigation proved to reduce RI in a series of well-designed (possibly 
multicenter) experimental studies and in clinical trials with predefined subgroups.
introduCtion
Preventing acute myocardial infarction (AMI) or limiting infarct size is critical to improve 
immediate and long-term outcome of patients with an acute coronary syndrome and to avoid 
the development of heart failure. Currently, the single established strategy to limit infarct size 
is early reperfusion with percutaneous coronary intervention (PCI) or thrombolytic therapy.1 
The importance of early reperfusion is not surprising as the primary insult is a decrease in oxy-
gen supply resulting in a decrease of free energy from ATP-hydrolysis beyond a critical level 
required for maintaining cell processes such as ion channel function. However, despite its 
clear benefit, reperfusion itself has been proposed to cause irreversible myocardial damage, 
termed “reperfusion injury” (RI), beyond that caused by the preceding period of ischaemia, 
implying that optimization of reperfusion therapy could further limit infarct size.
The mechanism of RI remains incompletely understood, but may include (i) cytosolic and 
mitochondrial Ca2+-overload, (ii) release of reactive oxygen species (ROS), (iii) an acute inflam-
matory response, and (iv) shift in substrate use.2-8 In concert, these perturbations might pro-
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duce irreversible damage to cardiomyocytes that are severely ischaemic but still salvageable 
at the time of reperfusion. Consequently, these pathways have been the therapeutic targets 
in experimental and clinical studies. Furthermore, despite restoration of epicardial coronary 
patency and blood flow, reperfusion after prolonged coronary occlusion is associated with 
secondary impairment of microcirculatory flow (“no-reflow” phenomenon), that is due to 
endothelial dysfunction, neutrophil plugging and oedema, but may also be aggravated by 
distal (micro-)embolization.9,10
Indirect evidence for the existence of RI stems from observations that reperfusion is 
associated with hypotension, temporary increase of chest pain, ST segment deviation and 
arrhythmias. However, direct evidence for the existence of RI stems from animal studies in 
which pharmacological agents administered just prior to reperfusion limit infarct size.3,11-15 
Pre-clinical studies, although sometimes equivocal, spurred a large number of clinical trials. 
The latter yielded mostly disappointing results and hence the existence of lethal RI in the 
clinical setting remains controversial.3,11-13,16
table 1. List of acronyms of randomized clinical trials in alphabetical order:
ADMIRE AmP579 Delivery for Myocardial Infarction Reduction65
AMISTAD Acute Myocardial Infarction Study of Adenosine63,64,109
APEX-AMI Assessment of Pexelizumab in Acute Myocardial Infarction56
ATTACC Attenuation by Adenosine of Cardiac Complications66
CASTEMI Caldaret (MCC-135) in ST Elevation Myocardial Infarction39
COMMA Complement Inhibition in Myocardial Infarction Treated with Angioplasty54
COMPLY Complement Inhibition in Myocardial Infarction Treated with Thrombolytics55
CORE Collaborative Organisation for RheothRx Evaluation47,48
CREATE-ECLA Clinical Trial of Reviparin and Metabolic Modulation in AMI Treatment and ECLA79
DATA Diltiazem as Adjunctive Therapy to Activase28
ECLA Evaluation-Estudios Clinicos Latino America71
ESCAMI Evaluation of the Safety and Cardioprotective Effects of Eniporide in AMI38
EXPEDITION Sodium-hydrogen Exchange Inhibition to Prevent Coronary Events in Acute Cardiac Conditions41
FESTIVAL F2G in Elevated ST Infarction Evaluation50
GIPS Glucose-Insulin-Potassium Study81,82
GUARDIAN Guard During Ischaemia Against Necrosis40,126
HALT-MI Hu23F2G anti Adhesion to Limit Cytotoxic Injury Following AMI51
h-SOD Human Super-Oxide Dismutase44
ISIS-4 International Study of Infarct Survival32
LIMIT-2 Leicester Intravenous Magnesium Intervention Trial-231
LIMIT-AMI Limitation of Myocardial Infarction Following Thrombolysis in AMI49
MAGIC Magnesium In Coronaries34
PARI-MI Protection Against Reperfusion injury with ITF-1697 in Acute Myocardial Infarction53
Pol-GIK Polish Glucose-Insulin-K+ 80
RAPSODY Efficacy of a Novel P-Selectin Antagonist, rPSGL-Ig for Reperfusion Therapy in AMI52
REVIVAL The Reevaluation of Intensified Venous Metabolic Support for Acute Infarct Size Limitation83
TAMI-9 Thrombolysis and Angioplasty in Myocardial Infarction-946
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The goal of the present review article is to discuss potential reasons why clinical studies have 
generally failed to show a beneficial effect of pharmacological interventions, despite benefi-
cial effects reported in many experimental studies. In addition, we propose some guidelines 
for improving future preclinical and clinical trials. In-depth overviews of the mechanisms of RI 
have been published previously,2,5,13,17 and are beyond the scope of this article.
Ca2+-overload (Table 2)
Intracellular Ca2+ increases during prolonged ischaemia and subsequent reperfusion. Ca2+-
overload during ischaemia is partially due to activation of the Na+/Ca2+-exchanger and open-
ing of L-type Ca2+-channels, in conjunction with inhibition of sarcolemmal and sarcoplasmic 
reticular Ca2+-pumps.13 During reperfusion, the Na+/H+-exchanger is activated to restore 
intracellular pH. However, the extrusion of H+ initiates a net influx of Na+ into the cardiomyo-
table 2. Randomized clinical trials on calcium homeostasis in patients with AMI
Author/year Trial Substrate N Thrombolysis PCI Time# Enzymatic
infarct size
Imaging Clinical
endpoints
Benefit in 
sub-
group?
Calcium channel blockers
Sheiban et al 199730 - Nisoldipine 36 - 100% 1,9hr - EF
echo
 ↑ -
Theroux et al 
199828 *
DATA Diltiazem 59 100% - 2,7hr ↔ EF
SPECT
 ↔ MACE ↓
Pizzetti et al 200129 - Diltiazem 90 100% - 2,2hr ↓ EF
echo
 ↑ ↔
Magnesium
Woods et al 199231 LIMIT-2 MgSO
4
2.316 36% - 3hr ↔ - Mortality ↓
ISIS-4 199532 ¥ ISIS-4 MgSO
4
58.050 70% - 8hr - - MACE ↔
Santoro et al 
200033 §
- MgSO
4
150 - 100% 3,5hr ↔ EF
echo
 ↔ ↔
MAGIC 200234 † MAGIC MgSO
4
6.213 19% 12% n.r. - - Mortality 
↔
NHE-inhibitors
Rupprecht et al 
200037
- Cariporide 100 - 100% 3,8hr CK(MB) 
↔(↓)
EF
angio
 ↑ Mortality 
↔
Zeymer et al 200138 ESCAMI Eniporide 1.389 61% 38% 3,1hr ↔ - ↔ Time† 
>4hrs
Bär et al 200439 ‡ CASTEMI Caldaret 247 - 100% 3,3hr - EF
SPECT
 ↔ ↔ Anterior MI
PCI = percutaneous coronary intervention; # approximate time from onset of symptoms to treatment; hr = hours; CK(-MB) = creatine kinase 
(-myocardial band isoenzyme subfraction); SPECT = single-photon emission computed tomography; MACE = major adverse cardiac events 
(death, recurrent myocardial infarction, recurrent ischaemia); ‡: TIMI 0-1 only; n.r. = not reported.
All substrates infused before the onset of reperfusion therapy, except for ¥: Bolus MgSO
4
 started after lytic phase, §: Bolus and infusion started 
before or after PCI; †: in 5% of all patients infusion started after reperfusion therapy. All substrates administered intra-venously except for *: 
intra-venous infusion for 48hr followed by oral treatment for 4wks
↑ significantly increased; ↔ no significant effect; ↓ significantly decreased.
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cyte, which via the Na+/Ca2+-exchanger leads to further increase in Ca2+-influx during early 
reperfusion.13 The Ca2+-overloaded myocytes enter into a state of hypercontracture when 
exposed to oxygen and energy, after reperfusion.13,14,18 Furthermore, Ca2+-overload induces 
protease activation, gap-junction dysfunction and membrane rupture that cumulatively 
contribute to cell death.19
Ca2+-channel blockers and magnesium
Blockade of the L-type Ca2+-channel can prevent Ca2+-overload during prolonged ischaemia 
and reperfusion.20 In experimental models of coronary occlusion, Ca2+-antagonists limit irre-
versible myocardial damage and reduce the degree of stunning, provided these agents are 
administered prior to ischaemia.21,22 MgSO
4
 also possesses Ca2+-channel blocking properties, 
which may aid in preventing Ca2+-overload during reperfusion20 and may protect against 
reactive oxygen species.23 Interestingly, intracellular Mg2+ levels are depressed during AMI,24 
while supplemental Mg2+ has been reported to reduce infarct size when administered prior 
to reperfusion.25,26
Clinical trials. Clinical evidence regarding the benefit of Ca2+-channel blockers in the set-
ting of AMI remains inconclusive when treated with Ca2+-channel blockers on top of reperfu-
sion therapy, despite their beneficial effects in reversible ischaemic syndromes.27 Two of three 
small pilot studies showed improvement of left ventricular function (echocardiography)(Table 
2).21,22,28-30 The DATA trial showed improved clinical outcome (n=59), despite a lack of efficacy 
of diltiazem on infarct size or left ventricular function.24 There is no indication for Ca2+-channel 
blockers as an adjunct to reperfusion therapy as large randomized trials are lacking. Trials 
on the use of MgSO
4
 (an endogenous Ca2+-antagonist) in patients with AMI showed similarly 
negative results in over 60.000 patients (Table 2).31-34
Na+/H+ exchange inhibitors 
Experimental studies have demonstrated marked limitation of infarct size when NHE-inhibitors 
are administered prior to ischaemia.35 However the efficacy of NHE-inhibitors administered 
just prior to reperfusion remains controversial.36
Clinical trials. Except for a pilot study in 100 patients with cariporide,37 NHE-inhibitors gen-
erally failed to demonstrate any benefit on infarct size or clinical outcome when given after 
onset of ischaemia in the setting of AMI (ESCAMI trial (n=1389) with eniporide and CASTEMI 
trial (n=247) with caldaret (Table 2).38,39 However, when the NHE-inhibitor cariporide was given 
before ischaemia in patients undergoing CABG, a reduction in peri-operative cardiac enzyme 
release was observed in the GUARDIAN CABG subgroup40 and the large EXPEDITION study 
(n=5761).41 This was associated with an improvement in outcome in the GUARDIAN CABG sub-
group, whereas the EXPEDITION trial showed an overall increase in mortality, and inexplicably, 
strokes.41 Nevertheless, GUARDIAN and EXPEDITION support the concept that that irreversible 
myocardial damage is reduced by NHE inhibitors administered prior to the onset of ischaemia. 
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table 3. Randomized clinical trials on anti-inflammatory agents in patients with AMI
Author/year Trial Substrate N Thrombolysis PCI Time# Enzymatic
infarct size
Imaging Clinical 
endpoints
Benefit in 
sub-
group?
Anti-reactive oxygen 
species
Flaherty et al 
199444
h-SOD h-SOD 120 - 100% 4.1hr - EF
angio
 ↔ Mortality 
↔
Tsujita et al 
200445 †
- Edaravone 80 - 100% 3,3hr ↓ EF
echo
 ↔ -
Endothelial preservation and PMN inhibitors
Wall et al 
199446
TAMI-9 Fluosol 430 100% - n.r. - EF
Thallium
 
↔
↔
Schaer et al 
199647
CORE-
Pilot
RheothRx 114 100% - 2,8hr - EF
MIBI
 ↑ ↔
CORE Group 
199748
CORE RheothRx 2.948 100% - 3.5hr - EF
SPECT
 ↔ Mortality/
CHF ↔
Baran et al 
200149
LIMIT-AMI RhuMab CD 18 394 100% - 3,4hr ↔ EF
SPECT
 ↔ ↔
Rusnak et al 
200150
FESTIVAL Hu23F2G 60 - 100% n.r. - EF
SPECT
 ↔ ↔
Faxon et al 
200251
HALT-MI Hu23F2G 420 - 100% 3.8hr ↔ EF
SPECT
 ↔ ↔
Tanguay et al 
200352 @
RAPSODY rPSGL-Ig 598 100% - < 6hr - EF
SPECT
 ↔ ↔
Dirksen et al 
200453
PARI-MI ITF-1697 393 - 100% 4.1hr ↔ ↔
Anti-
complement
Granger et al 
200354
COMMA Pexelizumab 814 - 100% 3,2hr ↔ - Overall ↔ 
Mortality ↓§
Mahaffey et al 
200355
COMPLY Pexelizumab 920 100% - 2,8hr ↔ - ↔
Armstrong et 
al 200656
APEX-AMI Pexelizumab 5745 100% - n.r. - - ↔
Adenosine
Mahaffey et al 
199963
AMISTAD Adenosine+lido 236 100% - 2,9hr ↔ EF
SPECT
 ↔ ↔ Anterior 
MI
Kopecky et al 
200365
ADMIRE AmP579 311 - 100% n.r. - EF
SPECT
 ↔ n.r. Anterior 
MI
Quintana et al 
200366
ATTACC Adenosine 608 100% - 3,3hr - EF
echo
 ↔ Mortality/
CHF ↔
Marzilli et al 
200067
- Adenosine₣ 54 - 100% 1,9hr ↔ EFecho ↑ Mortality 
and MI ↓
Ross et al 
200564
AMISTAD-
II
Adenosine+lido 2.118 58% 40% 3,3hr ↔ EF
SPECT
 ↔ Mortality/
CHF ↔
High-
dose
PCI = percutaneous coronary intervention; #: approximate time from onset of symptoms to treatment; hr = hours; †: TIMI 0-1 only; lido = 
lidocaine; SPECT = single-photon emission computed tomography; CHF: congestive heart failure; n.r. = not reported; @: Abstract only. §: No 
benefit in infarct size reduction or event free survival, however unexplained significant reduction of all cause mortality. 
All substrates administered before the onset of reperfusion therapy and all substrates administered intra-venously except ₣: intra-coronary.
↑ significantly increased; ↔ no significant effect; ↓ significantly decreased.
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The results of these trials are consistent with animal studies that show that NHE-inhibitors are 
principally only effective when given before ischaemia.
Anti-inflammatory strategies (Table 3)
Key events in the inflammatory response to ischaemia-reperfusion are the production of 
reactive oxygen species (ROS), complement activation, neutrophil activation and endothelial 
dysfunction. These processes may produce irreversible cardiomyocyte damage directly, but 
also indirectly via myocardial oedema and capillary plugging by polymorphonuclear cells 
(PMN) causing “no-reflow”.42,43
Clinical trials. Studies using anti-inflammatory strategies have generally yielded disap-
pointing results and will not be discussed in detail in this manuscript. These clinical trials 
are summarized in Table 3. Thus, pilot trials with anti-oxidants (a recombinant human SOD 
and edaravone, a ROS scavenger) in the setting of primary PCI for AMI failed to demonstrate 
efficacy (Table 3).44,45 In addition, despite equivocal experimental data regarding a causal role 
of PMNs in lethal RI, clinical trials were initiated using drugs that inhibit PMN tethering and 
activation [46-51], inhibit PMN adhesion molecules,52 or preserve endothelial function (Table 
3).53 Disappointing results were reported in these 8 (predominantly phase II) clinical trials 
with agents that inhibit PMN activation and endothelial dysfunction.46-53 Finally, complement 
inhibition with a monoclonal antibody (anti-C5), pexelizumab, was investigated in patients 
with AMI in the COMMA,54 the COMPLY55 and the APEX-AMI trial.56 All three trials failed to 
demonstrate a limitation of infarct-size (total CK-MB) or composite clinical endpoint. However, 
the COMMA-trial did show an unexplained decrease in overall mortality with pexelizumab 
(Table 3).54
Adenosine
Adenosine exerts a multitude of actions that can protect the myocardium against RI, including 
anti-ischaemic effects via pharmacological preconditioning, inhibition of PMN-activation and 
ROS formation, anti-inflammatory properties, preservation of endothelium and microvascular 
flow.57 Adenosine has demonstrated marked cardioprotection in animal studies, when admin-
istered before ischaemia. Conversely, administration after the onset of ischaemia has yielded 
variable results,58-60 that may in part be due to co-administration of lidocaine59-61 or collateral 
flow level.50
Clinical trials. Following a promising non-randomized pilot trial (n=45),62 the AMISTAD-I63 
and II64 trials investigated the effect of adenosine in combination with lidocaine as an adjunct 
to reperfusion therapy in patients with AMI. The first AMISTAD trial included 236 patients who 
were randomly assigned to either placebo or adenosine with lidocaine on top of thrombolysis 
for AMI. Although adenosine treatment did not modify overall infarct size (SPECT), the anterior 
infarct subgroup showed significant reduction. Consequently, the AMISTAD-II was conducted 
exclusively in patients (n=2.084) with anterior AMI. Although adenosine did not show an 
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overall benefit, the authors reported a trend towards a modest limitation in infarct size in the 
high-dose adenosine subgroup compared to placebo (Table 3).64 The ADMIRE (n=608; reper-
fusion by thrombolysis) and the ATTACC (n=311 with anterior MI; reperfusion by PCI) trials also 
failed to observe beneficial effects of adenosine treatment on infarct size or clinical outcome, 
although a trend towards greater myocardial salvage assessed by SPECT was apparent in the 
ADMIRE trial (Table 3).65,66
The anti-inflammatory and coronary vasodilator actions of adenosine may limit no-reflow 
following reperfusion and hence reduce secondary myocardial ischaemia.58 A pilot study 
(n=54) investigated the effects of intracoronary adenosine administered just before reperfu-
sion in patients with AMI.67 No-reflow was observed in 1 patient in the adenosine group and in 
7 patients in the placebo group (p<0.05), which was associated with significant improvement 
in ventricular function (echocardiography) and clinical improvement.
Taken together, clinical trials with adenosine as an adjunct to reperfusion therapy have 
failed to show a significant beneficial effect. However, the potential of adenosine to improve 
microvascular function and reduce infarct size when administered before the onset of 
ischaemia (similar to the experimental studies), e.g. in the setting of CABG, deserves further 
investigation.68
Metabolic interventions: glucose-insulin-potassium (table 4)
The concept of glucose-insulin-K+-therapy (GIK) was introduced 44 years ago by Sodi-Pallares 
and thought to be protective by stabilization of the membrane.69 From observations that glu-
cose is a preferential energy source during ischaemia and reperfusion the concept emerged 
that GIK therapy may limit infarct size.70-73 Additionally, GIK decreases circulating levels of 
free fatty acids and myocardial free fatty acids uptake, possibly limiting toxic concentrations 
in ischaemic myocardium.74 Finally, insulin can exert anti-RI effects by activation of Akt and 
p70s6 kinases.75 GIK has been shown to be protective against RI following AMI in the majority 
of animal studies, also when administered after the onset of ischaemia.75-78
Clinical trials. Meta-analysis of trials from the pre-thrombolytic era suggests therapeutic 
benefit of GIK treatment.72 Six recent trials also showed some benefit of GIK, but only in specific 
subgroups (Table 4).71,79-82 In the ECLA study (n=407) GIK therapy, starting 10-11 hours after 
onset of symptoms, improved clinical outcome in the reperfused patients (62% of total study 
population).66 In the CREATE-ECLA-trial (n=20.000; reperfusion therapy in 83%), GIK treatment 
failed to improve 30-days clinical outcome although there was a trend towards improved 
clinical outcome in patients undergoing reperfusion therapy by PCI (9% of all patients).79 
Conversely, the Pol-GIK-trial in a low-risk AMI patient population (Killip I-II) was terminated 
prematurely because of an increase in mortality in GIK-treated patients.80 The REVIVAL study 
evaluated GIK treatment started within 10 hours of start of symptoms in 312 patients undergo-
ing reperfusion therapy. No infarct size reduction as assessed by SPECT was shown, although 
GIK-treated patients with diabetes (n=35) showed improved myocardial salvage.83
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Recent studies performed in the Netherlands yielded similar results for GIK treatment on 
top of primary PCI in the setting of AMI (Table 4).81,82 Analysis of the total study population in 
the GIPS-I (n=904) and patients without clinical evidence of heart failure in the GIPS-II (n=889) 
failed to demonstrate a reduction in 30-days mortality or limitation in enzymatic infarct size, 
despite significant reduction in the subgroup with patients without evidence of heart failure 
in the GIPS-I.81,82
GIK has also been investigated as adjunctive therapy to CABG.84 A review of 91 studies 
indicates a benefit of insulin or GIK in 74 of these studies.85 Despite the reports in which GIK 
treatment suggested additive benefit on clinical outcome and peri-operative infarct size, GIK 
is currently not used routinely in clinical practice because of a lack of unequivocally positive 
results.85
Miscellaneous
Various other cardioprotective agents, such as trimetazidine, angiotensin converting enzyme 
(ACE)-inhibitors and nicorandil, have been evaluated in the setting of AMI. None of these tri-
als showed satisfactory proof of infarct size reduction in adequately sized trials (Table 5).86-90 
Consequently none of these agents is currently being used in AMI, and await evaluation in 
larger trials.
table 4. Randomized clinical trials with glucose-insulin-potassium (GIK) in patients with AMI
Author/year Trial N Thrombolysis PCI Time# Enzymatic
infarct size
Clinical
endpoints
Benefit in 
sub-group?
Díaz et al 199871 ECLA 407 59% 3% 10,5hr n.r. MACE* ↓ Reperfused 
patients
CREATE-ECLA 
Group 200579
CREATE-ECLA 20.201 74% 9% 4.7hr n.r. MACE§ ↔
Ceremuzynski et al 
199980 ¥
Pol-GIK 954 57-60% - < 24hr ↔ Mortality ↑
van der Horst et al 
200381
GIPS 940 - 100% n.r. n.r. Mortality 
↔
Killip class I
Timmer et al 
200682
GIPS-II╘ 889 12% 88% 3.7 ↔ Mortality 
↔
Pache et al 200483 REVIVAL 312 4% 89% 10hr n.r. Mortality 
↔
Diabetes
PCI = percutaneous coronary intervention; #: approximate time from onset of symptoms to treatment; hr = hours; *: death, nonfatal congestive 
heart failure, and nonfatal ventricular fibrillation; ¥: Terminated prematurely, because of an increase in mortality in GIK treated patients; §: MACE: 
death, recurrent-MI, cardiogenic shock, cardiac arrest; ╘: only patients with Killip class < II included.
All substrates administered intra-venously.
↑ significantly increased; ↔ no significant effect; ↓ significantly decreased.
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Mechanical modulation of reperfusion
Gradual reinstitution of blood flow during reperfusion has been shown to limit RI in the set-
ting of experimental ischaemia-reperfusion.91 Recently, this phenomenon was extended when 
Zhao et al showed that infarct size in dogs was reduced by a sequence of brief re-occlusions 
following prolonged ischaemia.92 This phenomenon, termed “postconditioning”, has been 
confirmed in several other animal species,93,94 and probably involves a reduced inflammation 
and oxidative stress,92 and the activation of reperfusion injury salvage kinase pathways93,94 
resulting in reduced mitochondrial permeability.95
Clinical trials. Staat et al investigated the effect of postconditioning in 30 patients with AMI 
and reported limitation of enzyme release and improvement of myocardial perfusion [95], 
supporting the concept that lethal myocardial RI in humans may be limited by (mechanical) 
intervention.95 However, these promising initial results await confirmation in large trials.
what is the Cause of the Predominantly neGative CliniCal trials?
A reconciliation of the discordance between the often positive findings in pre-clinical studies 
and the predominantly negative clinical trials requires a careful assessment of differences in 
methodology and biology between experimental and clinical studies.
table 5. Randomized clinical trials with miscellaneous agents in patients with AMI
Author/year Trial Substrate N Thrombolysis PCI Time# Enzymatic
infarct size
Imaging Clinical
endpoints
EMIP-FR Group 
200086
EMIP-FR Trimetazidine 19.725 56% - < 24hr n.r. - Mortality 
↔
Kurz et al 
200187 ¥
- Enalaprilat 22 - 100% < 5hr ↔ EF
angio
 ↔ -
Sakata et al 
199788 ¥
- Nicorandil 20 - 100% n.r. n.r. EF
echo
 ↑ n.r
Ito et al 199989 † - Nicorandil 81 - 100% < 12hr n.r. EF
echo
 ↑ AE§ ↓
Ono et al 200490 - Nicorandil 58 - 100% < 6hr n.r. EF
angio
 ↑ ↔
PCI = percutaneous coronary intervention; #: approximate time from onset of symptoms to treatment; hr = hours; *: death, nonfatal congestive 
heart failure, and nonfatal ventricular fibrillation; n.r. = not reported; §: AE: Adverse events: congestive heart failure, ventricular arrhythmias or 
pericardial effusion;.
All substrates administered intra-venously, except ¥: intra-coronary; †: anterior MI only.
↑ significantly increased; ↔ no significant effect; ↓ significantly decreased.
151
Reperfusion injury in humans
C
h
ap
te
r 
10
Co-morbid conditions
Concomitant disease
In contrast to the majority of pre-clinical studies, in which healthy young animals are typi-
cally employed, ischaemic heart disease and myocardial infarction in humans is principally a 
disease of the middle-aged and elderly. The co-morbid conditions leading to ischaemic heart 
disease (e.g. atherosclerosis, hypercholesterolemia, hypertension and diabetes), advanced 
age, and impaired nutritional status and that are typically absent in preclinical studies, may 
blunt the efficacy of cardioprotective therapies.53,96,97
Preconditioning
The hearts of healthy animals in the pre-clinical studies have not been exposed to ischaemia 
prior to infarction. In contrast, brief ischaemic episodes and gradual occlusion preceding 
myocardial infarction, as occurs clinically during episodes of pre-infarct angina pectoris,98 may 
modulate the protective effects of pharmaco-therapy by inducing ‘ischaemic preconditioning’.11 
Conversely, subsets of patients may have become tolerant to preconditioning due to repeated 
Figure 1. Flow-chart for suggested development of new reperfusion inhibitory drugs
5.3.3. Does medication reach the jeopardized myocardium
in sufficiently concentrations?
Another explanation for the inconsistent results, is that
drugs may not reach the area at risk in sufficiently high
concentrations prior to reperfusion. This concept is
supported by pre-clinical studies with NHE-inhibitors,
reporting that higher doses are required with delayed
administration [123] while resulting in only modest effects
[124,125]. The importance of sufficient dosing is also
suggested by the observations that benefits occurred only in
the high dose groups in several clinical studies [39,64,126].
In conclusion, there is evidence from CABG studies that
cardioprotection in humans does occur when pharmacolog-
ical agents are administered prior to ischaemia. Furthermore,
there is some experimental evidence that a sufficiently high
concentration during the first few minutes after reperfusion
can result in infarct size limitation. The inability to meet
these requirements might contribute to the failure to observe
RI limitation in the majority of clinical studies.
5.4. Methodology and study design
5.4.1. Choice of endpoints
The primary endpoint of the majority of animal experi-
ments is infarct size, expressed as a percentage of area at risk
[12,106,127]. Clinical endpoints, such as mortality, would
require unacceptably large numbers of animals. Histochem-
ical staining with tetrazolium salts has been thoroughly
validated, and remains the golden standard. In clinical trials
the primary endpoints often include mortality, recurrent
ischaemia, congestive heart failure and stroke. However,
reperfusion therapy (PCI and thrombolysis) has reduced
mortality after AMI to low levels (4–6%) [128], making
further significant reductions by adjunctive agents difficult
to achieve. Although all methods to assess infarct size,
including serum markers and imaging modalities, have their
limitations [127], in phase II “proof of concept” trials infarct
size is considered the most appropriate surrogate end-point
for evaluating the efficacy of RI-inhibitory drugs.
5.5. Biases
A ‘publication bias’ may also contribute to the discrep-
ancy between the weight of pre-clinical versus clinical data.
Thus, negative trial results are obviously less exciting and
often more difficult to get published. Similarly, there may be
bias in the evaluation of available experimental data before
starting a clinical trial [42]. Thus, clinical trials were often
initiated even though drugs showed inconsistent results in
experimental animal studies [12].
6. Summary, conclusion and future perspectives
Experimental observations that drugs are capable of
limiting infarct size when administered just prior to or at the
onset of reperfusion have prompted a large number of
clinical trials investigating the therapeutic potential of
several agents against RI in the setting of AMI, that gen-
erally have been disappointing. Potential explanations for the
discrepant findings between pre-clinical and clinical studies
are summarized in Table 6. Future studies into novel drugs
that have shown promise in the experimental setting,
including Na+/Ca2+-exchange inhibitors, protease inhibitors,
and cyclic GMP mimetics, should take these factors into
account.
Fig. 1 depicts a flow-chart from pre-clinical studies to
large randomized double-blind clinical trials that is recom-
mended for future evaluation of RI limiting strategies. For
example, timing of drug administration, animal species
(species with or without collaterals) and mode of occlusion
and reperfusion should be rationally chosen [129]. Further-
more, animal experiments should consider the impact of co-
morbid conditions and co-medication on the cardioprotective
efficacy of novel agents [12]. The occlusion of arteries should
mimic thrombotic occlusion in contrast to arterial clamping,
and reperfusion should mimic thrombolysis or PCI.
To prevent inappropriate clinical trials, an expert Working
Group recently proposed that clinical trials with new agents
should be initiated only after the therapy proves to be
reproducibly effective in multiple animal models, ideally
performed in a randomized, blinded and multicenter
approach analogous to clinical trials [12,121]. Only then
clinical testing should be started, initially focussing on
predefined subgroups for proof of concept, before conduct-
ing a large scale clinical trial. First, studies should be
performed in patients undergoing CABG to allow detection
Fig. 1. Flow-chart for suggested development of new reperfusion inhibitory
drugs. ⁎Prospective patient stratification with or without all confounding
factors as mentioned in Table 6, e.g.: TIMI flow grade 0–1, pre-infarct
angina, concomitant medication, young, anterior wall infarction, etc;
# administration of agent before the onset of ischemia, during ischemia
but minutes before reperfusion and at reperfusion.
9M.T. Dirksen et al. / Cardiovascular Research xx (2007) xxx–xxx
ARTICLE IN PRESS
Please cite this article as: Dirksen MT et al. Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc
Res (2007), doi:10.1016/j.cardiores.2007.01.014
*Prospective patient stratification with or without all confoundingfactors as mentioned in Table 6, e.g.: TIMI flow grade 0–1, pre-infarct
ngina, conco itant medication, young, anterior wall infarction, etc;
# administration f agent before the onset of ischemia, duri g ischemiabut m utes before reperfusion and at reperfusion.
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ischaemic episodes in which pharmacological protection may provide an important contribu-
tion to cardioprotection.99
Concomitant medication
The concomitant medication used during routine clinical practice, and which is typically 
absent in experimental studies, may influence the effectiveness of agents directed against 
RI.49,53 Current reperfusion therapy of acute myocardial infarction involves treatment with 
vasodilators (including nitroglycerin, opiates, nitroprusside or dobutamine), medication with 
specific effects on thrombus formation, coagulation and platelet activation (heparin, aspirin, 
clopidogrel and GPIIb/IIIa receptor blockers), substitution of lost electrolytes and diuretics in 
case of increased filling pressures. It remains unclear whether these drugs have an effect on RI 
or modify the cardioprotective effects of the drug under investigation, but heparin and GPIIb/
IIIa receptor blockers could influence the effect of agents RI inhibitory drugs on adherence 
and extravasation of PMNs via modulation of chemotactic cytokines such as CD11/CD18 and 
ICAM-1 receptors.100 Conversely, sub-analyses of patients treated with or without GPIIb/IIIa 
receptor blockers in the PARI-MI and LIMIT-AMI trial did not reveal a different effect of the rep-
erfusion inhibitory substrate interfering with this same pathway of PMN accumulation, adhe-
sion and activation.49,53 Nevertheless observations that GPIIb/IIIa receptor blockers improved 
microvascular flow may suggest that GPIIb/IIIa receptor blockers influence inflammation.101 
Similarly, the effect of agents such as NHE-blockers and adenosine on RI could be superseded 
by the effects of standard concomitant medication in patients with coronary artery disease 
influencing the cellular electrolyte homeostasis, such as beta-blockers, Ca2+-blockers and ACE-
inhibitors.102,103 Finally, it should be noted that many patients that encounter an AMI are already 
treated for hypercholesterolemia and hypertension. Recently, it was demonstrated that statin 
treatment started before ischaemia reduced infarct size in a rat ischaemia-reperfusion mod-
el.104 Several experimental studies showed a possible effect of widely used anti-hypertensive 
and/or anti-anginal medication on RI, such as ACE-inhibitors and Ca2+-channel blockers. 
In conclusion, co-morbid conditions are likely to modulate the efficacy of new cardioprotective 
drugs under investigation, but these are typically not taken into account in experimental studies. 
Future experimental studies should take into account these co-morbid conditions.
Determinants of infarct size
The main determinants of infarct size include the area at risk, the severity of ischaemia, the 
duration of ischaemia, and the mode of reperfusion.105 In contrast to the clinical setting, these 
factors can either be controlled or accurately determined in the experimental models.
Location and size of the area at risk
In contrast to preclinical studies in which infarct size is related to the anatomical area at 
risk, clinical studies typically express infarct size as a percent of the left ventricle, resulting 
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in greater infarct size variability. Furthermore, animal studies primarily examine anterior 
infarction, while the majority of clinical trials included both patients with anterior as well as 
inferior wall infarctions. Interestingly, there are some trials indicating beneficial effects of a 
reperfusion inhibitory drug in patients with anterior wall infarction.37,39,63 The explanation for 
this localized feature is unknown and may be related to anatomical and biological differences, 
including area at risk size and degree of collateral flow.
Severity of ischaemia
The severity of ischaemia is dependent on both the degree of residual antegrade flow and 
collateral flow.106,107 In animal studies total coronary occlusions are typically used. In contrast, 
in clinical studies coronary obstruction is variable, either gradual or abrupt, intermittent or 
constant, partial or complete, thereby increasing infarct size variability. In addition, collateral 
blood flow in individual humans demonstrates a high degree of variability (e.g. young patient 
versus an older patient with chronic coronary artery disease),108 but is rarely determined in 
clinical studies, which will increase infarct size variability.
Duration of ischaemia
The majority of animal studies use a prospectively determined duration of ischaemia ranging 
from 30-90 minutes. In the clinical setting, the exact duration of ischaemia and the onset of 
reperfusion are difficult to establish, particularly in thrombolytic trials, but the duration of 
ischaemia is typically much longer (>2 hours from onset of symptoms to reperfusion, see 
Tables 2-5) compared to the laboratory setting. This may result in extensive ischaemic dam-
age, leaving less room for RI limiting strategies.53,96 Indeed, this is supported by clinical event 
reduction in patients treated early (within 3.17 hours) in the AMISTAD-II trial.109 However, 
other clinical studies could not confirm such a benefit in the subgroup of patients with re-
established flow within two hours of symptom onset.49,53
Mode of occlusion and reperfusion
In experimental studies, ischaemia-reperfusion is typically produced by a mechanically induced 
abrupt and total coronary occlusion and reperfusion. This contrasts with the more unpredict-
able coronary occlusion in the clinical setting that may be either gradual or acute. Reperfusion 
by thrombolysis is gradual and intermittent33 and may result in incomplete reperfusion due to 
persistence of the coronary stenosis.110,111 Importantly, the repetitive-intermittent ischaemia 
caused by both thrombolysis (incomplete reperfusion) and PCI (balloon dilatation and stent 
implantation) may induce postconditioning, a feature that is typically avoided in experimental 
studies112 In support of this concept, a study in which coronary occlusion and reperfusion was 
produced by formation and lysis of a thrombus failed to show cardioprotection by the drug 
under investigation.42
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In conclusion, several determinants of infarct size have been identified in the experimental set-
ting and are typically controlled or measured and accounted for. In contrast, these determinants 
are frequently overlooked in clinical studies of AMI, thereby acting as confounders and hampering 
detection of a protective effect by the drug under investigation.
Treatment related aspects
Distal embolization
Impaired post-procedural perfusion could be, at least in part, the result of embolization 
of plaque debris and thrombus into the distal microvasculature rather than of the result 
RI.96,113-115 Macro- and micro-embolization are both associated with reduced myocardial 
reperfusion, more extensive myocardial damage and a poor prognosis.115,116 This emboliza-
tion can occur spontaneously or as a result of intracoronary manipulation (wires, balloon 
dilatation and stent implantation). The plaque and thrombus content is washed out into the 
distal microvasculature114,117 in 10-15% of patients,115,116,118 where they mechanically “plug” the 
microvasculature, but can also produce spasm and local inflammation.113
To prevent plaque and thrombus wash-out several distal protection devices are currently 
under evaluation, two of which did not show improvement in microvascular flow, infarct size 
or event-free survival.119,120
Timing of drug administration
Preclinical studies demonstrated that several drugs are beneficial when given before the 
onset of ischaemia but do not consistently exhibit a beneficial effect when given just prior to 
reperfusion.12,42,96,121 Clinical trials suggest a similar trend as the majority of drugs administered 
in the setting of an AMI before the onset of reperfusion failed to limit infarct size or improve 
outcome (Tables 2-5), compared to administration prior to ischaemia, in the setting of CABG. 
Thus, patients pretreated before CABG showed reduced peri-operative MI,40,41,122 suggesting 
that these drugs may simply not be effective against RI in the setting of AMI.
Does medication reach the jeopardized myocardium in sufficiently concentrations
Another explanation for the inconsistent results, is that drugs may not reach the area at risk in 
sufficiently high concentrations prior to reperfusion. This concept is supported by pre-clinical 
studies with NHE-inhibitors, reporting that higher doses are required with delayed adminis-
tration123 while resulting in only modest effects.124,125 The importance of sufficient dosing is 
also suggested by the observations that benefits occurred only in the high dose groups in 
several clinical studies.39,64,126
In conclusion, there is evidence from CABG studies that cardioprotection in humans does occur 
when pharmacological agents are administered prior to ischaemia. Furthermore, there is some 
experimental evidence that a sufficiently high concentration during the first few minutes after 
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reperfusion can result in infarct size limitation. The inability to meet these requirements might 
contribute to the failure to observe RI limitation in the majority of clinical studies.
Methodology and study design
Choice of endpoints
The primary endpoint of the majority of animal experiments is infarct size, expressed as a 
percentage of area at risk.12,106,127 Clinical endpoints, such as mortality, would require unac-
ceptably large numbers of animals. Histochemical staining with tetrazolium salts has been 
thoroughly validated, and remains the golden standard. In clinical trials the primary endpoints 
often include mortality, recurrent ischaemia, congestive heart failure and stroke. However, 
reperfusion therapy (PCI and thrombolysis) has reduced mortality after AMI to low levels 
(4-6%),128 making further significant reductions by adjunctive agents difficult to achieve. 
Although all methods to assess infarct size, including serum markers and imaging modalities, 
have their limitations,127 in phase II “proof of concept” trials infarct size is considered the most 
appropriate surrogate end-point for evaluating the efficacy of RI-inhibitory drugs. 
Biases
A ‘publication bias’ may also contribute to the discrepancy between the weight of preclinical 
versus clinical data. Thus, negative trial results are obviously less exciting and often more dif-
ficult to get published. Similarly, there may be bias in the evaluation of available experimental 
data before starting a clinical trial.42 Thus, clinical trials were often initiated even though drugs 
showed inconsistent results in experimental animal studies.12
summary, ConClusion and future PersPeCtives
Experimental observations that drugs are capable of limiting infarct size when administered 
just prior to or at the onset of reperfusion have prompted a large number of clinical trials 
investigating the therapeutic potential of several agents against RI in the setting of AMI, that 
generally have been disappointing. Potential explanations for the discrepant findings between 
preclinical and clinical studies are summarized in Table 6. Future studies into novel drugs that 
have shown promise in the experimental setting, including Na+/Ca2+-exchange inhibitors, 
protease inhibitors, and cyclic GMP mimetics, should take these factors into account. 
Figure 1 depicts a flow-chart from pre-clinical studies to large randomized double-blind 
clinical trials that is recommended for future evaluation of RI limiting strategies. For example, 
timing of drug administration, animal species (species with or without collaterals) and mode 
of occlusion and reperfusion should be rationally chosen.129 Furthermore, animal experiments 
should consider the impact of co-morbid conditions and co-medication on the cardioprotec-
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table 6. Major differences between animal versus clinical trials.
Animal experiments Clinical trials
Co-morbid conditions
Concomitant disease
Myocardium Naïve and young Atherosclerosis and senescence
Endothelium Naïve Atherosclerosis and endothelial dysfunction
Concomitant disease Rare Hypertension, diabetes mellitus, hypercholesterolemia, LVH
Preconditioning/pre-infarct angina No Yes
Concomitant medication
Pre-procedure No Beta-blockers, nitrates, statins, ACE-inhibitors, Ca2+ blockers
Peri-procedural Rare Aspirin, heparine, GP IIb/IIIa receptor blockers, clopidogrel
Determinants of infarct size
Location and size of area at risk
Area at risk Exact Rarely determined
Location of infarct Mainly anterior wall Variable
Severity of ischaemia
Degree of antegrade flow Abrupt and constant Gradual or abrupt; intermittent or constant
TIMI flow grade 0 0-2
Degree of collateral flow Variable, species dependent Variable, dependent on extent of disease
Determination of collateral flow Always determined Rarely determined
Duration of ischaemia
Determination Exact Uncertain
Time of occlusion 15-90 minutes > 2 hours (range 1.9-24 hours)
Mode of occlusion
Mode Mechanical clamping Atherosclerotic and/or thrombotic
Completeness 100% Incomplete or complete 
Onset Abrupt Gradual or abrupt
Mode of reperfusion
Mode Release of mechanical clamp PCI or thrombolysis
Completeness 100% Incomplete or complete 
Onset Abrupt Gradual with thrombolysis, abrupt with PCI
Postconditioning No Yes (especially with PCI)
Treatment related aspects
Distal embolization No Often, in PCI at least 10-15%
Timing of drug administration
Related to ischaemia Before or after onset of ischaemia After onset of ischaemia (except CABG)
Related to reperfusion Before onset of reperfusion Before or after uncertain reperfusion
Methodology and study design 
Choice of endpoints Infarct size Clinical follow-up, infarct size, (micro-)vascular perfusion
Infarct size TTC staining Imaging (SPECT, MRI, echocardiography) and serum markers
Functional Rare Imaging (SPECT, MRI, echocardiography)
Microvascular perfusion No Myocardial blush grade, ST-segment resolution
Study design
Randomized Rare The majority
Blinded Rare The majority
Multicenter Rare The majority
TIMI = Thrombolysis In Myocardial Infarction; PCI = percutaneous coronary intervention; TTC = tryphenyltetrazolium chloride; LVH = left 
ventricular hypertrophy; MI = myocardial infarction; CHF = congestive heart failure; SPECT = single-photon emission computed tomography; 
MRI = magnetic resonance imaging; CABG = coronary artery bypass graft.
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tive efficacy of novel agents.12 The occlusion of arteries should mimic thrombotic occlusion in 
contrast to arterial clamping, and reperfusion should mimic thrombolysis or PCI.
To prevent inappropriate clinical trials, an expert Working Group recently proposed that 
clinical trials with new agents should be initiated only after the therapy proves to be reproduc-
ibly effective in multiple animal models, ideally performed in a randomized, blinded and mul-
ticenter approach analogous to clinical trials.12,121 Only then clinical testing should be started, 
initially focusing on predefined subgroups for proof of concept, before conducting a large 
scale clinical trial. First, studies should be performed in patients undergoing CABG to allow 
detection of cardioprotection by drugs when administered prior to ischaemia. Subsequently, 
studies should be considered in subgroups of AMI patients that are more similar to the animal 
experimental, e.g. patients with naïve vessels (young, no previous cardiac history, without 
pre-infarct angina), anterior wall infarction, and a totally occluded infarct-related artery and 
no co-medication at presentation. Large scale clinical trials should only be performed after 
such initial trials turn out positive.
In conclusion, the evidence presented in this review suggests that future studies pertaining 
to limitation of ischaemia-reperfusion injury in patients with AMI have a very low likelihood 
of success. However, the limitation of myocardial infarct size reported in experimental studies 
when administered prior to ischaemia and reperfusion warrants further investigation into this 
field, taking into account the lessons taken from the animal experimental and clinical studies 
as presented in this review article.
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This thesis describes several aspects of pathophysiology, diagnosis and treatment of acute 
myocardial infarction (AMI). Specifically, its aim was to: 
1) Enhance our insight into the pathophysiology of plaque stability.
2) Evaluate the accuracy of the electrocardiogram for the diagnosis of AMI.
3) Improve treatment with primary percutaneous coronary intervention by the use of the 
transradial approach and drug-eluting stents.
4) Reduce the adverse sequelae of reperfusion therapy in AMI, i.e. limit purported reperfu-
sion injury in patients with AMI; and finally, review clinical trials on reperfusion injury 
inhibitory strategies in patients with AMI.
PathoPhysioloGy of aCute myoCardial infarCtion: Plaque 
stability
The distribution of macrophages and smooth muscle cells within atherosclerotic plaques 
is highly variable, which is clinically relevant because these cell types have opposite effects 
on the stability of atherosclerotic plaques.1 Several risk factors for atherosclerosis, including 
hemodynamic factors, may be implicated in determining the cellular composition of plaques. 
The study described in Chapter 2 was the first study that showed marked topographic 
variation in cellular composition within atherosclerotic plaques related to the direction of 
the blood stream. It was shown that there were significant differences in cell composition 
between upstream and downstream parts of plaques suggesting a role for arterial flow in the 
distribution of different cell types. The downstream areas of plaques contain significantly more 
smooth muscle cells, which could provide the background for slowly progressive growth at 
distal ends of plaques. In contrast macrophages are the dominant cell types in the upstream/
high shear stress areas, inducing plaque degrading. Plaque instability leading to plaque rup-
ture is currently considered to be an imbalance between reparative activities (smooth muscle 
cell growth and collagen synthesis) and degrading activities induced by macrophages.1-3 
Subsequent studies confirmed that plaque instability and rupture occurred predominately in 
the upstream stress areas4,5 and that this is, at least partly, related to shear stress patterns.5,6 
Obviously, we will not be able to change shear stress patterns, but it may be possible to influ-
ence macrophage recruitment and plaque stability with the use of fibrates and statins. Statins 
have been shown to improve clinical outcome in patients with coronary artery disease partly 
due to plaque stabilization, thereby reducing plaque vulnerability.7,8 These effects may be 
exerted independent of the effects on serum cholesterol.8,9 Novel agents, such as agents with 
mast-cell, integrin and chemokine blockade and interleukin-10, are now being investigated in 
experimental models with their respect to their macrophage and plaque stabilizing proper-
ties and need to be awaited.
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In conclusion, the large amount of macrophages in the upstream parts of plaques indicate a 
relationship between high flow/high shear stress and plaque content and plaque stability. This 
may result in an upstream site of plaque rupture, leading to acute coronary syndromes including 
acute myocardial infarction.
diaGnosis of aCute myoCardial infarCtion: the 
eleCtroCardioGram
More than 100 years after Einthoven’s first publication on the electrocardiogram,10 the inter-
pretation of the electrocardiogram, in combination with the clinical presentation, is crucial 
for diagnosis of AMI. It is a non-invasive, cheap and widely available diagnostic tool. Several 
electrocardiographic criteria to diagnose the site of occlusion in the coronary artery have been 
published and it has been claimed that, by careful interpretation of the electrocardiogram 
based on electrical vector theory, it is possible to predict the culprit coronary segment.11,12 
However these criteria were mainly based on (electrical vector) theories or non-blinded stud-
ies and there was a need to evaluate these criteria in clinical practice in a blinded setting, 
which was described in Chapter 3. The analysis of the electrocardiogram to predict the culprit 
coronary segment was correct in only 39% (60/153). Consequently, in the total study popula-
tion and in all subgroups the sensitivity and specificity values to detect a large area at risk 
due to a proximal site of coronary occlusion were low. Prediction of the culprit segment or 
the adjacent segment resulted in 75% correctness. Thus, in practice the electrocardiogram is 
appropriate for detection of an AMI, but it appeared to have low accuracy for exact prediction 
of the infarct related coronary segment or a large area at risk, even when interpreted by an 
expert. Large areas at risk were accompanied by electrocardiograms with limited ST-segment 
elevation in a considerable number of patients. Given this inaccuracy of the acute electro-
cardiogram, the electrocardiogram should not be used for selecting a treatment strategy in 
patients with suspected ST-segment elevation myocardial infarction. The findings of this study 
underscore the importance of immediate coronary angiography in patients with the typical 
clinical presentation of AMI and any degree of ST-segment elevation.
In conclusion, the electrocardiogram appeared to be inaccurate, with low sensitivity and speci-
ficity to predict the exact site of coronary occlusion. Despite these limitations, interpretation of 
the electrocardiogram remains the investigation of choice for the diagnosis of the presence of an 
acute myocardial infarction.
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treatment of aCute myoCardial infarCtion: novel treatment 
strateGies in Primary PCi
The principal therapy in patients with an AMI to limit infarct size is myocardial reperfusion by 
revascularization with a mechanical (percutaneous coronary intervention) or pharmacological 
intervention (thrombolysis).13 Limitation of myocardial infarct size is critical to improve imme-
diate and long-term outcome and to reduce the incidence and prevalence of heart failure.
Primary Percutaneous Coronary Intervention Using the Transradial Approach
In Chapter 4 it was demonstrated that the primary percutaneous coronary intervention 
using the transradial approach is feasible. It has been proven in prior studies that treatment 
with a glycoprotein IIb/IIIa receptor blocker improves clinical outcome in patients with an 
AMI.14-17 However, the use of glycoprotein IIb/IIIa receptor blockade may induce adverse 
bleeding complications.15 Additionally, it was recently shown that when a glycoprotein IIb/
IIIa receptor blocker was administered about one hour before primary percutaneous coronary 
intervention it did not result in improved outcome when compared to administration in the 
catheterization laboratory.18 Alternatives, such as bivalirudin, may result in similar beneficial 
effects, but less adverse bleeding complications.19 Using the transradial approach, primary 
percutaneous coronary intervention resulted in few entry-site complications and a high 
procedural success-rate (96%). More recent (unpublished) data show even higher success 
rates, that increase with experience. Although the transradial approach will take a few more 
minutes, the benefits may prevail especially concerning bleeding complications and early 
mobilization. Despite an aggressive anti-thrombotic treatment regimen with glycoprotein IIb/
IIIa receptor blockade there were very few bleeding complications. Other studies have also 
shown that with the transradial approach in acute coronary syndrome, bleeding complica-
tions were less compared to the more routinely used transfemoral approach.20 Bleeding has 
been shown to correlate with subsequent major cardiovascular events and patient mortality.21 
In addition, the results in Chapter 4 show that the strategy of early revascularization with 
stenting and the transradial approach under glycoprotein IIb/IIIa receptor blockade followed 
by early mobilization and early discharge was feasible. It should be appreciated that our study 
population consisted of a high risk group for adverse outcome: 31% of patients in the current 
study was ≥ 70 years, the percentage of anterior myocardial infarction was high (69%) and 
28% of patients had angiographic multi-vessel disease. Despite this, clinical adverse events 
remained low throughout one year follow-up.
In conclusion, the strategy of early revascularization by the transradial approach under gly-
coprotein IIb/IIIa receptor blockade followed by early discharge was feasible in patients with an 
acute myocardial infarction. The use of the transradial approach will likely result in fewer bleeding 
complications, even under aggressive anti-thrombotic regimen, and may therefore become the 
preferred method for primary percutaneous coronary intervention.
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Drug-Eluting Stents in Acute Myocardial Infarction
Drug-eluting stents have been shown to reduce target-vessel revascularization as compared 
with bare-metal stents in a variety of clinical settings.22,23 Chapters 5 and 6 contain the results 
of the PASSION trial, one of the first randomised trials, investigating the use of a drug-eluting 
stent in patients with AMI. The PASSION trial investigated the efficacy of the paclitaxel-eluting 
stent (TAXUS®) compared to conventional bare-metal stents in 619 patients with an AMI. The 
one and two year follow-up showed marked, but non-significant, reduction on the occurrence 
of major adverse cardiac events as cardiac death, recurrent myocardial infarction, and target 
lesion revascularization in patients treated with a paclitaxel-eluting stent compared to a 
conventional bare-metal stent. The risk reduction for the combined endpoint cardiac mor-
tality, recurrent myocardial infarction or target lesion revascularization was approximately 
30%, which certainly is clinically relevant. This risk reduction was predominantly caused by 
limitation of restenosis, thereby leading to a reduction of target lesion revascularization. At 
two years follow-up the relative risk reduction for target lesion revascularization was slightly 
higher (40%), but this failed to reach levels of statistical significance likely as a result of a lower 
than expected rate of target lesion revascularization in the bare-metal stent group (causing a 
type ß-error). The simultaneously published results of the Trial to Assess the Use of the Cypher 
Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) study, 
evaluating the efficacy of the sirolimus-eluting stent (Cypher®) in AMI with a similar number 
of patients, did show a significant benefit.24 Apart from the employed employ type of drug 
and stent, there were several distinct differences between these two trials, including: 1) A 
higher rate of need for revascularization in the bare-metal stent group in the TYPHOON study 
compared to the PASSION trial, 13.4% versus 7.8%; 2) Differences in the inclusion and exclu-
sion criteria; 3) The performance of control angiography in the TYPHOON study which may 
have increased the revascularization rate due to the “oculo-stenotic reflex”. The performance 
of control angiography in clinical trials does not only differ from routine clinical practice (the 
real-world) and induces bias, it also exposes the patients to additional risk from repeat cath-
eterization and revascularisation by percutaneous coronary intervention or coronary artery 
bypass grafting.
The results of the additional meta-analysis of eight randomised controlled trials in Chapter 
7 confirmed these beneficial effects of drug-eluting stents in AMI. The analysis included 2.786 
patients with a mean follow-up of 12 to 24 months and showed that the use of drug-eluting 
stents in AMI significantly limited the occurrence of major adverse cardiac events, both with 
the paclitaxel- and the sirolimus-eluting stent. Similar to all drug-eluting stent trials the ben-
efit was mainly driven by limiting the need for target lesion revascularization and a trends 
towards beneficial effects on the occurrence of recurrent myocardial infarction and death.
A statement was released by the Food & Drug Administration panel in November 2006 
which cautioned that off-label use of drug-eluting stents (including for AMI) is associated with 
increased risks of both early and late stent thrombosis. Restenosis is considered a relatively 
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benign entity resulting in stable coronary syndromes, while stent thrombosis can be a poten-
tially lethal adverse event. Since the event rates late after primary percutaneous coronary 
intervention for AMI with drug-eluting stents were unknown, longer follow-up after drug-
eluting stent implantation seemed warranted, especially after discontinuation of thienopyri-
dines (e.g. clopidogrel [Plavix®]). Our two year results of the PASSION trial in Chapter 6 did 
not show an increase of late-stent thrombosis 1 year after the discontinuation of clopidogrel. 
Additionally, the meta-analysis with a follow-up up to 18-24 months in Chapter 7 showed 
similar reassuring results . Nevertheless, the use of drug-eluting stents in AMI remains debat-
able, and it may not be mandated in view of the predominantly large size of culprit vessels 
with a low expected risk of restenosis, yet these trials demonstrate a reduction in procedures 
for restenosis and favourable trends to lower deaths and recurrent myocardial infarction with 
drug-eluting stents.
Overall, the beneficial effects of drug-eluting stents also appear to prevail in patients with acute 
myocardial infarction predominantly by a reduced need for target lesion revascularization com-
pared to bare-metal stent implantation. These beneficial effect were not statistically significant 
when evaluated in 619 patients in our studies, but were significant when evaluated in a larger 
study population (meta-analysis). Importantly, the rates of stent thrombosis were not increased 
after paclitaxel-eluting or sirolimus-eluting stent implantation in primary percutaneous coronary 
intervention for acute myocardial infarction two years after stent implantation and one year after 
discontinuation of clopidogrel. These observations warrant the execution of larger trials with lon-
ger follow-up to better assess the effectiveness, risks and cost-effectiveness of drug-eluting stents 
in acute myocardial infarction.
sequelae of aCute myoCardial infarCtion: rePerfusion injury
The importance of early reperfusion by thrombolysis or primary percutaneous coronary 
intervention is not surprising as the primary insult is a decrease in oxygen supply resulting 
in a decrease of free energy from ATP-hydrolysis beyond a critical level required for maintain-
ing cell processes. However, despite its clear benefit, reperfusion itself has been proposed 
to cause irreversible myocardial damage, termed “reperfusion injury”. The mechanism of 
reperfusion injury remains incompletely understood and direct evidence for the existence of 
reperfusion injury stems from animal studies in which pharmacological agents administered 
just prior to reperfusion limit infarct size.25-30 Pre-clinical studies, although sometimes equivo-
cal, spurred a large number of clinical trials (~ 39 trials). Chapters 8 and 9 describe the results 
of two of these randomised clinical trials which evaluated the efficacy of two reperfusion 
inhibitory agents (ITF-1697 in the Protect Against Reperfusion Injury with ITF-1697 in acute 
Myocardial Infarction [PARI-MI] and caldaret in the CAldaret [MCC-135] in patients undergoing 
primary percutaneous coronary intervention for ST-segment Elevation Myocardial Infarction 
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[CASTEMI] trial). The PARI-MI and the CASTEMI trial used agents that target two different path-
ways of the reperfusion injury cascade and showed similar disappointing results. Both agents 
failed to limit infarct size or improve clinical outcome. Although treatment with other agents, 
especially those agents affecting the inflammatory response to ischaemic and reperfusion 
injury,31,32 may theoretically cause adverse events by interfering the physiological healing and 
scarring process, treatment with ITF-1697 and caldaret appeared to be safe.
The pre-clinical data of both ITF-1697 and caldaret demonstrated beneficial effects in vari-
ous experimental models. However, the pre-clinical evidence was limited and predominantly 
based on unpublished data. In view of the disappointing results in the clinical setting of AMI 
both studies further amplified the need for more careful review of pre-clinical and clinical 
studies with reperfusion injury inhibitory agents in general. In Chapter 10 this topic was 
reviewed discussing the encouraging results from animal studies with absence of benefit in 
clinical studies on reperfusion injury inhibitory strategies. Potential explanations for these 
discrepant findings are numerous and include: the absence of co-morbid conditions and 
concomitant medication in the animal models; differences in duration and mode of vessel 
occlusion; timing of administration of the reperfusion injury inhibitory drug; and differences 
in study endpoints. Future studies into novel drugs that have shown promise in the experi-
mental setting should take these factors into account. Considering the numerous prior trials 
evaluating reperfusion inhibitory agents there is low likelihood of success in patients with 
AMI. To prevent inappropriate clinical trials with new agents, these trials should be initiated 
only after the therapy proves to be reproducibly effective and safe in different animal models, 
ideally performed in a randomised, blinded and multicenter approach, analogous to clinical 
trials. Only then clinical testing should be started, initially focusing on predefined subgroups 
for proof of concept, before conducting a large scale clinical trial.
In conclusion, the evidence presented suggests that future studies pertaining to limitation of 
ischaemia-reperfusion injury in patients with acute myocardial infarction have a low likelihood of 
success. There are numerous factors, in both the experimental and clinical studies, responsible for 
these disappointing results in patients with acute myocardial infarction, and future investigations 
into this field should take these factors into account.
reCommendations for state of the art CliniCal PraCtiCe
The results from this thesis warrant the following protocol for treatment of patients with an 
AMI: (1) An onsite electrocardiogram should be made by paramedics from all patients with 
suspected AMI. This electrocardiogram may be transferred to the nearest interventional cen-
ter and judged. (2) If, the electrocardiogram shows ST-segment elevation indicating an AMI, 
irrespective of the amount of ST-segment deviation, the patient receives a loading dose of 
aspirin and is transferred to the interventional center. (3) On arrival at the center the diagnosis 
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is verified at the catheterization laboratory, a loading dose of thienopyridines is administered 
and an emergency coronary angiography is performed. Although the use of a glycoprotein 
IIb/IIIa receptor blocker is recommended as an adjunct to primary percutaneous coronary 
intervention, in our center it is only added to the treatment regime in case of no-reflow or 
a complicated percutaneous coronary intervention, this is due to high costs and potential 
bleeding complications. At our center all patients undergo the procedure with the transradial 
approach. (4) Subsequently, a primary percutaneous coronary intervention with stenting is per-
formed when indicated. A drug-eluting stent is merely used in patients with a high likelihood 
to develop restenosis (e.g. diabetes mellitus, small diameter of the culprit vessel). Currently, 
there are no specific drugs administered to reduce reperfusion injury. (5) Once the patient 
is clinically stabilized, pharmacological treatment with daily asprin, thienopyridines, beta-
blockers, statins, and, if indicated, ACE-inhibitors is initiated. Finally, patients are discharged 
three to four days after the event, provided that hospital stay remained uncomplicated.
future direCtions in treatment of aCute myoCardial infarCtion
This thesis describes strategies to further improve treatment of patients with an AMI. Future 
treatments to further improve clinical outcome in patients with AMI should be aimed at reduc-
tion of the number of patients not receiving reperfusion therapy and limitation of infarct size 
by faster diagnosis and treatment, limitation of restenosis, limitation of stent thrombosis and 
regeneration of infarcted myocardium in patients with severe myocardial damage.
“Time is Muscle”: Faster Diagnosis and Treatment
The earlier an AMI is diagnosed and the sooner a patient is treated the better the outcome will 
be. Patient awareness and education in order to recognize ischaemic complaints earlier may 
prevent patient delay. Earlier diagnosis can be achieved by immediate pre-hospital electrocar-
diography, which might then be transmitted to an interventional center for verification or be 
interpreted by computer algorhythms. As discussed in chapter 3, patients with an electrocar-
diogram showing any ST-segment elevation should be transferred as soon as possible to the 
nearest interventional center for coronary angiography and, if indicated, primary percutane-
ous coronary intervention. In case percutaneous coronary intervention is unavailable immedi-
ate treatment with thrombolysis should be initiated, if possible administered already prior to 
arrival at the hospital. In addition, anti-thrombotic treatment with aspirin, thienopyridines 
and (low-molecular weight) heparin should be initiated as soon as possible. Finally, future 
strategies should also be aimed at improving pre- and in-hospital patient logistics, in order to 
reduce the time from onset of symptoms to reperfusion. 
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Improvements in Stent Design
Apart from the use of drug-eluting stent, limitation of restenosis and reduction of stent 
thrombosis may also be achieved by improved stent design, including the use of biodegrad-
able stent material. Animal studies and numerous randomised trials have indicated that stent 
design does indeed have a profound effect on the tissue response, thereby exerting a signifi-
cant influence on restenosis and stent thrombosis.33-35 Currently, stents have widely disparate 
strut thickness, shapes and surfaces, are made of different material, with a variant amount of 
strut-to-strut intersections, coatings and polymers (the latter in case of drug-eluting stents).36 
There is a fragile balance between the strut thickness of the stent and its short and long-term 
outcome. Although direct stent performance may be improved by increasing strut thickness 
which consecutively increases radio-visibility; radial force and arterial wall support, conversely, 
excessive strut thickness may induce vascular injury and trigger intimal hyperplasia, result-
ing in an increase of restenosis compared to thinner struts.34 In an effort to further reduce 
strut thickness while maintaining adequate radio-visibility and radial strength, novel metallic 
materials such as cobalt-chromium alloy are being used for the production of stents.35
On the other hand, the ideal drug-eluting stent may need to have a large surface area of 
contact with the vascular wall, minimal gaps, robust radial support and symmetrical expan-
sion to ensure uniform drug elution. At the same time, it would need to be slim and flexible 
to enable successful deployment in complex lesions. Moreover, there is a major concern for 
potential long-term adverse effects caused by the carrier of the drug. Synthetic polymers are 
the most widely used carriers for anti-mitotic drugs which may induce an enhanced inflam-
matory reaction and possibly a prothrombotic response.37 The latter could be avoided by the 
use biomimetic and biodegradable polymers which are currently developed.
In contrast to drug-eluting stents, that interfere with the natural healing response by pre-
venting the formation of a functional endothelial lining over the stent, early establishment of 
a functional endothelial layer after stent implantation may prevent of neointimal proliferation 
and thrombus formation.38,39 In two pilot studies it was investigated whether stents covered 
with monoclonal anti-human CD34 antibodies or integrin-binding cyclic Arg-Gly-Asp peptide 
could limit coronary neointima formation and accelerate endothelialization by attracting 
endothelial progenitor cells.40,41 Both bioengineered stents showed safety and promise in 
initial clinical studies, but still need to be evaluated in larger study populations.
Theoretically vessel scaffolding may be necessary only for a certain, limited time.36,42 Bio-
absorbable or biodegradable stents are made of material that will be totally absorbed within 
a few weeks or months. Consequently no stent or stent material will be left behind, thereby 
possibly reducing chronic inflammation aggravating restenosis. The need for long-term use 
of clopidogrel post-stenting will may also no longer be necessary, since the occurrence of 
stent thrombosis is not very likely, provided that the endothelium is functional. With the use 
of bioabsorbable stents it will be less problematic to re-intervene the treated lesion in case of 
restenosis with either percutaneous coronary intervention or coronary-artery bypass grafting. 
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Furthermore, bioabsorbable stents will allow the vessel to perform physiological positive out-
ward remodelling and may be associated with a normal endothelial function. Similar to elec-
tive percutaneous intervention, after AMI, healing of the endothelium is mandatory. Therefore 
improvements in stent design should be aimed at allowing normalisation of endothelial 
function. Nevertheless, there remain some challenges for the design and application of 
bioabsorbable stents, such as the time and rate of degradation (preferably 12-24 months),36 
biocompatibility, radio-opacity, and remaining polymer and elution of possible drugs from 
bioabsorbable stents. The first clinical trials with bioabsorbable stents in patients with stable 
coronary syndromes have already been performed in which they showed to be safe with an 
acceptable rate of restenosis and no occurrence of stent thrombosis.42 The employment of 
bioabsorbable stents in patients with AMI may have similar beneficial effects.
Regeneration of Infarcted Myocardium
It has been suggested that tissue regeneration with stem cell or gene therapy may restore left 
ventricular function after AMI.43 This may be of particularly interest to patients with extensive 
myocardial damage due to failure or inability of early reperfusion therapy. As left ventricular 
function is one of the most important parameters for survival and morbidity, restoration of 
left ventricular function remains one of the major targets in treatment of AMI. However, there 
is a need for intensive fundamental research in this field of tissue regeneration as there remain 
major issues to be resolved. First, there is a need for competent stem cells that are capable 
of self renewal and differentiation that are easily available and engraftable without inducing 
ventricular damage. Secondly, it remains complex to deliver these cells at the infarcted tissue 
in a proper fashion (direct ventricular injection or (intracoronary) catheter based injection). 
The injection of cells may also induce hazard such as myocardial necrosis with intra-coronary 
injection of large cells (e.g. mesenchymal stromal cells or umbilical cord derived somatic stem 
cells) or large numbers of cells44 and it may induce increased restenosis or atherosclerotic 
progression.45 Thirdly, the stem cells itself can cause an unexpected (local) adverse events, 
such as inflammation, fibrosis or calcification. Finally, injection of cells may cause inadvertent 
transmission of infectious agents (e.g. prions). 
Treatment aimed at regeneration with tissue regeneration with stem cell therapy would 
potentially meet a unmet need, especially with the high mortality in the high risk AMI groups. 
The experimental data is still incomplete, but promising. Some clinical studies have recently 
been initiated and initial results, although mixed, overall appeared promising.46,47 Analogous 
to the studies evaluating reperfusion injury inhibitory strategies the experimental data were 
far more promising. Future experimental trials, also in the field of tissue regeneration, should 
be performed in a multicenter, blinded and randomised manner and in models resembling 
the clinical setting of AMI more closely.
177
SUMMARY, CONCLUSIONS & FUTURE DIRECTIONS
C
h
ap
te
r 
11
referenCes
 1. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role 
of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-381.
 2. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen break-
down in fibrous caps of atherosclerotic plaques. Circulation 1995;92:1565-1569.
 3. Lendon CL, Davies MJ, Born GVR, et al. Atherosclerotic plaque caps are locally weakened when 
macrophages density is increased. Atherosclerosis 1991;87:87–90.
 4. Slager CJ, Wentzel JJ, Gijsen FJ, et al. The role of shear stress in the destabilization of vulnerable 
plaques and related therapeutic implications. Nat Clin Pract Cardiovasc Med 2005;2:456-64
 5. Helderman F, Segers D, de Crom R, et al. Effect of shear stress on vascular inflammation and plaque 
development. Curr Opin Lipidol 2007;18:527-33.
 6. Cheng C, Tempel D, van Haperen R, et al. Atherosclerotic lesion size and vulnerability are deter-
mined by patterns of fluid shear stress. Circulation 2006;113:2744-53.
 7. Libby P, Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulner-
ability. Clin Cardiol 2003;26(1 Suppl 1):I11-4.
 8. Houslay ES, Sarma J, Uren NG. The effect of intensive lipid lowering on coronary atheroma and 
clinical outcome. Heart 2007;93:149-51.
 9. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates 
independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002;22:1452-8.
 10. Einthoven W. Galvanometrische registratie van het menselijk electrocardiogram. In: Herinnerings-
bundel Prof. S.S. Rosenstern [Galvanometric registration of the human electrogram]. Leiden, the 
Netherlands: Eduard Ijdo;1902;101-6.
 11. Sclarovsky S. Electrocardiography of Acute Myocardial Syndromes. London, UK: Martin Duntz, 
Ltd;1999.
 12. Wellens HJJ, Gorgels APM, Doevendans PA. The electrocardiogram in Acute Myocardial Infarc-
tion and Unstable Angina: Diagnosis and Risk Stratification. Boston, Mass: Kluwer Academic 
Publishers;2003.
 13. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients 
presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial 
Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
 14. Brener SJ, Barr LA, Burchenal JE, et al ; RAPPORT Investigators. Randomised, placebo-controlled trial 
of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. 
Circulation 1998;98:734-41.
 15. Montalescot G, Barragan P, Wittenberg O, et al; ADMIRAL Investigators. Platelet glycoprotein IIb/
IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-
903.
 16. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abcix-
imab on clinical and angiographic restenosis rate after the placement of coronary stents following 
acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
 17. Stone GW, Grines CL, Cox DA, et al; CADILLAC Investigators. Comparison of angioplasty with stent-
ing, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
 18. Ellis S. Final results of the FINESSE trial: evaluation of abciximab + half-dose reteplase, abciximab 
alone, or placebo for facilitation of primary PCI for ST elevation MI. European Society of Cardiology 
Congress 2007; September 3, 2007; Vienna, Austria
 19. Stone G. A prospective, randomised comparison of bivaluridin versus heparin plus glycoprotein 
IIb/IIIa inhibitors during primary angioplasty in acute myocardial infarction. Transcatheter Cardio-
vascular Therapeutics 2007; October 20-25, 2007; Washington, DC.
 20. Mann T, Cubeddu G, Bowen J, et al. Stenting in acute coronary syndromes: a comparison of radial 
versus femoral access sites. J Am Coll Cardiol 1998;32:572-576.
Chapter 11
178
 21. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with 
acute coronary syndromes. Circulation 2006;114:774-82.
 22. Morice MC, Serruys PW, Sousa JE, et al; RAVEL Study Group. A randomised comparison of a sirolimus-
eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
 23. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent 
in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
 24. Spaulding C, Henry P, Teiger E, et al; TYPHOON Investigators. Sirolimus-eluting versus uncoated 
stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104
 25. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21:537-45.
 26. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clini-
cal implications: part 1. Circulation 2001;104:2981-9.
 27. Bolli R, Becker L, Gross G, et al. Myocardial Protection at a Crossroads: The Need for Translation Into 
Clinical Therapy. Circ Res 2004;95:125-34.
 28. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38:291-
300.
 29. Schafer C, Ladilov Y, Inserte J, et al. Role of the reverse mode of the Na+/Ca2+ exchanger in 
reoxygenation-induced cardiomyocyte injury. Cardiovasc Res 2001;51:241-50.
 30. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore open-
ing at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003;60:617-25.
 31. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody 
in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: The 
LIMIT-AMI study. Circulation 2001;104:2778-83.
 32. Faxon DP, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor 
on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The 
results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-204.
 33. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. 
Circulation 1995; 91:2995-3001.
 34. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thick-
ness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103:2816-21.
 35. Kereiakes DJ, Cox DA, Hermiller JB, et al; Guidant Multi-Link Vision Stent Registry Investigators. 
Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003;92:463-6.
 36. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95.
 37. Commandeur S, van Beusekom HM, van der Giessen WJ. Polymers, drug release, and drug-eluting 
stents. J Interv Cardiol 2006;19:500-6.
 38. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces 
neointima formation after vascular injury. Circ Res 2003;93:e17-e24. 
 39. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically 
engineered endothelial progenitor cells. Circulation 2004;109:1769-1775.
 40. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with 
antibody against CD34: the HEALING-FIM Registry. J Am Coll Cardiol 2005;45:1574-9.
 41. Blindt R, Vogt F, Astafieva I, et al. A Novel Drug-Eluting Stent Coated With an Integrin-Binding Cyclic 
Arg-Gly-Asp Peptide Inhibits Neointimal Hyperplasia by Recruiting Endothelial Progenitor Cells. J 
Am Coll Cardiol 2006;47:1786-1795.
 42. Erbel R, Di Mario C, Bartunek J, et al; PROGRESS-AMS Investigators. Temporary scaffolding of coro-
nary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre 
trial. Lancet 2007 Jun 2;369(9576):1869-75.
 43. Mathur A, Martin JF. Stem cells and repair of the heart. Lancet 2004;364:183-192.
 44. Vulliet PR, Greeley M, Halloran SM, et al. Intra-coronary arterial injection of mesenchymal stromal 
cells and microinfarction in dogs. Lancet 2004;363:783-784
179
SUMMARY, CONCLUSIONS & FUTURE DIRECTIONS
C
h
ap
te
r 
11
 45. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells 
mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and 
restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. 
Lancet 2004;363:751-756
 46. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarc-
tion: eighteen months’ follow-up data from the randomised, controlled BOOST trial. Circulation 
2006;113:1287-94.
 47. Schachinger V, Erbs S, Elsasser A, et al; REPAIR-AMI Investigators. Improved clinical outcome after 
intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarc-
tion: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27:2775-83.

nederlandse samenvattinG
Nederlandse samenvatting
182
Hart- en vaatziekten zijn nog altijd de meest voorkomende ziekte en de belangrijkste oorzaak 
van sterfte Westerse wereld. Het acute hartinfarct (myocardinfarct) is verantwoordelijk voor 
het grootste deel van de plotse doden. De behandeling van het hartinfarct is gericht op 
beperking van de infarctgrootte, die de prognose voor een groot deel bepaalt. Dit proefschrift 
beschrijft verschillende aspecten van het ontstaansmechanisme, de diagnose en de behande-
ling van het acute hartinfarct (myocardinfarct). Meer specifiek was het doel om:
1) meer inzicht te krijgen in het ontstaansmechanisme (de pathofysiologie) van atheroscle-
rotische plaque-instabiliteit op celniveau. 
2) de precisie te evalueren van het electrocardiogram ter diagnose van het myocardinfarct.
3) de spoed- of ‘primaire’ percutane coronaire interventie (de huidige standaard-behandeling 
van het hartinfarct) te optimaliseren. 
4) de eventuele nadelige gevolgen van deze behandeling, zoals de paradoxale ‘reperfusie-
schade’, te beperken.
PathofysioloGie van het aCute hartinfarCt
Atherosclerose (“aderverkalking”) is een ziekteproces in de wand van een slagader (arterie), 
die leidt tot hart- en vaatziekten. Wanneer een atherosclerotische plaque instabiel wordt met 
lokale stolselvorming en/of een ruptuur (openbarsten van een plaque), kan een plotse afslui-
ting (occlusie) van een slagader ontstaan. Op het moment dat een plotse afsluiting ontstaat 
in een van de kransslagaders (coronaire arteriën ), die het hart voorzien van bloed, krijgt een 
deel van het hart geen bloed en daardoor ook geen zuurstof. Dit deel van het hartspierweef-
sel (myocard) wordt dan ‘ischemisch’ en zal niet meer naar behoren functioneren. Blijft deze 
ischemische situatie langer dan een half uur bestaan dan zal het hartspierweefsel uiteindelijk 
afsterven (infarceren).
In hoofdstuk 2 is op celniveau gekeken naar de verdeling van gladde spiercellen (smooth 
muscle cells (SMC)) en macrofagen (afweercellen die lichaamsvreemde stoffen en beschadigde 
of gedode micro-organismen (o.a. bacteriën en virussen) en hun afvalstoffen in zich opnemen 
en onschadelijk maken) in 33 atherosclerotische plaques (aantastingen). Hieruit blijkt dat 
de groei en instabiliteit van een atherosclerotische plaque mogelijk afhankelijk is van de 
stroomrichting en de zogenaamde ‘shear stress’ op de plaque. Shear stress is de afschuifspan-
ning van de bloedstroom op de vaatwand. Stabiele en langzame plaquegroei onder invloed 
van gladde spiercellen vindt vooral plaats in het stroomafwaartse deel van een plaque, waar 
een lage shear stress heerst. Instabiliteit van een plaque, met een verhoogde kans op erosie 
en ruptuur tot gevolg, is onder andere geassocieerd met de aanwezigheid van macrofagen. 
Deze macrofagen zijn voornamelijk te vinden in het stroomopwaartse deel van een plaque. 
Hieruit blijkt dat de er een relatie bestaat tussen plaque-instabiliteit, de stroomrichting van 
het bloed en shear stress. Dit verband werd later bevestigd door onderzoeken waarin men 
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observeerde dat plaque-erosie en -ruptuur inderdaad vooral in de stroomopwaartse delen 
van de plaque plaatsvinden. Op grond deze en andere observaties is men thans naarstig op 
zoek naar geneesmiddelen met een plaquestabiliserende werking.
De grotere dichtheid van macrofagen in het stroomopwaartse deel van een atherosclerotische 
plaque wijst op een relatie tussen de stroomrichting van het bloed en shear stress met plaque-
instabiliteit, die op zijn beurt kan leiden tot een stroomopwaarts gelokaliseerde plaqueruptuur, 
met een acuut coronair syndroom zoals een acuut hartinfarct tot gevolg.
diaGnostiek van het aCute hartinfarCt: het eleCtroCardioGram
De typische presentatie van een acuut hartinfarct is een patiënt met pijn of druk op de borst, al 
dan niet met uitstraling naar de armen en/of kaken, met of zonder vegetatieve verschijnselen 
(misselijkheid, braken en overmatig zweten) gedurende tenminste 20 minuten. De diagnose 
wordt gesteld met behulp van het electrocardiogram (ECG) in combinatie met deze klachten. 
Meer dan 100 jaar na de introductie van het ECG door Einthoven is het ECG een onmisbaar 
diagnosticum voor een grote verscheidenheid aan cardiale pathologie, waaronder het acute 
hartinfarct. Het ECG (een registratie van de elektrische activiteit van de hartspier) is vrijwel 
overal beschikbaar, niet invasief en goedkoop. Het ECG is niet alleen van belang voor het stellen 
van de diagnose zelf, maar de mate en de lokatie van de ST-segmentsafwijkingen (ST-elevaties 
en –depressies) op het ECG weerspiegelen ook de grootte en de lokatie van het bedreigde 
gebied, zodat kan worden afgeleid in welk segment van welke kransslagader zich de afsluiting 
bevindt. De criteria hiervoor zijn gebaseerd op de zogenaamde elektrische vector theorie en 
het werd tijd voor een gevalideerde en geblindeerde toetsing van deze criteria (hoofdstuk 3). 
ECG’s (n = 153) werden door een expert in de electrocardiografie geïnterpreteerd, terwijl hij 
geblindeerd was voor de uiteindelijke bij coronairangiografie (röntgenfilm met contrast van 
de kransslagaders) vastgestelde afsluiting in de kransslagader. Het staat buiten kijf dat het ECG 
onmisbaar blijft om de diagnose acuut hartinfarct te stellen, doch het blijkt niet erg nauwkeu-
rig voor de bepaling van de precieze lokatie van de afsluiting in de kransslagader. Slechts in 
39% (60 van de 153 ECG’s) bleek de door interpretatie van het ECG voorspelde lokatie van de 
afsluiting in de kransslagader overeen te komen met de daadwerkelijk aangetoonde lokatie. 
De sensitiviteit (de hoeveelheid zieken die ook daadwerkelijk als ziek worden aangemerkt 
door de test) en de specificiteit (de hoeveelheid door de test aangewezen niet-zieken die 
daadwerkelijk niet ziek zijn) van het ECG om de precieze lokalisatie van de coronaire occlusie 
bij grote hartinfarcten aan te tonen waren dientengevolge laag, respectievelijk 47% en 57%. 
Het bleek dat een groot aantal patiënten met een groot bedreigd gebied maar weinig ST-
segmentsdeviatie op het ECG toonden. Ons inziens dient men dus niet te veel te varen op 
wat het ECG aangeeft met betrekking tot de lokatie van de afsluiting in de kransslagader en 
de grootte van het bedreigde gebied. Patiënten met een acuut ST-segment elevatie myocard-
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infarct (STEMI) dienen dan ook altijd met spoed coronairangiografie en zo nodig een spoed 
dotterprocedure (‘primaire’ percutane coronaire interventie (PCI)) te ondergaan, ongeacht de 
mate van en elektrische vector van de ST-elevaties. 
Concluderend, in patiënten met een acuut hartinfarct blijkt het ECG geen betrouwbaar diagnos-
ticum te zijn voor de bepaling van de grootte van het bedreigde gebied en/of exacte lokalisatie van 
het de afsluiting. Ondanks deze beperking blijft het ECG wel hét diagnosticum bij uitstek voor de 
diagnose van het hartinfarct. 
behandelinG van het aCute hartinfarCt: nieuwe 
behandelinGsstrateGieën ter verbeterinG van de Primaire 
PerCutane Coronaire interventie
De optimale therapie voor een acuut ST-segment elevatie myocardinfarct (STEMI) is het zo snel 
mogelijk revasculariseren (‘heropenen’) van het aangedane bloedvat, hetzij met een spoed 
dotterprocedure (‘primaire’ percutane coronaire interventie (PCI)), hetzij farmacologisch met 
trombolyse (het medicamenteus oplossen van het afsluitende stolsel). Zoals eerder gesteld, 
beperking van de infarctgrootte is het belangrijkste doel om de ziekte-vrije overleving en het 
ontstaan van hartfalen op korte en lange termijn te verbeteren. Thans wordt primaire PCI met 
stentimplantatie gezien als de optimale behandeling van patiënten met een STEMI en effec-
tiever dan trombolyse of ballondilatatie zonder stentplaatsing. In de hoofdstukken 4 tot en 
met 7 is onderzocht of nieuwe strategieën gericht op het verminderen van complicaties van 
PCI en restenose (het opnieuw vernauwd raken van een kransslagader ter plaatse van met PCI 
behandelde stenose) de resultaten van primaire PCI met stenting verder kunnen verbeteren.
Primaire Percutane Coronaire Interventie met de Transradiale Benadering
Rondom een primaire PCI kunnen medicijnen gegeven worden die tot doel hebben de 
uiteindelijke hartinfarctgrootte te beperken en tromobotische complicaties (bloedpropjes in 
de bloedbaan) ten gevolge van de PCI of stentplaatsing zelf te voorkomen. Momenteel is 
het gebruik van heparine en bloedplaatjesaggregatietremmers, zoals carbasalaatcalcium of 
acetylsalicylzuur (aspirine) en thienopyridines (clopidogrel en ticlopidine), standaardtherapie 
voor patiënten met een acuut coronair syndroom, waaronder ook het STEMI. De afgelopen 
jaren heeft men ook het effect geëvalueerd van de mogelijk meer potente intraveneuze 
bloedplaatjesaggregatietremmers glycoproteïne IIb/IIIa (GPIIb/IIIa) receptorblokkers (tiro-
fiban, abciximab, eptifibatide). GPIIb/IIIa receptorblokkers verbeteren de microvasculaire 
doorbloeding van het hartspierweefsel en verminderen de distale embolisatie (het verder 
meevoeren van bloedpropjes in de bloedbaan en het verderop afsluiten van een slagader) 
en de trombusmassa, waardoor de uiteindelijke schade aan het hart beperkt wordt. Bij een 
PCI wordt de stenose (vernauwing) in de kransslagader mechanisch met ballon en stent weg-
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geperst en opgeheven. Hierbij kan plaque- inhoud en trombotisch weefsel loskomen en raakt 
het endotheel (binnenste laag van de vaatwand) beschadigd. Hierdoor ontstaat een milieu 
dat stolselvorming bevordert. GPIIb/IIIa receptorblokkers gaan dit juist tegen.
Echter, het gebruik van GPIIb/IIIa receptorblokkers in combinatie met orale bloedplaat-
jesaggregatietremmers en heparine gaat ook gepaard met een verhoogd bloedingsrisico, 
voornamelijk ter plaatse van de insteekopening in de bloedbaan van de catheter (12% in the 
ADMIRAL-trial), met een verhoogde morbiditeit en een verlengd ziekenhuisverblijf als gevolg. 
Door gebruik te maken van de transradiale benadering of “transradial approach” (TRA), waar-
bij men de kransslagaders via de polsslagader (arteria radialis) benadert in plaats van via de 
liesslagader, kunnen belangrijke bloedingscomplicaties worden vermeden. In hoofdstuk 4 is 
geëvalueerd of het mogelijk was om patiënten met een acuut hartinfarct na een korte zie-
kenhuisopname (3-4 dagen) veilig naar huis te ontslaan na behandeling met primaire PCI en 
de transradiale benadering in combinatie met GPIIb/IIIa receptorblokkers. Honderd patiënten 
werden op deze wijze behandeld en ontslagen. Deze strategie bleek veilig en goed toepas-
baar in de klinische praktijk, hoewel grotere en eventueel gerandomiseerde onderzoeken 
zouden moeten worden uitgevoerd om te bestuderen of deze strategie ook daadwerkelijk 
superieur is aan andere strategieën. Primaire PCI via de transradiale benadering resulteerde 
in een hoog succespercentage (96%) en weinig complicaties. De behandelingsstrategie van 
primaire PCI via de TRA onder behandeling met GPIIb/IIIa receptorblokkers zorgde ervoor dat 
patiënten snel konden mobiliseren en reeds 3-4 dagen na het acute hartinfarct veilig uit het 
ziekenhuis konden worden ontslagen. Het optreden van ernstige klinische gebeurtenissen 
bleef gedurende het jaar na het hartinfarct laag in de studiepopulatie. Thans is de transradiale 
procedure de standaard in het Onze Lieve Vrouwe Gasthuis, met een inmiddels nog hoger 
succespercentage. Ondanks het feit dat de TRA een paar minuten extra tijd kost, lijken de 
voordelen van de TRA hier ruimschoots tegen op te wegen. Vooral door de vermindering 
van bloedingscomplicaties bij patiënten die met agressieve en intensieve antitrombotische 
medicatie worden behandeld.
Samenvattend kan gesteld worden dat de gecombineerde strategie van spoed PCI, de TRA, het 
gebruik van GPIIb/IIIa receptorblokkers en vroeg ontslag mogelijk is bij patiënten met een acuut 
hartinfarct. Zelfs bij patiënten die behandeld worden met agressieve antitrombotische medicatie, 
leidt het gebruik van de TRA mogelijk tot minder bloedingscomplicaties en zou derhalve te prefe-
reren zijn boven de meer conventionele transfemorale methode.
Drug-Eluting Stents bij Primaire PCI voor het Acute Hartinfarct
Een revolutie in de interventiecardiologie is het gebruik van een nieuw soort stent, de 
‘drug-eluting stent’ (DES). Bij patiënten met een acuut hartinfarct die behandeld zijn mid-
dels primaire PCI met plaatsing van een conventionele ofwel ‘bare-metal stent’ (BMS) kan 
restenose ontstaan. Er is zelfs melding gemaakt van een restenosepercentage van 20%. Een 
zogenaamde DES geeft een geneesmiddel af dat het opnieuw dichtgroeien van de lesie 
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(restenose) ter plekke tegengaat. Het opnieuw dichtgroeien wordt voornamelijk veroorzaakt 
door een ontstekingsreactie die het gevolg is van de schade die aan het bloedvat wordt 
toegebracht bij het aanbrengen van de stent. Bij die ontstekingsreactie worden nieuwe 
cellen aangevoerd die de stent inkapselen. De geneesmiddelen op een drug-eluting stent 
remmen deze ontstekingsreactie en de groei van weefsel in en rondom de stent. Het gebruik 
van deze DES in de behandeling van obstructief coronairlijden zorgt voor een dramatische 
afname van het optreden van restenose en leidt dientengevolge tot een lagere incidentie van 
angineuze symptomen (pijn op de borst), nieuwe hartinfarcten, sterfte en de noodzaak voor 
het opnieuw behandelen van dezelfde kransslagaders middels PCI of een open hartoperatie 
(CABG: coronary artery bypass grafting). Momenteel zijn er meerdere soorten DES op de markt 
van verschillende materialen die verschillende soorten medicatie afgeven. De eerste twee 
soorten DES die op de markt verschenen waren de sirolimus-eluting stent en de paclitaxel-
eluting stent (PES)(TAXUS®). Van beide is de effectiviteit aangetoond in het tegengaan van 
restenose in patiënten met stabiel obstructief coronairlijden. Deze DES waren echter nooit 
eerder onderzocht bij patiënten met een acuut hartinfarct die primaire PCI ondergingen. Aan-
gezien de atherosclerotische plaque bij stabiel coronairlijden belangrijke verschillen vertoont 
vergeleken met de instabiele en trombotische plaque bij instabiel coronairlijden, zoals het 
acute hartinfarct, is het de vraag of het gebruik van DES ook zinvol is in de behandeling van 
patiënten met een acuut hartinfarct.
In hoofdstuk 5 worden de resultaten beschreven van de PASSION trial (PAclitaxel-eluting 
Stent versus conventional Stent in myocardial Infarction with ST-Segment ElevatION), het 
eerste gerandomiseerde en geblindeerde onderzoek naar de effectiviteit van paclitaxel-
eluting stents (PES) in patiënten (n=619) met een acuut hartinfarct. De follow-up na 1 en 2 jaar 
(hoofdstuk 6) toonde aan dat het gebruik van PES bij patiënten met een acuut hartinfarct niet 
leidde tot significant minder nieuwe hartinfarcten, doden of nieuwe revasculariserende ingre-
pen van de behandelde kransslagader als uiting van minder restenose. Wel werd er een trend 
gezien tussen PES en BMS in deze setting (11.1% versus 15.4%), met een relatieve risicoreduc-
tie, ook twee jaar na het initiële hartinfarct, van 30-40%. Deze relatieve risicoreductie werd 
voornamelijk veroorzaakt door een trend in minder noodzaak voor nieuwe therapeutische 
interventies ten gevolge van restenose (6.0% versus 9.9%). Dat deze relatieve risicoreductie 
niet heeft geleid tot een statistisch significant verschil tussen PES en BMS is deels veroor-
zaakt doordat de studiepopulatie mogelijk te klein was (zogenaamde ‘bèta-fout’) en deels 
het gevolg van een lager dan verwacht restenosepercentage in de BMS groep. Wellicht kan 
dit lage percentage verklaard worden doordat de gebruikte BMS (Express2® en Liberté® stent) 
zelf een moderne, hightech, doorgeëvolueerde stent is met verbeterde biocompatibiliteit, 
flexibiliteit en dunne ‘struts’. Tegelijkertijd met de publicatie van de PASSION trial werd de 
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon 
Angioplasty (TYPHOON) studie gepubliceerd. De TYPHOON studie onderzocht het gebruik 
van een andere DES, de sirolimus-eluting stent, bij een zelfde hoeveelheid patiënten (n=712) 
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met een acuut hartinfarct. Dit onderzoek toonde wél significant betere resultaten met het 
gebruik van sirolimus-eluting stents vergeleken met een BMS. Afgezien van het feit dat de 
twee onderzoeken (PASSION en TYPHOON) het effect van twee verschillende soorten DES 
evalueerden, zijn deze studies zeker niet direct vergelijkbaar door een verschil in opzet, in- en 
exclusiecriteria en definities van eindpunten.
Een belangrijke onderzoeksmethode naar effectiviteit van een behandeling is het bekijken 
en analyseren van meerdere onderzoeken bij elkaar: Dit noemt men een meta-analyse. De 
totale studiepopulatie is dus groter, zodat de kans op vals-negatieve of vals-postieve ver-
schillen kleiner wordt (en de ‘bèta-fout’ voorkomen kan worden). In dit proefschrift is een 
meta-analyse opgenomen van onderzoeken naar het gebruik van DES bij acute hartinfarcten 
(hoofdstuk 7). Acht gerandomiseerde onderzoeken zijn geїncludeerd in deze analyse, met in 
totaal 2.786 patiënten en een klinische follow-up van 18 tot 24 maanden. Het aantal doden 
was niet verschillend tussen DES of BMS (4.1% versus 5.1%), maar wel verschillend ten aanzien 
van de noodzaak voor nieuwe interventies ten gevolge van restenose (5.1% versus 13.1%). De 
analyse ondersteunde de gevonden voordelen van het gebruik van DES bij patiënten met een 
acuut hartinfarct, zowel met PES als sirolimus-eluting stents.
Desalniettemin is er veel discussie over het gebruik van DES, niet alleen bij patiënten met 
een acuut hartinfarct, maar bij alle patiënten met obstructief kransslagaderziekte (coronair-
lijden). De aanleiding is het optreden van (late) stenttrombose. Stenttrombose is het plots 
afsluiten van een stent, doorgaans door een stolsel (trombus). Doordat het geneesmiddel dat 
afgegeven wordt door DES de groei van weefsel binnen de stent tegengaat, gaat het ook de 
noodzakelijke endothelialisatie tegen. Het endotheel, de binnenste laag van de vaatwand, 
moet het kale metaal van de stent bedekken, omdat kaal metaal in een bloedvat kan leiden 
tot trombusvorming met alle gevolgen van dien, waaronder acute hartinfarcten en zelfs dood. 
Eén van de belangrijkste medicijnen die worden gebruikt om stenttrombose tegen te gaan, 
ook na plaatsing van een BMS, zijn de thienopyridines, met name clopidogrel (Plavix®). Na 
een acuut hartinfarct worden patiënten 6 tot 12 maanden behandeld met clopidogrel. Er is 
gesuggereerd dat voornamelijk na het staken van clopidogrel een verhoogde kans (ongeveer 
0.6% per jaar) bestaat op het optreden van stenttrombose. Hoe vaak stenttrombose voorkomt 
na het staken van clopidogrel bij patiënten na een acuut hartinfarct was niet bekend, daarom 
voerden wij een langtermijnsfollow-up van 2 jaar uit van de PASSION trial. Zowel de follow-up 
van de PASSION trial als de resultaten van onze meta-analyse lieten zien dat het optreden 
van stenttrombose bij deze patiënten inderdaad optreedt. In de PASSION studie was dit 2.1% 
na DES versus 1.4% na BMS implantatie en dit was 1.7% versus 2.2% in de meta-analyse. Een 
significante toename van stenttrombose met het gebruik van DES werd dus niet aangetoond. 
Men moet echter wel in ogenschouw nemen dat het voordeel van het gebruik van DES (het 
verminderen van in-stent restenose), misschien niet opweegt tegen de potentieel schadelijke 
en zelfs dodelijke complicatie van stenttrombose. Studies hiernaar met een langere follow-up 
en grotere onderzoekspopulaties zijn dan ook noodzakelijk. 
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Concluderend kan gesteld worden dat het gebruik van DES in patiënten met een acuut hartin-
farct wel enig voordeel heeft, maar het blijft discutabel of het gebruik hiervan noodzakelijk is in 
alle patiënten met een acuut hartinfarct.
GevolGen van het aCute hartinfarCt: rePerfusiesChade
Zoals reeds genoemd is de behandeling van het hartinfarct gericht op beperking van de infarct-
grootte, omdat de prognose met name hiervan afhankelijk is. De therapeutisch of spontane 
rekanalisatie van het afgesloten vat en de gewenste reperfusie van het myocard die hierdoor 
optreedt, kan ook nadelige effecten hebben op het hartspierweefsel. Dit fenomeen noemt 
men ‘reperfusieschade’. Het precieze mechanisme van deze reperfusieschade is niet volledig 
bekend en het concept komt voort uit dierexperimenten, waarin farmacologische agentia 
werden toegediend vlak voor de reperfusie met als doel beperking van de infarctgrootte. Na 
gunstige observaties in vele pre-klinische onderzoeken is een groot aantal (± 39) klinische stu-
dies gestart, gericht op de behandeling/preventie van reperfusieschade. Hoofdstukken 8 en 
9 beschrijven de resultaten van twee gerandomiseerde onderzoeken met reperfusieschade-
remmende agentia (ITF-1697 in de “Protect Against Reperfusion Injury with ITF-1697 in acute 
Myocardial Infarction [PARI-MI]” en caldaret in de “CAldaret [MCC-135] in patients undergoing 
primary percutaneous coronary intervention for ST-segment Elevation Myocardial Infarction 
[CASTEMI]”). De PARI-MI (n=402) en de CASTEMI (n=387), waarin verschillende stoffen werden 
gebruikt, gericht tegen verschillende factoren die bijdragen tot reperfusieschade, toonden 
beide teleurstellende resultaten. Beide agentia hadden geen (positief noch een negatief ) 
effect op de uiteindelijke infarctgrootte of op het klinische beloop.
De pre-klinische data met betrekking tot zowel ITF-1697 als caldaret toonden veelbelo-
vende resultaten in meerdere, in opzet verschillende diermodellen. Niet alleen door deze 
twee onderzoeken (PARI-MI en CASTEMI), maar ook door alle voorgaande onderzoeken 
naar reperfusieschade-remmende medicatie met eenzelfde teleurstellend resultaat, leek 
het noodzaak om de pre-klinische en klinische onderzoeken die tot nu toe verricht werden 
onder de loep te nemen. Het laatste hoofdstuk van het proefschrift (hoofdstuk 10) is een 
overzichtsartikel over alle tot nu toe gedane pogingen reperfusieschade te behandelen in 
patiënten met een acuut hartinfarct. Het blijkt dat er vele mogelijke verklaringen zijn voor de 
discrepantie tussen de pre-klinische en klinische resultaten, zoals de afwezigheid van comor-
biditeit (o.a. diabetes mellitus, hypertensie, etc), aanvullende medicatie in de diermodellen, 
grote verschillen in de duur en wijze van vaatocclusie en verschil in onderzoekseindpunten. 
Toekomstige onderzoeken naar potentieel reperfusieschade-remmende agentia zouden deze 
en andere factoren meer in ogenschouw moeten nemen. Gezien de teleurstellende resultaten 
van voorgaande onderzoeken naar reperfusieschade-remmende agentia bij patiënten met 
een acuut hartinfarct, lijkt de kans op succes van dergelijke interventies klein. Om inadequate 
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en onvoldoende onderbouwde klinische onderzoeken in de toekomst te voorkomen zouden 
studies met nieuwe agentia alleen ondernomen mogen worden wanneer de therapie effectief 
is gebleken in meerdere en verschillende soorten diermodellen. Idealiter zouden deze studies 
uitgevoerd moeten worden in een geblindeerde, gerandomiseerde, multicenter setting, wat 
over het algemeen ongewoon is, analoog aan de klinische onderzoeken. Alleen dan zouden 
klinische onderzoeken opgezet kunnen worden, welke zich initieel zouden moeten richten 
op specifieke subgroepen ter bevestiging van de werking in patiënten met een acuut hart-
infarct.
De resultaten van voorgaande onderzoeken naar reperfusieschade-remmende agentia bij 
patiënten met een acuut hartinfarct zijn consistent teleurstellend, waardoor de kans op succes 
voor nieuwe agentia klein lijkt. Er zijn vele verklaringen voor de discrepantie tussen de pre-klinische 
en klinische studies die in toekomstige onderzoeken in ogenschouw genomen moeten worden.
ConClusie en aanbevelinGen voor ‘state-of-the-art’ klinisCh 
handelen
Dit proefschrift biedt een overzicht van de pathofysiologie, diagnostiek, behandeling en 
gevolgen van het acute hartinfarct. Op basis van onder andere de resultaten uit dit proef-
schrift is er een protocol voor te stellen voor de optimale behandeling van patiënten met een 
acuut hartinfarct: (1) Bij patiënten met een mogelijk acuut coronair syndroom (waaronder 
het acute hartinfarct) zou direct en ter plekke (dus ook thuis en op straat) een ECG gemaakt 
moeten worden door paramedici. Het ECG zou vervolgens per fax of e-mail ter beoordeling 
doorgestuurd, moeten worden naar het dichtstbijzijnde cardiologisch interventiecentrum. (2) 
Indien het ECG ST-segment elevaties toont passend bij een acuut hartinfarct zou de patiënt, 
ongeacht de hoeveelheid en lokalisatie van de ST-segmentselevaties, een oplaaddosis 
bloedplaatjesaggregatieremmers toegediend moeten krijgen en zo snel mogelijk naar het 
interventiecentrum getransporteerd moeten worden. (3) Bij aankomst aldaar zal de diagnose 
geverifieerd moeten worden op de hartcatheterisatiekamer. Na een oplaaddosis thienopyri-
dines en heparine zal met spoed coronairangiografie verricht moeten worden. Ondanks dat 
(nog) geadviseerd wordt een GPIIb/IIIa receptorblokker te starten voor of tijdens de interventie, 
wordt dit in ons centrum alleen toegediend in het geval van een gecompliceerde en/of niet 
volledig geslaagde interventie. Voornamelijk de verhoogde kans op bloedingscomplicaties 
en hoge kosten geeft aanleiding voor deze terughoudendheid. In ons centrum worden alle 
interventies gedaan via de transradiale benadering ter beperking van deze bloedingscom-
plicaties. (4) Indien geïndiceerd zal een primaire PCI met stenting volgen. Een drug-eluting 
stent is ons inziens slechts geïndiceerd bij patiënten met een hoog risico op het ontwikkelen 
van restenose, zoals patiënten met diabetes mellitus, kleine vaten en lange vernauwingen. 
Vooralsnog is er geen plaats voor reperfusieschade-remmende medicatie in de behandeling 
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van patiënten met een acuut coronair syndroom. (5) Na de interventie en zodra de patiënt kli-
nisch stabiel is, zal verder medicamenteus beleid ingezet worden met een dagelijkse dosering 
bloedplaatjesaggregatieremmers, thienopyridines, bètablokkers, statines, en ‘angiotensine 
converting enzyme’-remmers (ACE-remmers). Uiteindelijk zal de patiënt na 3-4 dagen naar 
huis ontslagen kunnen worden bij een ongecompliceerd ziekenhuisverblijf.
Dit proefschrift behelst de evaluatie van enkele strategieën ter verbetering van de behandeling 
van patiënten met een acuut hartinfarct. Toekomstige behandelingsstrategieën ter verbetering 
van de ziektevrije overleving zullen gericht zijn op het verdere beperking van de grootte van het 
hartinfarct door de diagnose vroeg te stellen, op het eerder starten van de behandeling, op beper-
king van restenose en stenttrombose, en zo mogelijk op regeneratie van myocardiaal (hartspier-) 
weefsel bij patiënten met grote hartinfarcten.
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Voor de totstandkoming van dit proefschrift is de medewerking en steun van collega’s, vrien-
den en familie waardevol, inspirerend en bovenal onontbeerlijk geweest.
Allereerst gaat mijn dank uit naar mijn copromotor, opleider en ‘spin-in-het-web’, GertJan 
Laarman. Beste GertJan, in 2002 bood je mij de kans me te storten op klinisch wetenschap-
pelijk onderzoek. Die kans heb ik na enig wikken en wegen met beide handen aangegrepen. 
Jaren later is hier dan het resultaat, dat onmogelijk tot stand had kunnen komen zonder 
jouw ongelimiteerde (‘24/7’ e-mailcontact) en nooit aflatende steun. De manier waarop en 
de ongeëvenaarde snelheid waarmee jij zaken regelde, waaronder de implementatie van de 
PASSION studie, zijn bewonderenswaardig. Bedankt.
Het was een voorrecht samen te werken met mijn beide promotoren, professor Simoons en 
professor Duncker. Beste professor Simoons, uw precisie én overkoepelend overzicht hebben 
steeds bijgedragen tot verbetering en doeltreffendheid van de manuscripten en de onderzoe-
ken in het algemeen; ik hoop dat ik mezelf ooit ook een deel van uw inzicht eigen kan maken. 
Professor Duncker, beste Dirk, nooit zal ik de vele keren vergeten dat ik naar je toe kwam voor 
een oppepbeurt op de momenten dat ik me weer op een dood spoor bevond en niet kon 
ophouden met navelstaren (in het bijzonder rondom het reperfusieschade overzichtsverhaal). 
Bedankt voor je aanhoudende enthousiasme, frisse blik en onbaatzuchtige steun.
Professor Tijssen, beste Jan, jouw hulp op methodologisch vlak was zeer waardevol en ik 
ben nog altijd blij dat je mij als methodologisch en statistisch analfabeet enigszins wegwijs 
hebt gemaakt in deze wereld. De overige leden van de promotiecommissie ben ik dank ver-
schuldigd voor de aandacht die zij besteed hebben aan mijn proefschrift: prof.dr. W.J. van der 
Giessen, prof.dr. J.J. Piek, prof.dr. P.M.T. Pattynama en prof.dr. P.J. de Feijter.
Mijn eerste wetenschappelijke ervaring (zie hoofdstuk 2 van dit proefschrift) deed ik op 
bij professor A.E. Becker en Allard van der Wal. Beiden wil ik bedanken voor deze eerste 
enthousiasmerende kennismaking met de wetenschap en voor de prachtige kans die jullie 
mij geboden hebben om mijn eerste artikel te publiceren in Circulation.
Alle participerende interventiecardiologen in het Onze Lieve Vrouwe Gasthuis, Sint Antonius 
Ziekenhuis en overige centra in binnen- en buitenland wil ik bedanken voor het uitvoeren 
van de primaire PCI’s, het nauwkeurig invullen van de databases en het corrigeren van 
manuscripten, onder andere: Ferdinand Kiemeneij (de snelste primaire PCI), Ron van der 
Wieken (door het vuur voor je patiënten), Ton Slagboom (scherp houden), Giovanni Amoroso 
(multipele culprit lesies), Mark Patterson (native English), Maarten-Jan Suttorp (PASSION-trial), 
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professor F.W.H.M. Bär (CASTEMI-trial), en Arnoud van ’t Hof (PARI-MI-trial). Furthermore, I 
greatly acknowledge the collaboration with the co-authors of the ‘DES in AMI’-meta-analysis, 
especially Dr. Adnan Kastrati.
Verder wil ik alle cardiologen in het Onze Lieve Vrouwe Gasthuis bedanken die mij in staat 
hebben gesteld om opleiding en promotie te combineren; in het bijzonder Jean-Paul Herrman 
(om me over te halen), Gijsbert de Ruiter (onnavolgbare 3D-imitatie van voorkamerwoelen 
en cirkeltachycardieën), en Aernout Somsen (‘jonge honden’-mentaliteit). Verder ben ik dank 
verschuldigd aan de internisten, cardiologen en arts-assistenten van het Sint Lucas Andreas 
Ziekenhuis, en dan met name aan de opleiders Juup van Meyel en Willem de Voogt.
Ook mijn onderzoekskameraden Maarten, Ferdinand en Loek wil ik bedanken voor het inter-
viewen van patiënten in de avonduren onder het genot van pizza (en bier). Dank ook aan mijn 
huidige en voormalige collega’s in het Onze Lieve Vrouwe Gasthuis, in het bijzonder Femke 
(voor de puntjes op de ‘i’), Braat(-jesmaker), Sander (ex-lotgenoot), Aukje (epicentrum van 
de ziekenhuisachterklap), Paco (maat) en Eelko (‘Wellens-project’ en jaloersmakend gevatte 
opmerkingen).
Zonder de bijdrage van de afdeling Research Cardiologie van het OLVG en Sint Antonius 
Ziekenhuis, secretaresses, bibliothecarissen, cath-kamerverpleegkundigen en -technici had 
dit proefschrift niet tot stand kunnen gekomen. Allen hartelijk bedankt. Speciaal genoemd 
mogen worden: Lyda Kloosterboer-Lalk en Jeanne ’t Hooft (secretariaat cardiologie OLVG), 
Annet Louw (EUR) en Simon Staphorst (hoofd cath-lab OLVG). Bedankt voor jullie ondersteu-
ning en nuttige tips.
Mijn vrienden wil ik bedanken voor hun uithoudingsvermogen. Het is een feest om zoveel 
goede vrienden te hebben, maar het is jammer dat ik slechts twee paranimfen mag aanstel-
len. Bedankt lieve zussen en mama! En natuurlijk, lieve Marije, de schittering in mijn leven, 
mijn Marietje. Bedankt.
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